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ABSTRACT 
 
COMPARISON OF THE EFFICACY OF ARV MEDICATIONS ALONE AND IN 
COMBINATION WITH HERBAL MEDICATIONS IN THE TREATMENT OF HIV 
AMONG NIGERIAN HIV+ PATIENTS 
 
MAY 2017 
 
ABDULFATTAH B. DUROJAIYE, BSN, UNIVERSITY OF MEDICINE & 
DENTISTRY OF NJ (NOW RUTGERS UNIVERSITY) 
BSc, UNIVESITY OF AGRICULTURE, ABEOKUTA, NIGERIA 
MSc, UNIVERSITY OF IBADAN, NIGERIA 
PhD, UNIVERSITY OF MASSACHUSETTS, AMHERST 
Directed by Prof. Donna Zucker 
 
Background/Purpose: There is disproportionate incidence of HIV in Sub-
Saharan Africa in comparison to the rest of the world. Of the estimated 35.3 million 
people living with HIV, Sub-Saharan Africa has the highest level of HIV infections, 
accounting for 69% of global HIV infection in spite of having only 12% of the global 
population. Nigeria, with over 3.2 million people living with HIV, has the second highest 
HIV/AIDS burden in the world, next only to South Africa (5.6 million) whose population 
is approximately one third of Nigeria’s population. According to the World Health 
Organization (WHO) an estimated 80% of Africans reportedly use herbal therapies in the 
treatment of many diseases (WHO, 2002). The use of herbal remedies in the treatment of 
HIV has gained currency in Nigeria. The purpose of this study was to investigate the 
efficacy of ARV- only therapy and a combined therapy of ARV and herbal medications 
                                                                      ix 
and to also investigate the effect of these treatment modalities on HIV symptoms and 
patients’ quality of life among HIV patients in Nigeria. 
Methods: This is a comparative analysis study designed to compare the efficacy 
of conventional antiretroviral (ART) medications with a combination therapy of ART and 
herbal therapies as they are already used by Nigerian HIV patients. The World Health 
Organization Quality of Life Instrument for HIV (WHOQOL-HIV BREF) and the Sign 
and Symptom Check-List for persons with HIV disease (SSC-HIV BREF) questionnaires 
were administered to 110 participants drawn from two groups of Nigerian HIV patients: 
those using conventional antiretroviral medications only and those using a combination 
of herbal remedies and conventional antiretroviral medications. Each group was 
composed of 55 participants. Physiological data (CD4 counts) was also collected for the 
two groups. Data generated from the study was analyzed using IBM SPSS Statistics 22 
software. Both descriptive and inferential data analyses were used to analyze study 
results. Descriptive statistics was used to analyze the demographic data (age, gender, and 
ethnicity) while inferential statistics was used to draw conclusion from study data. Paired 
Sample test was used to determine the differences between baseline CD4 counts and 
post-treatment CD4 counts in both groups. Analysis of covariance (ANCOVA) was used 
to statistically adjust and control the differences noted in baseline CD4 counts between 
the two groups before comparative analyses of the two groups’ CD4 counts were done. 
Independent t-test was used to compare the differences between ARV group and 
combined group. 
Findings: There was a statistically significant difference between baseline CD4 
counts and post- treatment CD4 counts after treatment with ARV only and combined 
                                                                      x 
therapies. However, no statistically significant difference was noted in the overall quality 
of life of patients receiving ARV only and those receiving combined therapies (p=.211). 
Statistically significant difference was noted in social relationship domain (p=.028) and 
health satisfaction domain (p=.049) of the WHOQOL BREF instruments. No statistically 
significant difference was noted in all the sign and symptom factors evaluated except in 
the fever factor (p=.003) and sore throat factor (p=.013).   
Conclusion: Findings from this study have shown that a vast majority of patients 
on combined therapy do so without disclosing the use of herbal remedies to their 
physicians and care providers. It is expected that physicians and care providers would 
incorporate this knowledge into their care model, build trusting and supportive 
relationships with patients and specifically solicit information about the use of herbal 
therapy in combination with ARV. This knowledge will enable physicians, nurses and 
other care providers to explore possible side effects and cross reactions between ARV 
and herbal remedies.  
Keywords: HIV, ARV, Herbal Medications, Nigeria 
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CHAPTER 1 
INTRODUCTION 
Background of the Study 
With infection rates at an alarming level, especially in developing countries, the 
HIV/AIDS epidemic is one of the greatest health challenges of our time (Short, 2006). 
Globally, the United Nations estimated that 35.3 million people are living with HIV 
(UNAIDS, 2013). Of this number, Sub-Saharan Africa has the highest level of HIV 
infections, accounting for 69% of global HIV infection in spite of having only 12% of the 
global population (UNAIDS, 2012). The global HIV epidemic has shown a decrease from 
the peak record of 3.4 million new infections in 1997 to an estimated 2.7 million new 
infections in 2010 (UNAIDS, 2011). This is a 21% decrease from the prevalent rate in 
1997 (UNAIDS, 2011). Nigeria has a disproportionately high incidence of HIV infection 
compared to other Sub-Saharan African countries (NACA, 2012).  
The HIV infection has been recognized as one of the biggest challenges facing 
humanity in this century (Durojaiye, 2009). The Nigerian census appears to be inaccurate 
and varies widely. Nigeria, with an estimated population of 177,072,561, is the most 
populated country in Sub-Saharan Africa (NACA, 2014). An estimated 3,229,757 people 
are currently living with HIV in Nigeria, ranking Nigeria second among the countries 
with the highest HIV/AIDS burden in the world, next only to South Africa (5.6 million) 
whose population is approximately one third of Nigeria’s population (NACA, 2014). An 
estimated 220,394 new infections occurred in 2013 alone (NACA, 2014).  
The lacks of political will as well as the inadequate resources are factors that 
continue to hamper the prevention of HIV infection in Sub-Saharan Africa (Uneke, Alo,  
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Ogbu, & Ngwu, 2007). HIV infections continue to spread among highly marginalized 
and stigmatized populations (Uneke et al., 2007). The first diagnosis of HIV in Nigeria 
was in 1986 with the diagnosis of a 13-year-old hawker (Alubo, Zwandor, Jolayemi & 
Omudu, 2002). HIV infections continue to decimate many communities in Nigeria 
(Durojaiye, 2009). From the first HIV diagnosis in 1986 to year 2011, 3,459,363 HIV 
infections have been recorded in Nigeria (NACA, 2012).  
Nigerian women are disproportionately affected by the HIV epidemic. Over 55% 
of HIV infections occur among the female population. HIV is the leading cause of death 
and disease among women of reproductive age (15-49 years old) (NACA, 2012). HIV 
prevalence among Nigerian women aged between 15 and 24 years is estimated to be three 
times higher than among men of the same age (NACA, 2011a). In Nigeria, 58% of the 
population of HIV-positive patients are women, with 55% of AIDS-related deaths 
occurring among female patients (NACA, 2012). 
The National HIV/AIDS and Reproductive Health Survey (NARHS) conducted in 
2012 reported a national prevalence of 3.4% (NACA, 2014). There are an estimated 3.2 
million HIV patients in Nigeria, which has a significant impact on the global HIV burden 
(NACA, 2014). 58% of HIV-positive people in Nigeria are women (NACA, 2012). This 
has resulted in a high population of pregnant HIV patients, showing a prevalence level of 
4.1% infection rate among this population (pregnant women) (NACA, 2012). This has 
translated into a staggering figure of 210,000 pregnant HIV patients (Afe, Adewumi, 
Fagorala, Disu, Ganikale, & Audu, 2011; NACA, 2011). Annually, there are 56,000 
births of HIV-positive babies in Nigeria (NACA, 2011). In 2011 the number of pregnant 
women living with HIV was estimated to be 221,129 with about 17.1% (37,868) of these 
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women receiving antiretroviral medications to prevent mother-to-child HIV transmission 
(NACA, 2012).  
Globally, Nigeria has the second largest population of HIV infection (NACA, 
2014). Nigerian women are disproportionately affected with HIV infection. Nigeria still 
lags behind in antiretroviral (ART) intervention and the country needs to scale up the 
uptake of prevention of mother-to-child transmission (PMTCT ) in order to catch up with 
global trend. 
Problem Statement 
With its physical and psychosocial aspects, HIV has been recognized as one of the 
biggest challenges facing humanity in this century (Alubo, et al., 2002; Gilbert & Walker, 
2010). The introduction of effective antiretroviral combination therapy (ART) in 1996 
helped curtail the epidemic nature of HIV (CDC, 2013). ART is commonly known as 
highly active antiretroviral therapy (HAART) or combination antiretroviral therapy 
(cART) (Dieffenbach & Fauci, 2011). ART therapy, which involves the use of a 
combination of three or more antiretroviral medications, brings a renewed hope of 
effective management of HIV (Gulick et al., 1997). With the use of HAART/cART, HIV 
is now considered a chronic disease with improved life expectancy (Dieffenbach & 
Fauci, 2011; Palella et al., 1998). ART has revolutionized the management protocol of 
HIV, increasing the hope of curtailing transmission of HIV to uninfected people. Results 
from HIV Prevention Trial Network (HPTN) 052 study shows that early HIV treatment 
with ART is capable of reducing HIV transmission to uninfected persons by 96% (Cohen 
et al., 2011). In addition, ART is very helpful in preventing mother-to-child HIV 
transmission by as high as 90% (CDC, 2006).  
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In Africa, the use of herbal remedies in treating many disease conditions is 
astronomically high, with the World Health Organization (WHO, 2002) reporting the use 
of herbal remedies among 80% of the population. Herbal remedies such as a-Zam have 
shown significant promise in improving the CD4 and reducing viral load of HIV patients 
in Nigeria. Studies have shown that a-Zam is an effective remedy in the management of 
HIV symptoms such as fatigue, fever, oral thrush, weight loss, appetite, skin lesions, 
malaise and diarrhea (Onifade, Jewell, & Okesina, 2011a). 
Outside the conventional ART management of HIV, multiple claims of non-
orthodox and traditional treatment have been made in different parts of the world 
(Abalaka, 2004; Amzat & Abdullahi, 2008; Igoli, Ogaji, Tor-Anyiin & Igoli, 2005: 
Kisangau, Lyaruu, Hosea, & Joseph, 2007; Oreagba, Oshikoya, & Amachree, 2011; Zou, 
Liu, Wang, Li, & Liao, 2012). However, there is little evidence of the support of Nigerian 
doctors and politicians for the use of herbal treatments for HIV that are prescribed by 
traditional healers. If there is any alternative treatment that is effective in the treatment of 
HIV/AIDS, it is imperative that the scientific world investigate such treatment protocols.  
Purpose 
With the increasing popularity of herbal remedies in the treatment of HIV in 
Nigeria (Abalaka, 2004), nurse scientists must investigate the efficacy of herbal remedies 
and compare the efficacy of herbal remedies with conventional anti-retroviral treatments. 
It is important to continue to seek remedies to this deadly disease that is ravaging our 
world and to seek better understanding of the experience of HIV patients using herbal 
remedies in their treatment.  
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Onifade et al (2011a) studied the effectiveness of a-Zam in HIV treatment by 
measuring the changes in CD4 and viral load of patients during the course of a-Zam 
treatment. However, Onifade et al. (2011a) did not compare outcomes of herbal treatment 
with outcomes of antiretroviral medications. Additionally, the study did not seek deeper 
understanding of the experience of patients during the course of the herbal therapy. The 
present study is designed to bridge these identified gaps and to seek deeper understanding 
of the experiences of Nigerian patients during treatment with ARV only and a combined 
treatment of ARV and herbal medications.  
The purpose of this study was to investigate the efficacy of ARV only therapy and 
a combined therapy of ARV and herbal medications and to also investigate the effect of 
these treatment modalities on HIV symptoms and patients’ quality of life among HIV 
patients in Nigeria. This is a comparative analysis study designed to compare the 
effectiveness of conventional antiretroviral (ARV) medications with a combination 
therapy of ARV and herbal therapies as they are already used by Nigerian HIV patients. 
The study consisted of two parts namely the pilot study and the actual study. The pilot 
study was designed to test the reliability of the two instruments used in obtaining data 
from the subjects. The actual study measured and compared the symptom experience and 
quality of life of patients using ARV only and those using a combination of ARV and 
herbal medications. Data collection was done using the Sign and Symptom Check-List 
for persons with HIV disease (SSC-HIVrev) (Holzemer et al., 2001) and the brief version 
of the World Health Organization Quality of Life instruments Instrument for HIV (WHO, 
2012). 
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Aims of Study 
The aims of this study are: 
1. To investigate the efficacy of antiretroviral (ARV) medications on the CD4 count 
among Nigerian HIV patients. 
2. To investigate the efficacy of a combination therapy of ARV and herbal 
medications on the CD4 count among Nigerian HIV patients. 
3. To investigate the difference in the CD4 counts of patients taking ARV only and 
patients that take a combination of ARV and herbal medications. 
4. To investigate the effects of ARV on patients’ quality of life. 
5. To investigate the effects of ARV on HIV symptoms. 
6. To investigate the effects of a combination of herbal therapies and ARV on 
patients’ quality of life. 
7. To investigate the effects of a combination of herbal therapies and ARV on HIV 
symptoms. 
Research Questions 
The research questions for this study are: 
1. How do CD4 counts differ after treatment with antiretroviral medications only?” 
2. How do CD4 counts differ after treatment with a combined therapy of herbal 
treatment and conventional antiretroviral medications? 
3. What is the difference in CD4 counts of patient taking ARV only and those taking 
a combination of herbal therapies and conventional antiretroviral medications? 
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4. What is the difference in the symptom experience of patients taking ARV only 
and those taking a combination of herbal therapies and conventional antiretroviral 
medications? 
5. What is the difference in the quality of life of patients taking only ARV, and those 
taking a combination of herbal therapies and conventional antiretroviral 
medications? 
Significance of the Study 
HIV/AIDS has reached an epidemic level, especially in developing countries 
(Short, 2006). Nigeria, with a median age of 17 years, is a youthful nation of 
approximately 177 million people. NACA (2012) estimates that the population of people 
living with HIV/AIDS is 3.2 million. Globally, Nigeria is reported to have the second 
highest incidence of new HIV infections (UNAIDS, 2012). Heterosexual relationships are 
known to contribute to approximately 80 percent of new infections in Nigeria (UNAIDS, 
2012), while blood transfusion and mother-to-child transmission accounts for 
approximately 20% of infections. Multiple studies have shown that most pediatric HIV 
infection is associated with mother-to-child transmission (MTCT), which occur during 
childbearing, labor, delivery and breastfeeding (Buskens, Jaffe, & Mkhatshwa, 2007; 
Coetzee, Hilderbrand, Boulle, Draper, Abdullah, & Goemaere, 2005; Futterman, Shea, 
Besser, Stafford, Desmond, Comulada, & Greco, 2010; Hembah-Hilekaan, Swende, & 
Bito, 2012). In 2011, the number of pregnant women living with HIV was estimated to be 
221,129 with about 37,868 (17.1%) of these women receiving antiretroviral medications 
to prevent mother-to-child HIV transmission (NACA, 2012). An estimated 26.5% of 
HIV-infected pregnancies resulted in child infection in 2011 (NACA, 2012). The fact that 
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HIV has no known cure at present and HAART is not readily available provides impetus 
for people to seek cures outside the conventional health care model (Onifade, Jewel, 
Okesina, Yong, Ojezele, Nwanze, Adejumo, Oladeinde, Osakue, & Uwaifo, 2011b). 
UNAIDS (2012a) estimates that about 35.3 million people worldwide are living 
with HIV, with over 3.2 million people living with the disease in Nigeria (NACA, 2014). 
The prevalence of HIV in Nigeria has recorded a remarkable increase from the time of 
the first infection in 1986. The prevalence of HIV infection among adults aged 15-49 
years was reported to have increased from 1.8% in 1991 to 5.8% in 2005 (UNAIDS, 
2007; USAIDS/PEPFAR, 2008). Although the trend decreased to 3.9% in year 2005 
(UNAIDS, 2007), an estimated 3.2 million Nigerians are still living with HIV (NACA, 
2014). 
HIV infection continues to decimate many communities in Nigeria (Durojaiye, 
2009). The number of weekly cases of HIV in many secondary health facilities in Nigeria 
averages 20 per week, and AIDS-related disorders account for up to 40% of hospital 
admission (Soyinka, 1998). The transmission of HIV continues to increase at an alarming 
rate. According to Alubo et al (2002), up to 30% of the hospitalized patients in Otukpo 
General Hospital (OGH) in Benué State, Nigeria were admitted with AIDS-related 
conditions.  
A similar trend was recorded in a Catholic-run diagnostic center, where 29 out of 
250 voluntary blood donors tested positive for HIV in 1996, and AIDS-related deaths 
averaged 2 per week (Alubo et al., 2002). There is high discrimination and stigma 
attached to HIV infection in Nigeria. This is because the mode of transmission of HIV in 
Nigeria is predominantly through heterosexual means (UNAIDS, 2012) and there is a 
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general perception that people living with AIDS (PLWA) are people of low morals who 
have brought HIV/AIDS upon themselves (Alubo et al., 2002). These people are 
generally regarded as “loose” people who deserve neither sympathy nor empathy (Alubo 
et al., 2002). 
HIV infections have a multitude of symptoms that can manifest in different ways, 
and in an extremely unpleasant manner. Symptoms associated with HIV include fatigue, 
pain, fever, and memory problems (Siegel, Lekas, Schrimshaw, & Brown-Bradley, 
2011). Other commonly reported HIV-related symptoms are headaches, herpes zoster, 
throat pain, and arthralgia (Singer, Zorilla, Fahy-Chandon, Chi, Syndulko & Tourtellotte, 
1993). A comprehensive HIV symptom list is adequately captured in the Sign and 
Symptom Check-List for persons with HIV disease (SSC-HIVrev) (Holzemer, Hudson, 
Kirksey, Hamilton & Bakken, 2001). The HIV symptoms cluster identified by Holzemer 
et al (2001) in the instrument are: fatigue, fear, fever, GI upset, shortness of breath, sore 
throat, numbness, headache, rectal itch, bruising/bleeding, body changes and 
gynecological-related problems for women. Posttraumatic and depressive symptoms are 
also known to be associated with diagnosis of HIV (Klis, Velding, Gidron, & Peterson, 
2011). 
The debilitating nature and multiplicity of HIV symptoms are known to impact 
significantly on patients’ quality of health. According to Fatiregun, Mofolorunsho & 
Osagbemi (2009) quality of life is a function of the overall well-being of patients, which 
can foster happiness and contentment. The state of health could influence quality of 
health. The WHO’s (2012) conceptualization of quality of life within the context of 
individual culture and value system provides a unique definition of quality of life. Quality 
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of life is individualistic in nature. Factors such as religion, financial need/status, culture, 
educational level, culture and health will influence an individual’s perception of quality 
of health. Health is a major determinant of quality of life. Because of the centrality of 
health to quality of life, the quality of life of HIV patients could be used as a way to 
evaluate the effectiveness of HIV treatment and/or management. 
According to the World Health Organization (WHO) herbal remedies have been 
used throughout the world to treat many ailments (WHO, 2002). An estimated 80% of 
Africans reportedly use herbal therapies in the treatment of many diseases (WHO, 2002). 
Herbal therapy is used either as a complementary treatment or as an alternative treatment 
to conventional or orthodox medicine in treating different disease conditions (Onifade et 
al., 2011a; Patel, Bessong & Liu, 2011). Herbal remedies have been found to inhibit 
some steps associated with HIV replication (De Clereq, 2000; Kong, Goh, Chia, & Chia, 
2003). Herbal remedies have shown to be effective in reducing viral load and increasing 
CD4 counts (Onifade et al., 2011a). According to Matthee, Wright & Konig (1999) 
alkaloid-derived herbal remedies such as Ancistrocladus korupensis, which is extracted 
from the tropical liana plant, inhibit reverse transcriptase and HIV-induced cell fusion. 
Dhamaratne, Tan, Marasinghe & Pezzuto (2002) reported that Coumarin herbal remedy 
in the form of canolides extracted from a tropical forest tree, Calophyllum lanigerum, 
was classified as a potent non-nucleoside reverse transcriptase inhibitor. Coumarin from 
plant sources and their analogs (i.e. synthetic coumarins) have shown to be potent 
nonnucleoside RT-inhibitors, or inhibitors of HIV-integrase, or HIV-protease (Kostova, 
2006). 
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Historically, herbal therapies have recorded groundbreaking successes, as in the 
clinical success of quinine and quinidine isolated from the Cinchona tree bark, and  
artemisinin from Artemisia annua, in the treatment of malaria (Igoli, Ogaji, Tor-Anyiin & 
Igoli, 2005). Ufo opioko (Ageratum conyzoides Linn) is an herbal therapy that is 
reportedly widely used in treating HIV in Nigeria (Igoli et al., 2005). The efficacy of Ufu 
opioko (Ageratum conyzoides Linn) in the treatment of HIV is yet to be scientifically 
established.  
Onifade et al (2011a) studied the use of herbal therapy with a-Zam and showed 
that a-Zam is an effective anti-HIV agent as it resulted in significant increase in CD4 
counts and significant decrease in viral load. This study showed no remarkable harmful 
drug interaction with Highly Active Anti-Retroviral Therapy (HAART). Onifade et al 
(2011a) study did not carry out comparative analysis of the efficacy of a-Zam with the 
efficacy of HAART. The study only investigated the efficacy of a-Zam on the 
physiologic (CD4 and viral load) aspect of HIV management. The effects of a-Zam on 
HIV symptoms were not investigated in detail. These obvious knowledge gaps 
necessitate the investigation of the impact of herbal therapies and HAART on HIV 
symptoms and patients’ quality of life.  
Operational Definitions of Concepts or Terms 
The meaning of Nigeria and Nigerians as used in this review need to be 
operationally defined for proper understanding of these two concepts. Nigeria refers to 
the geographical location of the country in West Africa. This excludes all the foreign 
embassies and high commissions of the country that are located all over the world. Also, 
the term Nigerians refers to those individuals that were born in Nigeria by Nigerian 
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parents and are currently living permanently in Nigeria. For the purpose of this study, all 
diasporic Nigerians were not classified as Nigerians. This differentiation is necessary 
because residency abroad may introduce different dynamics that may not be prevalent in 
Nigeria’s geographical space.  
For the purpose of this study, WHO’s (2000) definition of herbal 
medicines/therapies provided an operational definition. Herbal therapies are herbs, herbal 
materials, herbal preparations and finished herbal products whose active ingredients 
include plants parts or plant materials, or combination (WHO, 2000). For the purpose of 
this study, herbal homes are local traditional healer homes where herbs, herbal materials, 
herbal preparations and finished herbal products are used in treatment of different disease 
conditions.  
Theoretical Framework 
The theory of symptom management (TSM) (Dodd, Miaskowski, & Lee, 2004; 
Humphreys et al., 2008) provided the theoretical framework for this study. Symptom 
management is central to the management and treatment of HIV. The TSM helped to 
adequately conceptualize symptoms and helped to develop pragmatic means of 
eliminating or ameliorating these symptoms.  
Concepts of TSM 
The three major concepts of the TSM are symptom experience, symptom 
management strategies and symptom status outcomes. These concepts are embedded 
within the nursing dimensions of person, environment and health and illness (Humphreys 
et al., 2008). 
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Symptom Experience 
This is described as “a simultaneous perception, evaluation and response to a 
change in one’s usual feeling” (Humphrey’s et al., 2008, p. 147). It is known that the 
response to symptom experience is a function of the severity of the symptom as well as 
the context (environment) of the experience (Humphreys et al., 2008).  
Symptom Management Strategies 
These are the pragmatic ways to reduce the frequency of the symptom experience 
or minimize the severity of symptom or ameliorate the distress associated with the 
symptom experience (Portenoy et al., 1994). Symptom management strategies require an 
aggregate information on the who (i.e. the individual patients), how (dose), where 
(whether home or health care setting), when (timing of intervention) and what (type of 
intervention) are involved in the interventional protocols employed in symptom 
management (Humphreys et al., 2008). The combination of these strategic management 
approaches is capable of having profound effects on the management outcomes 
(Humphreys et al., 2008). 
Symptom Status Outcomes 
These are objective, measurable outcomes resulting from symptom management 
strategies. Outcomes could be reduction in the intensity, or frequency or distress level of 
the symptom, resulting in improved physical and psychological well being. Other 
possible outcomes could be early return to optimum functional level, cost containment 
and/or early discharge from the healthcare setting (Humphreys et al., 2008). 
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Relationships Between the Concepts of TSM 
The three concepts of the TSM are known to have simultaneous interactions with 
each other. The symptom experience is a function of the strategies employed in symptom 
management and the outcomes of such management strategies. According to the authors 
of the theory, “the symptom experience is conceptualized as influencing and being 
influenced by both symptom management strategies and symptoms status outcomes. As 
individuals become aware of symptoms, initiate strategies, and assess symptom 
outcomes, their symptom perception is affected” (Humphreys et al., 2008, p. 147).  
The reciprocal interaction between these three concepts is a continuous process 
until the resolution or stabilization of symptoms. The effects of non-adherence to 
management strategies are shown by the broken arrows between symptom management 
strategies and symptom status outcomes components of the TSM (in Appendix 1). Non-
adherence could adversely affect the symptom status outcome. Factors such as the 
complexity or difficulty of symptom management strategies and the factors embedded in 
the nursing dimension of person, environment and health and illness could impede 
adherence to symptom management protocol (Humphreys et al., 2008). The bi-directional 
arrows seen in Appendix 1 indicate a simultaneous interaction among the three concepts 
of the TSM. Non-adherence to management strategies could result when treatments or 
interventions are too challenging, are not followed, or are not followed consistently. 
Adequacy of TSM for HIV Symptom Management 
The TSM has shown great promise in explaining, conceptualizing and 
contextualizing symptom experiences among HIV patients. The symptom experience is 
conceptualized as affecting and being affected by both symptom management strategies 
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and symptoms status outcomes (Humphreys et al., 2008). The theory was used to explore 
the association between symptom experience and the use of behavioral response (prayer) 
in the management of HIV-related symptoms of fatigue, nausea, depression and anxiety 
among HIV-positive African American patients (Coleman et al., 2006). To investigate the 
applicability of study results from the United States to Taiwan, Tsai, Hsiung, & Holzemer 
(2002) used the TSM and concluded that symptom management strategies had not been 
fully explored. The theory of symptom management has played a useful role in 
explicating the experience of depressive symptoms among HIV-positive patients (Eller et 
al., 2005) and in testing the effectiveness of symptom management information manuals 
among Taiwanese patients (Tsai, Holzemer, & Leu, 2005). Voss, Dodd, Portillo, & 
Holzemer (2006) were able to provide extensive explication of the symptom of fatigue in 
HIV patients by clearly integrating the three components of the TSM: symptom impact, 
symptom management & symptom outcomes. The TSM has been hailed as one of the 
prominent theories for enhancing understanding in nursing research on fatigue associated 
with HIV (Voss et al., 2006). 
The central constructs of the TSM provided a suitable framework for this study. 
Patients’ perception of their quality of life is a function of the effective symptom 
management strategies employed. In the context of this study, symptom management 
strategies are related to whether the patients are taking herbal remedies, or HAART, or a 
combination of both. The symptom management strategies will also influence patients’ 
experience of the symptoms. Conversely, the symptom status outcomes will be dependent 
on the combination of symptom management strategies used. Similarly, the experience of 
symptom and the perception of symptoms will be dependent on the outcome of the 
                                                                16 
 
management protocol. The three concepts of the TSM perfectly provide pragmatic 
explanation for this study.   
 
Hypothesis 
This study seeks to compare the efficacy of conventional antiretroviral 
medications with a combined therapy of ARV and herbal remedies in the treatment of 
HIV among Nigerian HIV patients. This study is predicated on certain hypotheses. The 
hypotheses for this study are as follows:  
1. There is no significant difference in the quality of life of HIV patients using a 
combined therapy of ARV and herbal medications and those using conventional 
antiretroviral medications only, 
2. There is no significant difference in the symptom improvement of HIV patients 
using a combined therapy of ARV and herbal medications and those using 
conventional antiretroviral medications only, and 
3. There is no significant difference in the improvement in CD4 counts of HIV 
patients using a combined therapy of ARV and herbal medications and those 
using conventional antiretroviral medications only. 
 If these hypotheses are true, the use of a combined therapy of ARV and herbal 
medications would hold great promise in HIV treatment in Nigeria and in other resource 
constraint countries. It is known that accessibility to ARV medication is still grossly 
limited in Nigeria. Likewise, in spite of the wide availability of ARV medications in 
western countries, ARV is still not readily available in Nigeria and other Sub-Saharan 
African countries. Also high proportions of patients are using herbal medications as 
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complementary medication to ARV. A comparable treatment outcome between patients 
using a combined therapy of ARV and herbal medications and those using ARV 
medications only would mean that herbal remedies could be safely used concomitantly 
with ARV. This would greatly help many HIV patients in Nigeria who use herbal 
remedies. With this information, Nigerian authorities could concentrate efforts on 
improving herbal treatment of HIV through research and appropriate data gathering to 
continually evaluate herbal therapies. 
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CHAPTER 2 
LITERATURE REVIEW 
Introduction 
The purpose of this literature review is to seek insight into HIV and the use of 
herbal remedies in the treatment of HIV in Nigeria. This review examines current trends 
in the treatment of HIV and reviews the epidemiology of HIV in Sub-Saharan Africa and 
Nigeria and the use of herbal therapies in the treatment of HIV. The review also 
synthesizes information about the vertical transmission of HIV in Sub-Saharan Africa, 
with special attention on the Nigerian situation. Stigmatization and discrimination of HIV 
patients will also be discussed. 
The literature review of HIV treatment modalities is conducted with special 
emphasis on the use and safety of herbal remedies in HIV treatment. Many research 
works have been carried out on the use of herbal remedies in the treatment of HIV 
(Dhamaratne, Tan, Marasinghe & Pezzuto, 2002; Hodgson & Rachanis, 2002; Igoli, 
Ogaji, Tor-Anyiin & Igoli, 2005; Kisangau, Lyaruu, Hosea, & Joseph, 2007; Kostova, 
2006; Langlois-Klassen, Kipp, Jhangari, & Bubaale, 2007; Matthee, Wright & Konig, 
1999;  Mills, Cooper, Seely & Kanfer, 2005; Onifade, Jewell, & Okesina, 2011a; 
Orisatoki & Oguntobeju, 2010; Patel, Bessong & Liu, 2011). Specifically, literature on 
the use of the herbal remedy a-Zam in HIV treatment were reviewed.  
Epidemiology of HIV 
 The advent of HIV in 1981 heralded the era of serious global health challenges. 
The scourge of HIV was first noticed in a San -Francisco clinic when a group of 
homosexual men presented with symptoms of rare opportunistic infections, which 
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included Pneumocystic carinii pneumonia, extensive mucosal candidiasis and multiple 
viral infections (Gottlieb et al., 1981). The first presentations of HIV symptoms were 
noted mainly in homosexual men and drug abusers (Masur et al., 1981). Subsequent 
evaluations of these men revealed that they were suffering from severe immune 
deficiency, which led to the tagging of the disease as acquired immune deficiency 
syndrome (AIDS) (Costin, 2007), while the virus causing this syndrome was named 
human immunodeficiency virus (HIV) in 1983 (Levy, 1993). At present, the majority of 
people infected are between the ages of 15-40 and are the most productive, agile and 
sexually active group in a society (Amzat & Abdullahi, 2008). 
HIV infection is usually characterized by three distinct clinical stages: acute  
viremia, a latency phase which could be of variable duration, and a classification of 
clinical AIDS (Costin, 2007). During the acute viremia stage the virus can be detected in 
the blood of patients (Daar, Moudgil, Meyer, & Ho, 1991; Zhu et al., 1993). Following 
the initial viremia peaks, the level of virus in the blood declines to a very low to non-
detectable level, signifying the latency phase (Coffin, 1995; Perelson, Newmann, 
Markowitz, Leonard, & Ho, 1996; Wei et al., 1995). This stage is characterized by high 
turnover of CD4+ T cells with accompanying HIV virion production (Ho et al., 1995; 
Piatak et al.., 1993). During this stage the CD4+ T cells begin to decline (Costin, 2007; 
Esbjournsson et al., 2012). Clinical diagnosis of AIDS occurs when the CD4+ T cell 
count falls below 200cells/mm3, and when a patient presents with at least one 
opportunistic infection such as Pneumocystic carinii (Costin, 2007). This is the final stage 
of immune compromise leading to high susceptibility to secondary infections. This may 
manifest as rare cancers such as Kaposi’s sarcoma and/or neuropathy (Costin, 2007; 
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Esbjournsson et al., 2012). The progressive manifestation of opportunistic infection is a 
result of the dysfunctional immune system (Esbjournsson et al., 2012) 
HIV is known to contain reverse transcriptase and belongs to a subgroup of 
retroviruses known as the lentiviridae (Arnaout et al.., 1999; Fahey et al.., 1998; Garry, 
1989; Levy, 1993). The infection’s latency stage could last for a considerably long time, 
sometimes more than 20 years (Costin, 2007). During the latency phase, HIV continues 
to have destructive effects on immunological and neurological systems of the body 
(Costin, 2007). 
There are two types of retroviruses (lentiviruses) namely pandemic HIV type 1 
(HIV-1) and HIV type 2 (HIV-2) (De Silva, Tienen, Rowland-Jones & Cotton, 2010; 
Esbjornsson et al.., 2012; Nyamweya et al.., 2013). These retroviruses are closely related. 
Both types are transmitted in similar ways, exhibit similar cellular targets and manifest 
similar AIDS-related opportunistic infections (Di Silva, et al., 2010; Esbjornsson et al.., 
2012). HIV-2 is predominantly restricted to West Africa, but an increasing number of 
cases have been seen in the U.S, Europe and India (Campbell-Yesufu, & Gandhi, 2011; 
Thiébaut et al., 2012). In comparison to HIV-1, the main characteristics of HIV-2 are that 
it has lower transmission rates, a longer latency period, slower reduction in CD4+ T cell 
count and lower mortality rates (De Silva et al., 2010; Esbjornsson et al., 2012). HIV-1 is 
reported to have been introduced to human through multiple interspecies transmission 
from simian immunodeficiency virus in chimpanzees, while HIV-2 is thought to have 
been introduced to human through sooty mangabeys (De Silva et al., 2010; Esbjornsson 
et al., 2012). 
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Globally, there are approximately 34 million people living with HIV, the virus 
which causes AIDS (UNAIDS, 2013). New cases of HIV infection continue to be 
recorded in all regions of the world. However, 95% of new infections happen in 
individuals that live in low-and middle-income countries, especially in Sub-Saharan 
Africa (UNAIDS, 2013). Globally, there were over 700,000 fewer new HIV infections in 
2011 compared to in 2001 (UNAIDS, 2012). Nonetheless, large improvements have been 
recorded in different parts of the world, including Sub-Saharan Africa. Africa has 
reduced AIDS-related death by one third in recent years (UNAIDS, 2012). The global 
HIV epidemic appears to be in check, with a record 50% reduction in new HIV infection 
in low-and middle-income countries between 2001 and 2011. However, there still exists 
sharp disparities in the incidence of HIV infection in low-income countries as compared 
with the industrialized nations of the world.  
HIV in Sub-Saharan Africa 
The United Nations estimated that 34 million people were living with HIV at the 
end of 2011 (UNAIDS, 2012). Of this number, Sub-Saharan Africa has the highest level 
of HIV infection, accounting for a disproportionate 69% of global HIV infection despite 
having only 12% of the global population. On average, 1 in every 20 adults (amounting 
to 4.9% of the population) in Sub-Sahara Africa live with HIV (UNAIDS, 2012).  
There is a disproportionate impact of HIV on women and children, who continue 
to experience high rates of new infection, with attendant HIV-related illness and death 
(WHO, 2011). Sub-Saharan Africa has been greatly hit by the HIV epidemic. Of the 
children who contracted HIV in 2011, 90% live in Sub-Saharan Africa. Also, 92% of the 
global HIV-positive pregnant women live in Sub Saharan Africa (UNAIDS, 2012). In 
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2011, 59% of women living with HIV in Sub-Saharan Africa received ART medication 
during pregnancy and delivery (UNAIDS, 2012).  
HIV in Nigeria 
Nigeria, with an estimated population of 177,072,561, is the most populated 
country in Sub-Saharan Africa (NACA, 2014). An estimated 3.4 million people are 
infected with HIV in Nigeria, ranking Nigeria third among the countries with the highest 
HIV/AIDS burden in the world, next only to India and South Africa (NACA, 2012). The 
lack of political will and inadequate resources are factors that continue to hamper the 
prevention of HIV infection in Sub-Saharan Africa (Uneke et al., 2007).  
HIV was first noted in Nigeria in 1986 with the diagnosis of a 13-year-old hawker 
(Alubo et al., 2002), and continues to decimate many communities in Nigeria (Durojaiye, 
2009). From the first HIV diagnosis in 1986 to year 2011, 3,459,363 HIV infections have 
been recorded in Nigeria (NACA, 2012), with 388,864 new infections recorded in 2011 
alone (NACA, 2012). Despite declines in global HIV prevalence, incidence has increased 
in Nigeria between 2008 and2012. Table 1 below shows the epidemiology of HIV in 
Nigeria. Table 1 shows the overall HIV statistic while table 2 shows the HIV statistic for 
year 2010 and 2011 alone. Although table 1 shows an increase in total HIV population, 
there was actually a decrease in new infection rate in 2011 as shown in table 2. This 
decline is a result of increase awareness and proactive efforts on the part of all the 
stakeholders in the country. 
HIV among Women in Nigeria 
As shown in Table 2, Nigerian women are disproportionately affected by the HIV 
epidemic. Over 55% of HIV infection occurs in female population. HIV is the leading 
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cause of death and disease among women of reproductive age (15 and 49 years) (NACA, 
2012). HIV prevalence among Nigerian women aged 15 and 24 is estimated to be three 
times higher than among men of the same age (NACA, 2011a). In Nigeria, 58% of the 
population of HIV-positive patients are women, with 55% of AIDS related deaths 
occurring among female patients (NACA, 2012). 
In 2011 the number of pregnant women living with HIV was estimated to be 
221,129 with about 17.1% (37,868) of these women receiving antiretroviral medications 
to prevent mother-to-child HIV transmission (NACA, 2012). This is a 45% increase in 
ARV treatment for pregnant women from the 2010 figure. An estimated 26.5% of HIV 
infected pregnancies resulted in child infection in 2011 (NACA, 2012). Only about 4.7% 
of antenatal care (ANC) facilities in Nigeria provide prevention of mother-to-child 
transmission (PMTCT) services (WHO, 2011). In 2011, less than 18% of pregnant HIV 
infected women received ARVs for PMTCT while 11% of babies born in 2010 to HIV 
infected mothers received ARVs for PMTCT (NACA, 2012). Only 4% of babies born to 
HIV patients were tested for HIV within 2 months of life (WHO, 2011). In Nigeria 
prophylactic maternal triple ARV is the treatment of choice for HIV-infected pregnant 
women (NACA, 2012). 
Mother-to-Child Transmission in Sub Saharan Africa 
Multiple studies have shown that most pediatric HIV infection is associated with 
mother-to-child transmission (MTCT), which occurs during childbearing, labor, delivery 
and/or breastfeeding (Buskens, Jaffe, & Mkhatshwa, 2007; Coetzee, et al., 2005; 
Futterman, et al.., 2010; Hembah-Hilekaan, Swende, & Bito, 2012). Pregnant women 
living with HIV have a high risk of passing the infection to their babies if no intervention 
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is initiated to prevent such transmission (De Cock et al., 2000). In the absence of any 
intervention, the risk of transmission could be as high as 15-30% (Anoje et al., 2012). 
However, a combination of approaches could help reduce the risk of MTCT of HIV to 
less than 2% (De Cock et al., 2000). Interventions that could reduce incident of MTCT of 
HIV include prophylactic administration of antiretroviral (ARV) during pregnancy and 
labor and to the infant in the first few weeks of life, through an obstetrical intervention 
which includes elective caesarean delivery of the baby before the onset of labor and 
rupture of membranes. Safe infant feeding practices could help in the prevention of 
mother-to-child infection (Hembah-Hilekaan et al., 2012). 
Some of the interventions to prevent MTCT, such as the avoidance of breast-
feeding, may have cultural implications that make its acceptance difficult in Sub Saharan 
Africa. Similarly, the use of elective caesarean may not be safe nor available in resource-
constrained communities in Sub Saharan African (De Cock et al., 2000). Prevention 
methods tend to focus on administration of ARV regimen from the third trimester of 
pregnancy (Chabikuli et al., 2013), which is reported to reduce the risk of transmission 
during pregnancy and childbirth to between 2-4% (Chabikuli et al., 2013). In response to 
the need for effective prevention regimen, different countries in Sub Saharan Africa are 
adopting different protocols to prevent MTCT. 
Mother-to-child transmission is responsible for the high prevalence of pediatric 
HIV in Sub-Saharan Africa (Coetzee et al., 2005; Koo, Makin, & Forsyth, 2013; 
Kouanda et al., 2010). Of the two million global pediatric HIV infections, Sub-Saharan 
Africa accounts for 90% of infections (Kouanda et al., 2010). A UNAIDS (2008) 
estimate shows that over 90% of pediatric infections occur during pregnancy, birth or 
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breastfeeding. As a result of effective medical intervention in most industrialized 
countries, the rate of perinatal HIV transmission has decreased to 2% or less (Ghanotakis 
et al., 2012; Kouanda et al., 2010). This level was achieved through a combination of 
novel antiretroviral therapy, obstetrical intervention and re-definition of infant feeding 
that emphasize the use of infant formula and exclusion of breastfeeding for HIV-positive 
mothers (Cooper et al., 2002). However, the prevalence of MTCT in Sub-Saharan Africa 
is still as high as 40% pediatric infection rate among HIV-positive women (Kouanda et 
al., 2010).    
Unlike the prevailing situation in high-income countries where the incidence of 
mother-to-child transmission of HIV has been almost completely eliminated, there is still 
high incidence of mother-to-child transmissions of HIV in Sub-Saharan Africa 
(UNAIDS, 2006). The effective voluntary testing and counseling services, increased 
access to antiretroviral medications, safe delivery practices and widespread availability 
and safe use of breastfeeding substitute have reduced the incidence of MTCT of HIV in 
high-income countries (UNAIDS, 2011).  In spite of the improvement in the western 
world in the prevention of mother-to-child transmission of HIV, Sub-Saharan African 
countries still record high rates of pediatric HIV infection (Stringer et al., 2008). The lack 
of medical infrastructure, shortage of PMTCT services and shortage of medical personnel 
result in ineffective coordination of PMTCT services in Sub-Saharan African countries 
(Stringer et al., 2008). 
Contrary to what is obtainable in developed countries of the world, most Sub-
Saharan African countries have limited access to ARV regimens. Similarly, there exists 
scarce access to elective Caesareans or safe alternatives to breastfeeding (Stringer, et al.., 
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2008). This situation is also compounded by a lack of evenly distributed basic antenatal 
services. The resultant effect of this situation is the disproportionately high incidence of 
mother-to-child transmission of HIV in Sub Saharan African.   
The 2009 HIV estimate among pregnant women in eastern and southern Africa 
was 750,000 (Kasenga et al., 2007). Sub-Saharan Africa accounts for about 90% of the 
incidence of MTCT (UNAIDS, 2006). Figures 1 and 2 below show the number of adults 
and children receiving and eligible for ARV therapy and estimated coverage in low-and 
middle-income countries by region in December 2010.  
 
 
 
Figure 1: Number of Adults and Children Receiving and Eligible for ARV Therapy and 
Estimated Coverage in Low- and Middle-Income Countries by Region in December 
2010. 
Data Source: UNAIDS (2011). Retrived from www.unaids.org 
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Figure 2: Number of Adults and Children Receiving and Eligible for ARV Therapy and 
Estimated Coverage in Low- and Middle-Income Countries by Region in December 
2010. 
Data Source: UNAIDS (2011). Retrived from www.unaids.org 
For both figures 1 and 2  
Receive = Number of people receiving ARV therapy 
Need = Estimated number of people in need of ARV therapy 
The trend in the availability of PMTCT in low-and middle-income countries, by 
geographical region in 2010 is depicted in figures 3 and 4. 
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Figure 3: Estimated Number of Women Living with HIV Needing and Receiving ARV to 
Prevent New Infection Among Children, and Excluding Single-Dose Nevirapine in Low-
and Middle-Income Countries, by Geographical Region in 2010. 
Data Source: UNAIDS (2011). Retrived from www.unaids.org 
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Figure 4: Estimated Number of Women Living With HIV Needing and Receiving ARV 
to Prevent New Infection Among Children, and Excluding Single-Dose Nevirapine in 
Low-and Middle-Income Countries, by Geographical Region in 2010. 
Data Source: UNAIDS (2011). Retrived from www.unaids.org 
For both figures 3 and 4  
A = Estimated number of pregnant HIV women in need of ARV 
B = Number of pregnant HIV women on ARV 
Figure 5 and Table 3 show the estimated prevalence of HIV among women and 
the general population and PMTCT services in selected Sub-Saharan African countries. 
As shown in Figure 6, PMTCT services in Nigeria were as low as 3.6% in 2010 
(UNAIDS, 2011). The figure compares the HIV prevalence in the general population and 
among pregnant women in 2009 with the percentage of PMTCT services in 2010. Nigeria 
was seen to underperform at 4.7% in PMTCT services when compared with South Africa 
(94%), Tanzania (90.4%), Kenya (92.5%), Mozambique (86%), Uganda (81%), and 
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Zimbabwe (74%) (UNAIDS, 2010). This poor performance requires positive action on 
the part of Nigerian authorities. 
 
Figure 5: Estimated Prevalence of HIV Among Women and General Population and 
PMTCT Services in Selected Sub-Saharan African Countries 
Sources: UNAIDS (2010)-UNAIDS Report on the Global AIDS Epidemic; UNICEF 
(2009). Prevention of Mother-to-Child Transmission (PMTCT) of HIV.  
 
Figure 6 shows the percentage of women receiving ARV therapy to reduce HIV 
transmission during pregnancy, percentage of eligible children younger than 15 years old 
receiving ARV therapy in 2010 and the percentage of HIV testing among pregnant 
women in 2010. From this figure it could be seen that South Africa (95%) is 
outperforming other sub-Saharan African countries in the percentage of women receiving 
ARV therapy to reduce HIV transmission during pregnancy (UNAIDS, 2010). Similarly, 
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South Africa (95%), Zambia (94%), and Zimbabwe (90%) have a higher percentage of 
HIV testing among pregnant women in 2010 (UNAIDS, 2010). South Africa (58%) also 
has the highest number of eligible children younger than 15 years old receiving ARV 
therapy in 2010 as shown in table 4. 
 
 
Figure 6: Percentage of Women and Children Receiving Antiretroviral Therapy in 
Selected Sub-Saharan African Countries for the Prevention of Mother-to-Child HIV 
Transmission                                                                                                                                                                      
Blue=% of eligible children younger than 15 years old receiving ARV therapy in 
2010.  
Red=% of women receiving ARV therapy to reduce HIV transmission during 
pregnancy 2010. 
Green=% of HIV testing among pregnant women in 2010. 
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MTCT in Nigeria 
Data shows that among 388,864 new HIV infections which occurred in Nigeria in 
2012, only about 56,000 new HIV clients were put on ARVs (NACA, 2013). Nigeria is 
lagging behind countries such as South Africa and Ghana in ARV coverage. South 
Africa, which has about 350,000 new HIV infections annually, puts about 277,000 HIV-
positive persons on ARVs annually. In 2012 PMTCT coverage in Nigeria was about 
18%, which was one of the lowest in Sub-Saharan Africa. In contrast, South Africa and 
Ghana achieved over 95% and over 75% PMTCT coverage respectively (NACA, 2013). 
About a quarter of all babies born with HIV in the world are Nigerians (NACA, 2013). 
Pediatric ARV coverage and treatment is about 13% in Nigeria. This is considerably low 
when compared with South Africa’s coverage of 88% (NACA, 2013). To improve on its 
PMTCT coverage and ARV treatment, Nigeria is in the process of decentralizing its 
PMTCT and ARV treatments to primary care centers (NACA, 2013). 
In 2011, an estimated 210,000 pregnant women (15+) were living with HIV in 
Nigeria. Only 13% of these women were tested for HIV. Only 22% of pregnant HIV 
patients received ARV treatment in 2009. The estimated number of children (0-14) living 
with HIV in 2009 was 360,000 and prophylactic ARV was given to only 8% of HIV-
exposed infants (UNICEF, 2010). The Global HIV/AIDS initiative, Nigeria (GHAIN) is 
at the forefront in providing facilities for PMTCT services in Nigeria (Chabikuli et al., 
2013). GHAIN is supporting PMTCT programs in 157 sites across the 36 states of the 
Federation. The primary focus of the government is to incorporate PMTCT treatment into 
primary health care system in Nigeria (NACA, 2011). 
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As a result of the emergence of the HIV epidemic in Nigeria, a national health 
sector-based response was established in 1986 with the Federal, State and Local 
Government Area structures driving the response (FMH, 2010). In 2000, a national 
multisectoral response was put in place to combat HIV in Nigeria. This includes the 
establishment of a Presidential Council on AIDS (PCA) and National Action Committee 
on AIDS (NACA) to drive the response. Also, state Action Committees on AIDS 
(SACA) and Local Government Action Committees on AIDS (LACA) were also 
established (FMH, 2010). Several PMTCT sites were established in all major federal 
health care facilities (Ugboaja, 2011). These interventions are guided by the appropriate 
policies namely the National HIV/AIDS Policy, HIV and AIDS Emergency Action Plan 
(HEAP) and National Strategic Framework (NSF). 
 Prophylactic treatment for HIV-positive women in Nigeria include: 
• Co-trimoxazole 960mg once daily or every three days given to women with CD4 
cell counts below 200cells/ul,  
• Sulfadoxine-pyrimethamine for malaria and  
• Iron, folate and multivitamin supplement are given to HIV-positive patients.  
All infants born to HIV-positive mothers are given post-exposure prophylaxis. 
This includes a single dose of Nevirapine (NVP) of 2mg/kg within 72 hours and 
Zidovudine (ZDV) 2mg/kg twice daily for one week. A single dose of NVP 2mg/kg stat 
within 72 hours is given to infants where ZDV is not available (FMH, 2010). 
In summary, Nigeria is reported to have 3.6% HIV prevalence. In Nigeria there is 
an estimated 3.5 million HIV patients, which has a significant impact on the global HIV 
burden (UNAIDS, 2010). 58% of HIV-positive people in Nigeria are women. This has 
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resulted in a high population of pregnant HIV patients, showing a prevalence level of 
4.1% infection among pregnant women. This has translated into a staggering figure of 
210,000 pregnant HIV patients (Afe et al., 2011; NACA, 2011). Annually, there are 
56,000 births of HIV-positive babies in Nigeria (Oliver, et al., 2012). The uptake of 
interventions for preventing mother-to-child HIV transmission is low in Nigeria in spite 
of the staggering prevalence of pediatric HIV infection (Olugbenga-Bello et al., 2012). 
The national target in Nigeria is to achieve a 90% reduction in the mother-to-child HIV 
transmission by 2015 (NACA, 2011).   
PMTCT Services in Nigeria 
Skilled personnel deliver only 39% of births in Nigeria. Traditional birth 
attendants (TBAs) or relatives deliver 41% of births while the remaining 20% are 
unassisted deliveries (FMOH, 2010). Nigerian health care system is organized under a 
three-tier arrangement composed of primary, secondary and tertiary health facilities. In 
2003 provision of PMTCT services were initially restricted to 11 tertiary health facilities 
in the country (FMOH, 2010). The gradual scale-up of PMTCT services has brought the 
availability of PMTCT services to 640 facilities. In all, the formal health sector has about 
22,726 health care facilities. Grossly limited number of PMTCT or HCT (HIV counseling 
and testing) services is available in these facilities. Of the 22,726 health care facilities, 
only 63 tertiary, 482 secondary and 473 primary health facilities are providing PMTCT or 
HCT services (FMOH, 2010). PMTCT services are available in tertiary, secondary, 
primary, private and faith-based health facilities across the country while the government 
is striving to achieve a target of at least 90% PMTCT uptake by 2015 (NACA, 2011a). 
The policy thrust of the government is to decentralize PMTCT services from tertiary and 
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secondary facilities to primary care facilities to ensure accelerated scale-up towards 
elimination of mother-to-child transmission of HIV (FMOH, 2010). 
In 2010 the Nigerian government set the following goals for PMTCT program; 
• At least 90% of all HIV-positive pregnant women and breastfeeding 
infant-mother pairs receive ARV prophylaxis by 2015. 
• At least 90% of all HIV exposed infants have access to early infant 
diagnosis services by 2015. 
• At least 90% of pregnant women requiring ART for their own health 
receive life long ART. 
• At least 90% of all pregnant women have access to quality HIV 
counseling and testing by 2015. 
• At least 90% reduction in unmet need for family planning among women 
with HIV by 2015. 
• At least 50% reduction in HIV incidence among 15-49 years old women 
by 2015. 
(FMOH, 2010 P. 17) 
Due to poor implementation, the ministry of health has unequivocally admitted that 
Nigeria will not be able to achieve the above goals by 2015 (FMOH, 2012).      
Stigmatization and Discrimination of HIV Patients 
HIV infection has physical as well as psychosocial aspects. There is still a heavy 
stigma associated with the diagnosis of HIV in Africa (Alubo, Zwandor, Jolayemi & 
Omudu, 2002), with many consequences for HIV patients’ psychosocial well-being. 
There is high discrimination and stigma attached to HIV infection in Nigeria. This is 
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because the mode of transmission of HIV in Nigeria is predominantly through 
heterosexual means and there is general perception that people living with AIDS (PLWA) 
are people of low morals who have brought HIV/AIDS upon themselves (Alubo et al., 
2002). These people are generally regarded as “loose” people that deserve neither 
sympathy nor empathy.  
Research has shown that stigmatization and discrimination constitute major 
challenges to HIV treatment and prevention efforts (Reis et al., 2005). Discrimination and 
stigmatization associated with HIV constitute major barriers to HIV testing, counseling 
and status disclosure (Rankin et al., 2005). In spite of gains recorded in curtailing new 
infections and the treatment of HIV, the full benefit of national and the US Presidential 
Emergency Plan For Aids Relief (PEPFAR) programs are hampered by discrimination 
and stigmatization (Monjok, Smesny & Essien, 2010). Discrimination and stigmatization 
associated with HIV are believed to emanate from a culture of fear, ignorance and a lack 
of adequate information about HIV (Valdiserri, 2000). 
A study by Uwakwe (2000) on the effectiveness of HIV/AIDS educational 
program among BSc nursing students at the University of Ibadan revealed that 79% of 
nurses expressed reservations about caring for HIV/AIDS patients at the beginning of the 
study. After three months of intense instruction on HIV/AIDS, AIDS patient care and 
compliance with universal precaution, 53% of the nurses still expressed reservations 
about caring for HIV/AIDS patients. Similarly, Oyelese’s study on stigma, discrimination 
and ostracization of HIV patients in Nigeria (2004) revealed that a significant 
stigmatization and discrimination is still directed at HIV patients, albeit in subtle and 
suppressed manners.   
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Using a combination of semi-structured interview and focus group methodologies, 
Alubo et al (2002) investigated the acceptance and stigmatization of people living with 
HIV/AIDS (PLWA) in Benue state, Nigeria. A total of 40 PLWA and 10 family members 
were interviewed for the study while focus group discussions were held with male and 
female members of the community to assess their general perceptions of, acceptance of, 
and reactions to PLWA. Findings from this study showed that the level of stigmatization 
is high and the rate of acceptance is low. Fear of contracting this deadly disease and lack 
of knowledge about mode of transmission of the disease were found to be responsible for 
this trend, with some participants suggesting that PLWA be eliminated before they infect 
the entire community.    
Healthcare workers have also been found to discriminate against HIV patients 
(Reis et al., 2005: Sadob et al., 2006). Such discrimination results in poor quality care, 
breaches of confidentiality (Ehiri et al., 2005), and complete refusal to provide treatment 
(Sadob et al., 2006). Multiple studies in Nigeria have shown that healthcare professionals, 
including physicians, nurses and laboratory scientists in many cases have refused to treat 
or been unwilling to care for HIV patients (Reis et al., 2005: Sadob et al., 2006). Refusal 
to care for HIV patients is usually attributed to a lack of adequate knowledge about HIV. 
However, studies have shown that significant acceptance of HIV patients is achievable 
with adequate and continuous education (Ezedinachi et al., 2002; Fawole, Asuzu, 
Oduntan, & Brieger, 1999). 
The impact of stigmatization and discrimination on HIV patients may result in 
social isolation, may foster low self-esteem (Valdiserri, 2000), and discourage adherence 
to preventive practice (Nyblade, Stangle, Weiss, & Ashburn, 2009). Similarly, 
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individuals are discouraged from checking their HIV status and subsequently prevent 
sero-positive individuals from seeking treatment (Rankin et al., 2005). Vertical 
transmission of HIV is also adversely affected by stigmatization and discrimination, as 
many pregnant women may refuse or avoid voluntary counseling and testing which 
would enable them to know their status and subsequently commence treatment to prevent 
mother-to-child transmission of the infection (Odimegwu, Adedini, & Ononokpono, 
2013). Also, stigmatization may prevent HIV patients from disclosing their status to 
sexual partners and families. This could adversely affect the efforts to prevent the spread 
of the disease (Ehiri et al., 2005). Breastfeeding is a common practice in Sub-Saharan 
Africa, including Nigeria. Stigmatization and discrimination may prevent HIV-positive 
nursing mothers from practicing alternative feeding techniques, thereby exposing their 
babies to HIV infection, for fear of rejection or chastisement from the public (Okonkwo 
et al., 2007) In a nutshell, stigmatization is known to promote fatalism, social isolation 
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Herbal Treatment of HIV 
Herbal therapy includes the use of herbs, herbal materials, herbal preparations and 
finished products in the treatment of different disease conditions (WHO, 2002). Herbal 
therapy is used either as a complementary treatment or as an alternative treatment to 
conventional or orthodox medicines in treating different disease conditions (Onifade et 
al., 2011a; Patel, Bessong & Liu, 2011). Historically, herbal therapies have recorded 
groundbreaking successe,s as in the clinical success of quinine and quinidine isolated 
from the Cinchona tree bark and artemisinin from Artemisia annua used in the treatment 
of malaria (Igoli, Ogaji, Tor-Anyiin & Igoli, 2005). Ufo opioko (Ageratum conyzoides 
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Linn) is a herbal therapy that is reportedly widely used in treating HIV in Nigeria (Igoli et 
al., 2005). The efficacy of Ufu opioko (Ageratum conyzoides Linn) in the treatment of 
HIV is yet to be scientifically established.  
It is estimated that about 80% of Africans reportedly use herbal therapies in the 
treatment of many diseases (WHO, 2002). The inaccessibility and unavailability of 
orthodox medical treatment, especially in rural communities in developing countries, 
provides the impetus for the increased patronage of herbal therapies (Orisatoki & 
Oguntobeju, 2010). However, the increasing acceptability and popularity of herbal 
remedies is eliciting concern from orthodox health care professionals because of safety 
issues (WHO, 2002). The use of herbal remedies is not restricted to developing countries. 
Even in the United States, 35% of the American population is reported to use 
complementary and alternative medicine (CAM) (Lee, Andrade, & Flexner, 2006). 
Herbal medicine is reported to be the most commonly used CAM. 18.6% of adults in the 
U.S. reported using herbal therapy in 2002 (Tindle et al., 2005). 
The search for an HIV cure is currently assuming different dimensions. Apart 
from the use of conventional antiretroviral medications, the use of herbal remedies is 
growing in different parts of the world (Mills, Cooper, Seely & Kanfer, 2005; Orisatoki 
& Oguntibeju, 2010; WHO, 2002). Herbal therapy is reported to be higher among HIV 
patients even with the availability of ARV (Lee et al., 2006). The use of natural health 
products (NHP) is reported to be as high as 67% among HIV patients receiving 
conventional ARV (Gore-Felton et al., 2003). Among the NHP users, 63% reported the 
use of vitamin C, 54% multivitamin, 53% vitamin E, 53% garlic and 20-50% of patients 
reported using vitamin B12, vitamin B6, vitamin A, aloe, zinc, beta-carotene, 
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acidophilus, ginseng, selenium, Echinacea species, folate, Chinese herbs, marijuana, 
goldenseal and coenzyme Q10 (Standish et al., 2001). 
Herbal remedies are largely used to treat fungal and bacterial opportunistic 
infections that are associated with HIV infection (Kisangau, Lyaruu, Hosea, & Joseph, 
2007). Similarly, herbal remedies have been used as primary treatment modalities for 
HIV/AIDS and associated problems such as dermatological disorders, insomnia, 
weakness, nausea and depression (Hodgson & Rachanis, 2002). Herbal remedies are 
reported to have been used by individuals in different stages of HIV infection (Langlois-
Klassen, et al., 2007). 
Studies have shown that herbal remedies are effective or helpful in HIV treatment 
(De Clereq, 2000; Dharmaratne, Tan, Marasinghe & Pezzuto, 2002; Kong, Goh, Chia, & 
Chia, 2003; Kostova, 2006; Matthee, Wright & Konig, 1999; Onifade et al., 2011a). 
Different herbal remedies are currently used in the treatment of HIV in different parts of 
the world. In Sub-Saharan Africa, two herbal remedies used for HIV treatment are 
Hypoxis hemerocallidea (African potato – an immunostimulant) and Sutherlandia (Mills, 
Cooper, Seely & Kanfer, 2005; Orisatoki & Oguntibeju, 2010).  
The South African government has incorporated hypoxis into the primary health 
care system and used it as an immunostimulant in the treatment of HIV/AIDS (Mills et 
al., 2005). Hypoxis reportedly contains sterols and sterolins. These constituents of 
Hypoxis are believed to act as immune boosters but concrete evidence of this is lacking 
(Bouic et al., 2001). The corms of H. hemerocallidea are widely used in the treatment of 
immunity-related illnesses such as cancer, HIV/AIDS and the common cold. Herbal 
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remedies have gained governmental acceptance in South Africa despite a lack of 
empirical evidence of efficacy and safety (Mills et al., 2005). 
Amzat and Abdullahi (2008) reported that a study in Senegal showed that a herbal 
formulation known as METRAFAIDS was able to decrease viral load by more than 66% 
in 54% of HIV patient population. This remarkable efficacy was achieved without any 
adverse reaction during the course of this study. METRAFAIDS is now trademarked and 
has been patented by the association for the promotion of traditional medicine 
(PROMETRA) (Amzat & Abdullahi, 2008). 
Another study by Tumbare et al. (2012) on the safety and efficacy of a 
combination of three herbal drug preparations showed that 80% of the subjects achieved 
viral load reduction below detection level and the remaining 20% recorded a reduction in 
viral load. Included in this 80% was a patient with co-diagnosis of tuberculosis who was 
receiving anti-tuberculosis medications in conjunction with his herbal treatment. 
Tumbare et al. (2012) recorded no side effects in patients who were using both ARV and 
herbal therapies together. 
The Chinese government provided a dynamic response to combat HIV epidemic 
with the formation of a National Free Antiretroviral Treatment Programme (NFATP), 
which is also known as a comprehensive acquired immuno-deficiency syndrome (AIDS) 
response program. A tripartite approach is used in Chinese communities in the treatment 
of HIV. These approaches are:  
(a). Conventional antiretroviral medications (HAART), 
(b). Buyao which include tea, soups, tablets, herbal preparations and tonics, sold 
over-the-counter, and 
                                                                42 
 
(c). Traditional Chinese medicine (TCM) (Zou et al., 2012). 
Traditional Chinese herbal medicine (TCHM) is widely used in China to treat 
HIV. TCHM is used to enhance immunity, treat HIV symptoms, reduce medication side 
effects and improve quality of life (Liu, 2007). Many studies have shown that TCHM is 
effective in decreasing HIV RNA levels (Sangkitporn, 2005; Shi, & Peng, 2003), provide 
significant increase in CD4 counts (Shao, 2008; Wang et al., 2006), provide significant 
improvement of symptoms of oral candidiasis with no side effects (Jiang et al., 2009) and 
improve the symptom of diarrhea (Wang et al., 2008; Xu et al., 2011). TCHM has proven 
to significantly increase peripheral leukocytes with no serious adverse effects (Jiang et 
al., 2011), resulting in improvement of symptoms of anepithymia (loss of natural 
appetite) and nausea (Wang  et al.., 2008) and improvement in overall life satisfaction 
(Burack, Cohen, Hahn, & Abrams, 1996). However, some TCHM show no significant 
difference in CD4 count and symptom severity (Burack, Cohen, Hahn, & Abrams, 1996) 
and no significant difference in viral load (Wang et al., 2008; Wang et al., 2006) between 
treatment groups and placebo groups. TCHM is known to have undesirable effects such 
as gastroenterological adverse effects (Shi & Peng, 2003) and other adverse effects 
(Weber et al., 1999). 
An herbal formulation, known as SH, is reported to be effective in HIV treatment. 
SH, which is widely used in China, is a formulation containing five herbs (Sangkitporn et 
al., 2005). Each constituent of SH is reported to be an individually effective anti-HIV 
agent, and the combined herbs are also reported to possess anti-retroviral activity 
(Sangkitporn et al., 2005). A randomized, double blind placebo controlled clinical trial 
was conducted to investigate the effectiveness of co-administration of SH with 
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antiretroviral medications. Two groups of subjects were used. A group of 40 subjects 
were given a combination of Zidovudine (ZDV) 200mg, Zalcitabine (ddC) 0.75mg and 
SH herbs 2.5grams three times daily. A control group consisting of 20 subjects was 
administered a combination of ZDV 20mg, ddC 0.75mg and placebo 2.5grams three 
times daily for a period of 24 weeks. Findings from Sangkitporn et al. (2005) showed that 
HIV RNA from week 4 and beyond significantly decreased from the baseline value in 
both the experimental and control groups. But the SH group recorded a significantly 
lower HIV RNA compared to the control group. Similarly, the CD4 counts after 12 
weeks and beyond showed a significant increase in SH group from baseline value. 
Finding from this study showed that a combination of SH herbs with two nucleoside 
reverse transcriptase inhibitor has a greater antiviral ability than conventional 
antiretroviral medications (Sangkitporn et al., 2005). The combination of SH with 
conventional antiretroviral medications resulted in no serious adverse effects. 
 In a chemical study conducted by Onifade, Jewel & Okesina (2010) on the 
efficacy of herbal remedies used to treat HIV in Zaria (Kaduna state, Nigeria) and 
Osogbo (Osun state, Nigeria), it was found that about 20% of herbal homes have 
potentially effective herbal remedies for HIV infection. Sixty percent of these herbal 
homes were able to provide symptomatic treatment, but potentially toxic products were 
noted in 20% of the herbal homes (Onifade et al., 2010). 
Herbal remedies have been found to inhibit some steps associated with HIV 
replication (De Clereq, 2000; Kong, Goh, Chia, & Chia, 2003). Herbal remedies have 
shown to be effective in reducing viral load and increasing CD4 counts (Onifade et al., 
2011a). According to Matthee, Wright & Konig (1999) alkaloid-derived herbal remedies 
                                                                44 
 
such as Ancistrocladus korupensis obtained from tropical liana plant inhibit reverse 
transcriptase and HIV-induced cell fusion. Dharmaratne, Tan, Marasinghe & Pezzuto 
(2002) reported that Coumarin herbal remedy in the form of canolides obtained from a 
tropical forest tree, Calophyllum lanigerum, was classified as a potent non nucleoside 
reverse transcriptase inhibitor. Coumarin from plant sources and their analogs (i.e. 
synthetic coumarins) have shown to be potent nonnucleoside RT-inhibitors, or inhibitors 
of HIV-integrase, or HIV-protease (Kostova, 2006). 
Herbal Treatment of HIV in Nigeria 
Nigeria has embraced ARV therapy in the treatment of HIV. However, herbal 
remedies have also been used in HIV treatment in Nigeria since its discovery (Awodele et 
al., 2012). A descriptive cross-sectional survey conducted in Lagos, Nigeria showed that 
8.2% of respondents used herbal therapy as a complementary medicine with conventional 
ARV therapy (Awodele et al., 2012). Herbal therapies reportedly used include jobelyn 
(Sorghum bicolor plant leaves), garlic (Allicin, Y-glutamyl(s)-ally-L-Cysteine), ginger 
(Essential oil) and aloe vera (Hydroxyanthracene derivatives expressed as Barbaloin) 
(Awodele et al., 2012). Findings from Awodele et al. (2012) study showed marginal, but 
not significant, improvement in CD4 counts and viral load of HIV patients using these 
herbal therapies compared to those who do not use herbal therapies. 
In Nigeria, many herbal remedies have proven to be effective in the treatment of 
HIV (Elujoba, 2005). Mostly, herbal remedies have been effective in treating the 
opportunistic infections associated with HIV (Abere & Agoreyo, 2006; Elujoba, 2005). 
Findings from Mbah et al. (2007) showed that a widely used herbal medicine, neem 
leaves, is effective in HIV management as it is found to bring about significant increase 
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in CD4 and improvement in general well-being of HIV patients. Similarly, Baissea 
axillaries Hua is found to be effective in treating HIV opportunistic infections of bacteria 
origin (Abere & Agoreyo, 2006).  
Similarly, herbal remedies, such as a-Zam, which contain alkaloid have shown to 
be effective in the treatment of HIV (Bringmann et al., 1999). A-Zam is a herbal remedy 
used in HIV treatment in Nigeria. The exact components of a-Zam are not known. 
However, disclosure by the herbal therapist revealed that the major constituents of a-Zam 
are black seed (nigella sativa), honey and water (Onifade et al., 2011a). Phytochemical 
analysis of a-Zam revealed further constituents such as alkaloids, saponins, tannins, 
cardenolides and anthraquinones (Onifade et al.., 2011a). 
Previous use of a-Zam in the treatment of disease conditions is not found in the 
literature. However, the constituents of a-Zam are known to be used in treating different 
disease conditions. For instance, alkaloids such as physostigmine that are isolated from 
natural sources has gained acceptance as acetyl-and butyrylcholinesterase (BChE) 
inhibitors and is being used in the treatment of Alzheimer’s disease (Konrath, Passos, 
Klein-Junior & Henriques, 2013). Saponins are known to have direct beneficial effects on 
the heart and are useful in the treatment of heart and circulatory-related ailments. Saponin 
helps in reducing blood coagulation, cholesterol and sugar levels in blood while helping 
to promote systemic immunity and enzymic functions (Purmova & Opletal, 1995). Plant 
tannins are known to be useful in decreasing inflammation of ulcerative colitis (Clinton, 
2009). Cardenolide is a class of cardiac glycosides. Cardiac glycosides have a long 
history of use in the treatment of congestive heart failure (Schoner & Scheiner-Bobis, 
2007). Cardenolides are known to bind to the sodium pump producing a resultant effect 
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on multiple signaling pathways leading to remarkable anti-tumor effects (Mijatovic et al., 
2006). Anthraquinone is reported to have diverse pharmacologic potentials. It is known to 
possess antiviral activities against HIV-1, human cytomegalovirus (HCMV), vesicular 
stomatitis virus, herpe simplex virus type 1 and 2, parainfluenza virus and vaccinia virus 
(Dave & Ledwani, 2012). 
A clinical study conducted by Onifade et al. (2011a) on the effectiveness of a-
Zam in HIV treatment show that a-Zam is effective in increasing the CD4 count and in 
reducing the viral load of HIV patients. Findings from Onifade et al. (2011) show that 
there was a statistical significance difference (p<0.05) between pre-treatment CD4 count 
and post-treatment CD4 count. Also, a significant reduction in viral load was obtained 
after treatment with a-Zam. Onifade et al. (2011a) study show no negative drug 
interaction in patients that used both ARV and a-Zam. 
Nigerian Government Policy on Herbal Medications 
In spite of the astronomical usage of herbal remedies in the treatment of diseases 
in Nigeria, the Nigerian government appears not to have a clearly defined policy on the 
use of herbal remedies. The Nigerian government, through the National Agency for Food 
and Drug Administration (NAFDAC) and Nigeria Institute of Pharmaceutical Research 
and Development (NIPRID), was in the process of conducting limited clinical trial on 
selected herbal medications used for HIV treatment (Obinna, 2013). One of the core 
mandates of NAFDAC is to ensure that only high quality, safe, and effective herbal 
medicines are released into the Nigerian market. Stemming from the proliferation of 
claims of herbal cure, the NAFDAC had set up a National Expert Committee to work in 
conjunction with NIPRID to verify claims of potency of herbal HIV medications. The 
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expect committee was scheduled to commence evaluation of herbal medicine in the first 
quarter of 2014 (Obinna, 2013). But as it is typical of Nigerian agencies, no information 
is found on the activity of this committee, and it is not clear if the committee has 
commenced work as scheduled. 
Safety of Herbal Remedies Used in HIV Treatment 
There is an erroneous belief that herbal remedies are harmless because they are 
obtained from natural sources. However, health care professionals have always been 
concerned about the risks associated with the use of herbal therapy (Corns, 2003). 
Despite this, increasingly large numbers of patients continue to use herbal remedies to 
treat minor and major infections (Gardiner, 2007; WHO, 2002) because of their 
accessibility, availability, affordability and acceptability in many communities in 
developing countries (Amzat & Abdullahi, 2008; Tamuno, 2011). 
Possible interactions between herbal medicine and ARV could lead to therapeutic 
failure (Awodele et al., 2012). Studies have shown that herbal therapies such as St. John’s 
wort, herbally derived vitamins and garlic are capable of causing negative drug 
interaction with antiretroviral medications (Dhalla et al., 2006; Nyika, 2007). Similarly, 
Awodele et al. (2012) showed that concurrent use of herbal remedies with ARV could 
result in potential adverse effects. Studies have shown that garlic has the potential to 
reduce pharmacokinetic concentration of Saquinavir in plasma and cause a reduction in 
the effectiveness of ARV (Borrelli, Capasso, & Izzo, 2007; Piscitelli, Burstein, Welden, 
Gallicano, & Falloon, 2002).  
Investigation of the toxicological profile of herbal remedies has largely been 
carried out using animal populations. Onifade et al. (2011b) conducted a toxicological 
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study of a-Zam using 20 rats that were subdivided into four different groups. Different 
dosages of a-Zam (400mg/kg, 800mg/kg, 1600mg/kg and 3200mg/kg) were administered 
daily to each group over a period of 84 days to test for chronic toxicity after the initial 
acute toxicity test. A control group was administered rat chow and water only. Physical 
examination and hematological studies were performed. Histological studies were done at 
85th day of drug administration. Onifade et al. (2011b) found no physical or physiological 
alteration in any group. Similarly, blood test and histological studies only showed mild to 
moderate derangement. Renal function test (electrolytes, urea & creatinine) and liver 
function test (high density lipoprotein, HDL, triglyceride, low density lipoprotein and 
total cholesterol) were done. It was found that, even at a higher daily dose of 3200mg/kg, 
a-Zam was safe, as it resulted in no severe injury in any of the groups. 
The use of herbal remedies in conjuction with ARV is likely to produce beneficial 
or detrimental effects. When St. John’s Wort, which is generally used by HIV patients, is 
taken with protease inhibitor (PI) and non-nucleoside reverse transcriptase inhibitor 
(NRTI) can cause a reduction in PI and NRTI concentration leading to possible 
therapeutic failure (Mannel, 2004). As a result of the possible safety issues associated 
with herbal remedies when taken alone or with ARV, it is important that health care 
professionals should always review herbal remedies that patients may be taking during 
the course of treatment. 
Conclusion 
A-Zam is found to be beneficial in increasing the CD4 counts and in reducing the 
viral load in Nigerian HIV patients (Onifade et al., 2011a). However, Onifade et al. 
(2011a) study did not investigate in detail the experience of patients who used a-Zam. 
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Also, the study did not compare the symptom and treatment outcome of patients using the 
herbal remedy a-Zam with those patients using conventional antiretroviral medications. 
As a result of these identified knowledge gaps, it is imperative to conduct study to further 
our knowledge of the experience of HIV patients in Nigeria in the course of using herbal 
remedies. Therefore, the goals of this study are to investigate the effectiveness of the 
herbal remedy a-Zam and to investigate the impact of herbal remedies and HAART on 
HIV symptoms and patients’ quality of life. 
Table 1: Epidemiology of HIV in Nigeria: Key Facts 
 
 
 
2008 2012 
National Median HIV Prevalence 
 
4.6% 4.1% 
Estimated Number of PLWHIV 
 
2,980,000 3,459,363 
Annual AIDS Deaths 
 
192,000 217,148 
Number requiring Antiretroviral Therapy 
 
857,455 1,449,166 
New HIV infections 
 
336,379 388,864 
Total number of AIDS orphans 
 
2,175,760 2,193,745 
Source: National Agency for the control of AIDS (NACA, 2012). Federal Republic of 
Nigeria Global AIDS Response Country progress report in 2012. Retrieved from 
http://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012co
untries/Nigeria%202012%20GARPR%20Report%20Revised.pdf 
                                                                50 
 
Table 2: Trends in HIV incidence in Nigeria 2010 and 2011 
  2010 2011 
Total population 319,322 310,322 
Adult > 15  years 247,718 243,430 
Children < 15 years 71,604 67,190 
Male 144,258 140,169 
Female 175,064 170,431 
 
Source: National Agency for the control of AIDS (NACA, 2012). Federal Republic of 
Nigeria Global AIDS Response Country progress report in 2012. Retrieved from 
http://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012co
untries/Nigeria%202012%20GARPR%20Report%20Revised.pdf 
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Table 3: Estimated Prevalence of HIV among Women, Children and General Population 
in Selected Sub-Saharan African Country and the Percentage of PMTCT Services.  
Sub-Saharan 
African 
Countries 
HIV 
prevalence 
in 2009 (%) 
HIV 
prevalence 
among 
pregnant 
women 2009 
PMTCT 
Services (%) 
2010 
Number of 
Pediatric (0-
14) HIV 
2009 
Number of 
pregnant 
women 
living with 
HIV 2009 
Nigeria 
 
3.6 3.6 4.7 360,000 230,000 
South Africa 
 
17.8 25.6 94 330,000 330000 
Tanzania 5.6 5.5 90.4 160,000 73,000 
 
Kenya 
 
6.3 5.6 92.5 180,000 87,000 
Zimbabwe 14.3 
 
14.3 74 150,000 62,000 
Mozambique 
 
11.5 10.4 86 130,000 98,300 
Uganda 6.5 6.1 81 150,000 96,700 
 
 
Sources:UNAIDS (2010)-UNAIDS Report on the Global AIDS Epidemic; UNICEF 
(2009). Prevention of mother-to-child Transmission (PMTCT) of HIV.  
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Table 4: Percentage of Women and Children receiving Antiretroviral Therapy in Selected 
Sub-Saharan African Countries for the Prevention of Mother-to-Child HIV Transmission 
 
Sub-Saharan 
African Countries 
% of women 
receiving ARV 
therapy to reduce 
HIV transmission 
during pregnancy 
2011 
% of eligible 
children younger 
than 15 years old 
receiving ARV 
therapy 2010 
HIV Testing among 
pregnant women 
2010 (%) 
Nigeria 
 
18 13 14 
South Africa 
 
95 58 95 
Tanzania 
 
74 14 86 
Kenya 
 
67 31 83 
Zimbabwe 
 
54 34 90 
Ghana 
 
75 14 68 
Mozambique 
 
51 20 87 
Uganda 
 
45 22 63 
Zambia 
 
86 31 94 
Lesotho 
 
62 25 57 
 
Sources:UNAIDS (2010)-UNAIDS Report on the Global AIDS Epidemic; UNICEF 
(2009). Prevention of mother-to-child Transmission (PMTCT) of HIV.  
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CHAPTER 3 
RESEARCH METHOD AND DESIGN 
Introduction 
 This chapter discusses the research design and methodological approaches used in 
this study.  In this chapter, the aspects of the study that will be discussed are research 
design, research setting, gaining access, instrument/questionnaire, sample and sampling 
plan, recruitment problems, inclusion and exclusion criteria, control of threats, protection 
of human subjects, data collection, methods and procedures, data analysis and 
management, methods used to analyze research questions, trustworthiness of research 
data, eliminating confounding variables and summary statement. 
This is a comparative analysis study designed to compare the effectiveness of 
conventional antiretroviral (ART) medications with a combination therapy of ART and 
herbal therapies as they are already used by Nigerian HIV patients. The study would 
consist of two parts namely the pilot study and the actual study.  
The Pilot Study 
 The pilot study was designed to test the reliability of the two instruments used in 
obtaining data from the subjects. The two instruments used for data collection are the 
brief version of the World Health Organization Quality of Life Instrument for HIV 
(WHOQOL-HIV BREF) (WHO, 2012) and the Sign and Symptom Check-List for 
persons with HIV disease (SSC-HIVrev) (Holzemer et al., 2001). Although these two 
questionnaires have been widely tested among different populations, the instruments have 
not been tested extensively among Nigerian HIV population. The integrity of the data 
obtained from this study is a function of the reliability of the instruments used in data 
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collection. The researcher considered it imperative to ascertain the reliability of the study 
instruments before they are used in the main study. The pilot study also enables the 
researcher to socialize into the research environment in Nigeria, to assess and identify 
possible problems that could arise during questionnaire administration and strategize to 
resolve any problem before the actual study. 
Questionnaire Administration for Pilot Study 
 Before the actual study, a pilot study was carried out. This is a reliability pilot 
test of the two instruments (SSC-HIVrev and WHOQOL-HIV BREF) used in this 
study. Both questionnaires were administered to 20 randomly selected HIV patients 
receiving treatment at the State Specialist Hospital Osun-State, Nigeria. Randomization 
was done by flipping a coin. A coin was flipped for each subject that agrees to participate 
in the study. If the coin comes up “heads”, the subject was included in the pilot study. If 
the coin comes up “tails”, the subject was excluded from the pilot study. This method 
provided equal opportunity for all participants to be included in the actual study, 
irrespective of characteristics such as sex, age, tribe, or educational levels (Polit & Beck, 
2012). The research assistant helped situate the patients for questionnaire administration. 
Questionnaires were administered by the principal investigator via phone 
and/or Skype. Each participant was required to put completed questionnaire in an 
envelope provided for that purpose and sealed. The sealed envelope was given to the 
research assistant. All sealed envelopes were sent to the researcher in the U.S. for 
reliability test.  
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Analysis of Pilot Study 
Data obtained from the pilot study was analyzed using IBM SPSS Statistics 22 
software. The Cronbach alpha reliability tests were carried out for both the SSC-HIVrev 
and WHOQOOL-HIV Bref. Similarly, descriptive analyses were done to analyze the 
demographic information of the pilot study participants. The pilot study helped the 
researcher to determine if the two instruments are suitable for use in the actual study. 
The Actual Study 
The actual study is divided into two parts namely; 
1. Collection and analysis of physiological data (CD4 counts) and 
2. Collection of data about patients’ symptom experience and quality of life 
during treatment with ARV only and combination of ARV and herbal 
remedies. 
Collection and Analysis of Physiological Data (CD4 Counts) 
 The first component of this study was the collection and analysis of the 
physiological data. The CD4 was used as a biomarker of HIV treatment outcome. The 
initial intention of this researcher was to obtain and analyze the CD4 counts and the viral 
load of HIV patients during the course of treatment.  But data regarding viral load was 
not available in the Specialist Hospital and in many clinics in Nigeria. The CD4 counts 
were obtained from patients’ medical records. The purpose of the quantitative 
comparative analysis was to examine the impact of ARV only and combination of ARV 
and herbal therapy on CD4 counts of HIV patients during treatment. This component 
involved the analysis of the improvement in the CD4 counts of patients taking ARV only 
and those using combination of ARV and herbal remedies during the course of treatment. 
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Each participant’s CD4 counts were obtained from patients’ medical records by the 
record staff. To ensure credibility of study results, only CD4 counts results obtained from 
patients’ medical records were used. The CD4 counts that were measured before the 
commencement of treatment were used as baseline CD4 counts. CD4 counts obtained at 6 
months post treatment were used as post treatment CD4 counts. Six month duration was 
used because CD4 count is typically expected to increase rapidly in the first few months 
of ARV treatment, followed by a more gradual increase until an optimum count is 
achieved (Gengis & Deeks, 2009). 
Collection of Patients’ Symptom Experience and Quality of Life Data During 
Treatment 
 
The second part of the actual study included the administration of dual 
questionnaires to Nigerian HIV patients who were taking conventional antiretroviral 
medications only (ARV group) and those who were taking a combination of conventional 
antiretroviral medications and herbal remedies (combined group). The focus of the 
questionnaire was to compare the experience of these two groups in the course of their 
respective therapies. The goal was to investigate the impact of treatment on relief of HIV 
associated symptoms and the patients’ quality of life in the course of treatment. This was 
done by administering questionnaires to obtain information about treatment experience 
and patients’ quality of life during the course of their treatment with herbal remedies 
and/or conventional antiretroviral medications.  
Questionnaire administration for the actual study was done in a fashion similar to 
that of the pilot study. Each participant enrolled in the actual study was given the two 
questionnaires. The research assistant helped situate the patients for questionnaire 
administration. Questionnaires were administered by the principal investigator via phone 
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and/or Skype. After the completion of the questionnaires, participants were required to 
put completed questionnaires in an envelope provided for that purpose. The envelopes 
were sealed by each participant before handing it over to the research assistant. All sealed 
envelopes were sent to the researcher in the U.S. for analyses.  
Analysis of Actual Study 
Data generated from the actual study was analyzed using IBM SPSS Statistics 22 
software. Descriptive statistics was used to analyze the demographic data (age, gender, 
and ethnicity) while inferential statistics was used to draw conclusion from study data. 
Pair sample t-test was used to compare the difference between pre-treatment CD4 counts 
and post treatment CD4 counts within each group. Independent t-test was used to 
compare the difference between pre-treatment CD4 counts and post treatment CD4 
counts across both groups (i.e. between the ARV group and the combined group). 
Analysis of covariance (ANCOVA) was used to statistically control the effect of baseline 
CD4 counts and to examine the difference between the baseline and post treatment CD4 
counts.  
Research Questions 
This study was designed to answer the following questions: 
1. How do CD4 counts differ after treatment with antiretroviral medications only?” 
2. How do CD4 counts differ after treatment with a combined therapy of herbal 
treatment and conventional antiretroviral medications? 
3. What is the difference in CD4 counts of patient taking ARV only and those taking 
a combination of herbal therapies and conventional antiretroviral medications? 
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4. What is the difference in the symptom experience of patients taking ARV only 
and those taking a combination of herbal therapies and conventional antiretroviral 
medications? 
5. What is the difference in the quality of life of patients taking only ARV, and those 
taking a combination of herbal therapies and conventional antiretroviral 
medications? 
Research Design 
This study is designed to start with a pilot test. This is a reliability test of the two 
instruments (SSC-HIVrev and WHOQOL-HIV BREF) used in data collection. Both 
questionnaires were administered to twenty randomly selected HIV patients receiving 
treatment at the State Specialist Hospital Osun-State, Nigeria. The research assistant 
helped situate the patients for questionnaire administration. The questionnaires were 
administered via phone and/or Skype. Each participant was required to put completed 
questionnaire in an envelope provided for that purpose and sealed. The sealed envelope 
was given to the research assistant. All sealed envelopes were sent to the researcher in 
the U.S. for reliability test.  
After the reliability test, the actual study commenced. The actual study compared 
the effectiveness of ARV only with combined therapy of ARV and herbal remedies 
among Nigerian HIV patients. Using power calculation (Cohen, 1988), 110 participants 
were drawn from Nigerian HIV patients using conventional antiretroviral medications 
only and those using a combination of herbal remedies and conventional antiretroviral 
medications. Two groups of matched randomly selected HIV participants were utilized. 
Each group was composed of 55 participants. Group A participants were drawn from 
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patients who were using conventional antiretroviral medications only. Group B 
participants were drawn from patients who were using a combination of herbal therapies 
and conventional antiretroviral medications for their treatment. Subjects were placed in a 
group on the basis of the treatment protocol (medications) used in the management of 
their HIV prior to contact for this study. No participants were required to change the kind 
of medication he/she was taking prior to contact for this study.  
Participants in each group were selected randomly from matched subjects that are 
similar in terms of important extraneous variables. For each group, subjects with similar 
treatment protocol, same treatment duration and same duration of HIV diagnosis were 
included in the study. Subjects in each group have started their treatment about the same 
time and taking the same antiretroviral medications. All participants were diagnosed 
within the last two years and also commenced treatment in the last two years. All patients 
receiving ARV treatment at Osun State Specialist hospital received first and second line 
HAART. Specifically, a combination of AZT+3TC+NVP (300mg +150mg +200mg) bd 
or AZT+3TC(FTC)+ EVF (300mg+150mg+600mg) or TDF+3TC+EVF ( 300mg 
+150mg +600mg ) and 2nd line, 3TC+TDF+LPV/r or with ATV/r are the treatment of 
choice at State Specialist Hospital, Osun. The herbal medications used by participants in 
this group include a-zam, ufo-opioko and numerous herbal concoctions popularly known 
as “agbo” in western part of Nigeria. The herbal medications were prescribed by non-
orthodox traditional medical practitioners. 
The methods described above helped to eliminate extraneous variables that could 
affect study results. From the matched samples, participants in each group were selected 
by flipping a coin. For each group, a coin was flipped for each subject who agreed to 
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participate in the study. If the coin came up “heads”, the subject was included in the 
actual study. If the coin came up “tails”, the subject was excluded from the study. This 
method provided equal opportunity for all participants to be included in the actual study, 
irrespective of characteristics such as sex, age, tribe, or educational levels (Polit & Beck, 
2012).  
Symptoms assessment was done using the Sign and Symptom Check-List for 
persons with HIV disease (SSC-HIVrev) (Holzemer et al., 2001). The quality of life 
assessment was done using the brief version of the World Health Organization Quality of 
Life instrument for international assessment of HIV/AIDS (WHOQOL-HIV BREF) 
(WHO, 2012). The physiologic assessment was done by collecting and analyzing CD4 
counts obtained from patients’ medical records. To protect the integrity of the study, 
questionnaire administration was conducted in the clinic during clinic hours. 
Arrangements were made to provide transport assistance to all subjects that have 
difficulty with transportation.  
Research Setting 
A designated area was provided for the purpose of data collection and 
administration of questionnaires to patients. This space was used throughout the duration 
of the study. To promote the integrity of data collection process and prevent the data from 
being compromised, all questionnaires and interviews were carried out in this location. It 
is necessary to dedicate a specific space for the administration of the questionnaire, as 
this would ensure that questionnaires were administered under a controlled environment. 
Trained research assistant was present at the time of the questionnaire administration. 
The principal investigator administered the questionnaire over the phone.  
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Gaining Access 
In order to gain access to the subjects for this study, there was collaboration with 
HIV specialist hospital in Osun State, Nigeria, as well as with physicians, scientists and 
researchers in this center. Collaboration with these professionals helped to facilitate 
necessary access to study subjects. The stigma and discrimination attached to HIV 
infection initially made the recruitment of subjects extremely difficult. Many scientists 
and researchers were contacted but many of them were unwilling to provide access to 
their HIV patients. After extensive contacts, a seasoned HIV scientist and researcher 
committed to helping provide access to potential subjects. Similarly, two medical doctors 
agreed to help in the recruitment efforts. A lot of resistance was encountered from 
subjects but the strong assurance of confidentiality eventually persuaded some of the 
patients contacted to agree to participate in the study. Contact was established with the 
patients with the help of the care providers who coordinated their treatment. Recruitment 
fliers were distributed to patients receiving treatment at the hospital. The process of 
establishing contact with the patients was done with strict adherence to confidentiality. 
Only patients who consented to participating in the study were included in this study.  
Instruments/Questionnaires 
Data collection was done using two well-tested instruments. This study seeks to 
gain insight into the changes that occur in symptoms and quality of life of HIV patients 
during treatment with antiretroviral medications only and with a combination of herbal 
therapies and conventional antiretroviral medications. Two instruments that 
incorporate/embed these two constructs were used in data collection. The quality of life 
of subjects was measured using the brief version of the World Health Organization 
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Quality of Life Instrument for HIV (WHOQOL-HIV BREF) (WHO, 2012). The 
symptom outcome was measured using the Sign and Symptom Check-List for persons 
with HIV disease (SSC-HIVrev) (Holzemer et al., 2001).  
WHOQOL-HIV BREF Instrument 
Investigation of the quality of life of HIV patients was done using the brief 
version of the World Health Organization Quality of Life Instrument for International 
Assessment of HIV/AIDS (WHOQOL-HIV BREF). This instrument provides insight into 
the quality of life of participants in the course of their treatment with herbal remedies 
and/or conventional antiretroviral medications. This instrument also provided an 
opportunity for patients to provide information on their experiences in the course of their 
treatment. According to the World Health Organization, quality of health (QOL) is 
defined as “an individual’s perception of their position in life in the context of the culture 
and value system in which they live, and in relation to their goals, expectations, standards 
and concerns”  (WHO, 2012 p. 3). Looking beyond the mechanistic focus of medicine on 
the treatment of the signs and symptoms of diseases, the WHO quality of life assessment 
instrument provides a tool that extends beyond the traditionally used indicators of disease 
morbidity and mortality (Sharpe, 1994).  
The WHOQOL-HIV was developed from an extensive test of 115 questions that 
incorporate the WHOQOL-100 in 10 centers around the world (WHO, 2012). The quality 
of life assessment tool is a valuable instrument in understanding the impact of HIV 
infection on individual lives (O’Connell, Skevington, Saxena, WHOQOL HIV Group, 
2004). The WHOQOL instrument is individualized, as it measures the satisfaction of 
individuals vis-a-vis the impact of disease condition on vital aspects of their lives and 
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their interpretation of such experience (Skevington, Lotfy, O’Connell, 2004). The 
WHOQOL-HIV BREF, used in this study, is an abridged version of the original 
WHOQOL-HIV assessment instrument. The brief version became necessary because of 
the cumbersome and time-consuming nature of the original version (WHOQOL-HIV), 
which made it difficult to be used in large studies or in resource constraint regions like 
sub-Saharan Africa. 
The WHOQOL-100 assessment version is a cross-culturally valid assessment 
instrument of wellness and well-being (Skevington, Lotfy, O’Connell, 2004). WHOQOL-
100 is operationalized through 100 items that denote 25 facets organized into six domains 
(WHOQOL Group, 1998). The conceptualization of WHOQOL instrument is based on 
the realization that the determinants of health status could not be completely understood 
through the measure of disease alone. Progressively, health status measures have come to 
be conceived as incorporating both the objective measures of final health status and 
subjective measures of health and well-being (Muldoon, Barger, Flory, & Manuck, 1998; 
Wood-Dauphine, 1999). 
Although many instruments have been previously developed for measuring the 
quality of life of HIV patients, the WHOQOL-HIV instrument provides a unique 
opportunity for cross-cultural measurement of the quality of life of people living with 
HIV/AIDS. Some of the previously developed quality of life assessment instruments for 
HIV include the HIV overview of problems-evaluation system (HOPES) (O’Leary et al., 
1998) and the medical outcomes study-HIV (Smith et al., 1996). The WHOQOL-HIV has 
shown a high level of adaptability, as its use has extended beyond HIV patients. The 
instrument is suitable for assessing the quality of life outcomes resulting from multiple 
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opportunistic infections associated with HIV infection such as tuberculosis (Deribew et 
al., 2009), depression (Pereira, Martins, Alves, & Canavarro, 2014) and Hepatitis C 
(Preau et al., 2008). The instrument can be used by a broad spectrum of HIV patients at 
different stages of infection (O’Connell, Saxena, Skevington, for the WHOQOL-HIV 
Group, 2004) and by specific subgroups such as sex workers, injecting drug users, and 
homosexual males (O’Connell & Skevington, 2012).  
The WHOQOL-HIV instruments have gained wide acceptance internationally, 
and different versions have been used across nations to measure quality of life of 
HIV/AIDS patients in Iran (Razavi et al., 2012), in Taiwan (Fang et al., 2002; Hsiung et 
al., 2011), in India (Chandra et al., 2006) in Burkina Faso (Bakiono et al. 2014), in Italy 
(Starace et al., 2002), in Rwanda (Mutimura, Stewart & Crowther, 2007), in Brazil 
(Berlim, Pavanello, Caldieraro, & Fleck. 2005) and in Nigeria (Agu et al., 2012; 
Fatiregun et al., 2009; Mofolorunsho et al., 2013; Odili et al., 2011).  
The WHOQOL-HIV BREF instrument consists of 31 items using a five point 
Likert-type scale. The items are distributed into the following six domains: physical 
health domain, psychological health domain, level of independence domain, social 
relationship domain, environmental domain and spirituality/religion/personal beliefs 
domain. The physical health domain measures pain and discomfort, energy level, fatigue, 
sleep and rest. The psychological health domain measures positive and negative feelings, 
thinking, learning, memory and concentration, self-esteem, body image, and appearance. 
The level of independence domain measures mobility, daily life activities, level of 
dependence on medication or treatment and work capacity. The social relationship 
domain measures personal relationship, social support and sexual activity. Environmental 
                                                                65 
 
domain measures physical safety and security, home environment, financial resources, 
health and social care, accessibility and quality, opportunities for acquiring new 
information and skills, participation in and opportunities for recreation and leisure 
activities and physical environment. Spirituality/religion/personal beliefs domain 
measures forgiveness and blame, as well as concerns about future and death and dying 
(Odili, Ikhurionan, Usifoh, & Oparah, 2011). 
Validity and Reliability of WHOQOL-HIV Instrument 
The WHOQOL-HIV has been widely evaluated for reliability and validity in 
different parts of the world. In Iran, Razavi et al. (2012) assessed the reliability of the 
instrument using Cronbach’s α (alpha) for internal consistency and found the 
Cronbach’s alpha for the six domain to be 0.8 (for spiritual/religion/personal beliefs 
domain), 0.78 (level of independence domain), 0.72 (psychological domain), 0.65 
(environmental domain), 0.63 (social relationships domain), and 0.61 (physical domain) 
showing that the instrument has good reliability. The French version of WHOQOL-HIV 
is reported to have high reliability with Cronbach’s alpha of 0.944 (for 
spiritual/religion/personal beliefs domain), 0.94 (level of independence domain), 0.937 
(psychological domain), 0.938 (environmental domain), 0.94 (social relationships 
domain), and 0.942 (physical domain) (Reychler, Caty, Vincent, Billo, & Yombi, 2013). 
Similarly, the Malay version was found to have internal consistency ranging from 0.60 to 
0.87 across all the domains indicating that the Malay version of WHOQOL-HIV is a 
valid and reliable instrument for measuring the quality of life of HIV patients (Saddki et 
al., 2009). The Nigerian version of WHOQOL-HIV BREF has good internal consistency 
and reliability with Cronbach’s alpha ranging between 0.81 and 0.85 (Akinboro et al., 
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2014). Akinboro et al. (2014) reported the Cronbach’s alpha for the six domains to be 
0.81 (physical domain), 0.81 (psychological domain), 0.82 (level of independence 
domain), 0.83 (social relationships domain), 0.83 (environmental domain), and 0.85 (for 
spiritual/religion/personal beliefs domain). 
SSC-HIVrev Instrument 
The other information collected in this study was the participants’ symptom 
experience in the course of their treatment with herbal remedies and conventional 
antiretroviral medications. The Sign and Symptom Check-List for persons with HIV 
disease (SSC-HIVrev) (Holzemer et al., 2001) was used to evaluate symptom experience 
and/or improvement. This instrument consists of six symptom clusters, namely: 
malaise/weakness/fatigue (consisting 6 items), confusion/distress (4 items), fever/chills (4 
items), gastrointestinal discomfort (4 items), shortness of breath (3 items) and 
nausea/vomiting (3 items). Specifically, the symptoms cluster to be evaluated are fatigue 
(muscle aches, weakness, painful joint, fatigue), fear (difficulty concentrating, 
depression, memory loss, fear/worries), fever (fever, chills, day sweats, night sweats), GI 
upset (loose stool, diarrhea, gas/bloating, abdominal pain, nausea and vomiting), 
shortness of breath (shortness of breath at rest, wheezing and shortness of breath with 
activities), sore throat (sore throat, painful swallowing, mouth ulcers, and white spots in 
mouth/thrush), numbness (numbness/tingling of arms, hands/fingers, legs, feet/toes), 
headache (dizziness, headaches, heart racing, chest pain), rectal itch (rectal itching, 
bleeding and discharge), and bruising/bleeding (sore/bleeding gums, nose bleeds, easy 
bruising, blood in spit/sputum). Body changes (weight gain, concern over weight gain, 
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hump on back of neck/shoulders) was omitted from this questionnaire because it was 
culturally not considered to be an important factor for the population in this study.  
Validity and Reliability of SSC-HIVrev Instrument 
To control the threat to internal validity, extensively used and well-tested 
instruments was used for data collection. The Sign and Symptom Check-List for persons 
with HIV disease (SSC-HIVrev) (Holzemer et al., 2001) is a reliable and highly valid 
instrument. This instrument is reported to have high internal validity. The six symptom 
clusters, the number of items in the factor and the Cronbach’s alpha reliability estimates 
for this instrument were Malaise/Weakness/Fatigue (six items with Cronbach alpha of 
0.90), Confusion/Distress (four items with Cronbach alpha of 0.90), Fever/Chills (four 
items with Cronbach alpha of 0.85), Gastrointestinal Discomfort (four items with 
Cronbach alpha of 0.81), Shortness of Breath (three items with Cronbach alpha of 0.79) 
and Nausea/Vomiting (three items with Cronbach alpha of 0.77 (Holzemer et al., 2001, p. 
1041). The reliability estimate of the instrument ranges between 0.76 to 0.94, showing 
strong reliability and validity for this instrument. 
Sample and Sampling Plan 
Using power analysis (Cohen, 1988), 110 subjects (each group was composed of 
55 subjects) were drawn among HIV patients receiving treatment at the Specialist 
Hospital, Osun- State, Nigeria. This hospital was chosen because of the cosmopolitan 
nature and large population of Osogbo, the location of the hospital. Osogbo is the capital 
city of Osun state. The city has a population of approximately 250,951. This site provided 
access to different ethnic groups in Nigeria, which could provide a broad generalization 
for the study findings. The sample size was based on .05 significance level with an effect 
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size of 0.4 and power of 0.8. To account for attrition from the study, an additional 15 
percent increase in sample size was factored in. 
Recruitment Problems 
Selection criteria were based on the diagnosis of HIV. For the purpose of this 
study, patients who have used or were using only herbal remedies for their HIV treatment 
were contacted for participation in this study. However, it was very difficult to recruit 
into this group. It appears that patients using only herbal therapy were trying to hide their 
HIV status from their families, friends, and orthodox health care providers. Several 
attempts were made to enlist patients into this group. The identified patients in the herbal 
group only stalled this study for several months, as they kept requesting for time to think 
about their participation in the study. After prolonged wait, this group fell out of this 
study because of insufficient enrollment. 
Only two groups were used in this study. The two groups are;  
➢ Group A which included patients who were using conventional 
antiretroviral medications only (ARV group).  
➢ Group B which included patients who were using a combination of herbal 
therapies and conventional antiretroviral medications for their treatment 
(combined group). 
Patients that meet the inclusion criteria were randomly selected from matched 
participants as previously described. Informed consent was obtained before the inclusion 
of subjects in the study. Participants were given full disclosure about the nature of the 
study, the extent of their participation and voluntary nature of their participation in the 
study. Subjects were able to voluntarily discontinue participation in the study at any time. 
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Disclosure was made to subjects that the study may involve minimal risks, and these risks 
were fully disclosed to subjects. All subjects who agreed to participate in the study were 
required to sign the informed consent form.  
Inclusion Criteria 
Inclusion criteria for this study are as follows; 
• Age between 18 and 65 
• Diagnosis of HIV 
• Nigerian citizenship and  
• Residency in Nigeria  
• Ability to read, write, speak and understand English 
• Subjects must be receiving either antiretroviral medications only or herbal 
medications only or a combination of antiretroviral medications and herbal 
medications. 
Exclusion Criteria 
 For the purpose of this study, patients with full-blown AIDS were excluded from 
the study, as the aim of this study was to investigate and compare the efficacy of different 
treatment protocols on HIV infection. Determination of full blown AIDS status was 
based on the physical health of the patients. Non-ambulatory and bed-ridden patients 
were considered to be a function of disease progression to full blown AIDS status. Such 
patients were excluded from this study. Similarly, non-English speaking subjects were 
excluded from the study. Subjects included men and women and selection was done 
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based on inclusion and exclusion criteria. Full disclosure was given to research subjects 
and written informed consent was obtained from each participant. 
Control of Threats 
To control the threats to the internal validity of the study result, subjects were 
randomly selected from matched samples. Matching is a useful method in eliminating 
confounding variables, as it will eliminate the sources of bias in the treatment. Also 
randomization is a useful method in assigning treatment or intervention to study 
participants, as it eliminates the sources of bias in the treatment (Polit & Beck, 2012; 
Vickers, 2003 and Wendler, 2009). Randomization will also enhance the external validity 
of the study finding, as it will ensure representative sampling, thereby enhancing the 
generalizability of study findings to bigger population. The use of matching and 
randomization will enhance the internal validity of the study results. An important 
extraneous variable is the differences noted in the baseline CD4 counts among patients.  
Analysis of covariance (ANCOVA) was used to statistically control the effect of baseline 
CD4 counts. 
Protection of Human Subjects 
In the process of carrying out this study, appropriate attention was given to ethical 
issues in research. Research subjects’ confidentiality was protected. Detailed information 
about the study was explained to subjects and full disclosure of risks associated with the 
study was made. The subjects were informed of their right to discontinue participation in 
the study at any point during its course. Each subject was required to sign an informed 
consent paper. Because of the initial apprehension of participants and the dynamic nature 
of this study, process consent was used in combination with informed consent (Munhall, 
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2007). Process consent is a way to continuously renegotiate informed consent to meet the 
changing situation in the process of a study (Munhall, 2007; Usher & Arthur, 1998). 
Process consent enables the participants to opt out of the study at any point if he/she 
becomes uncomfortable or unable to go on with the study for whatever reason. 
Throughout the process of this study, participants received continuous explanations of 
and information about the study, and their permissions were sought on a continual basis. 
This approach guaranteed necessary ethical issues needed in this study.  
Patient confidentiality was maintained and a commitment to this effect was 
provided to subjects in writing. Trained research assistant was strictly requested to not 
disclose subjects’ information to anyone outside the research group. The research 
assistant was required to sign a written commitment to maintain subjects’ privacy and 
confidentiality at all time. Patient information was electronically stored in a password-
protected computer system. All paper copies were stored under lock and key in a 
fireproof cabinet. The paper copies were shredded after information was stored 
electronically.         
These measures also mitigate the risks involved in this study. This study involves 
minimal risks. The risks associated with this study include potential breaches of 
confidentiality and deep emotional and psychological trauma that could be precipitated 
by discussion of health issues. To prevent psychological trauma to participants during 
this study, informed consent was continuously renegotiated at different time during the 
study. Participants were free to withdraw from the study at any point during the study. 
Before the commencement of this study, ethical approvals were obtained from 
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appropriate and relevant authorities in Nigeria and the U.S. Ethical approvals for this 
study were obtained from the following authorities; 
➢ Osun State Ministry of Health, Health Planning, Research and Statistics 
Departments. 
➢ Osun State Specialist Hospital, Osogbo Health Research Ethics Committee 
(SHOSREC) and  
➢ University of Massachusetts, Amherst Institutional Review Board (UMASS IRB). 
Data Collection Methods and Procedures 
Data collection was done for a period of five months and a week from November 
16, 2015 to March 23, 2016. The study started on November 16, 2015 with the 
identification of subjects using conventional anti-retroviral medications and those using a 
combination of ARV and herbal medications. Subjects that meet the inclusion criteria 
were randomly chosen from each group. The study was comprised of two groups (Group 
A comprised of subjects using antiretroviral medications only {ARV group}; Group B 
comprised of subjects using both herbal therapies and conventional antiretroviral 
medications {Combined group}). General demographic information about the research 
subjects was collected. Both SSC-HIVrev and WHOQOL-HIV BREF questionnaires 
were administered to both groups.  
HIV symptom management outcome was measured using the revised edition of 
the Sign and Symptom Check-List for persons with HIV disease (SSC-HIVrev) 
(Holzemer, Hudson, Kirksey, Hamilton & Bakken, 1999). For this instrument, subjects in 
each group were asked to rate each sign or symptom on a three-point Likert scale as mild, 
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moderate or severe. Subjects were asked to rate the symptoms as they experience them on 
a daily basis. If a subject is not experiencing a symptom on the day of the assessment, 
he/she was instructed to record “not applicable”. With this, each item was scored as no 
symptom= 0; mild= 1; moderate= 2; and severe= 3. The items within a factor will be 
summed for a scale score. The symptoms cluster to be evaluated are; fatigue, fear, fever, 
GI upset, shortness of breath, numbness, headache, rectal itch, bruising/bleeding, body 
changes and gynecological-related problems for women. Appendices A and B shows the 
SSC-HIVrev instrument and demographic questionnaire respectively. The quality of life 
of HIV subjects was measured using the brief version of the World Health Organization 
Quality of Life for HIV (WHOQOL-HIV BREF) instrument. Appendix C shows 
WHOQOL-HIV BREF instrument/questionnaire. The questionnaires were administered 
to patients in Groups A and B. 
Data Analysis and Management 
Data generated from the pilot study was analyzed using IBM SPSS Statistics 22 
software. The reliability of both the SSC-HIVrev and WHOQOOL-HIV BREF were 
analyzed using IBM SPSS Statistics 22 software. Both descriptive and inferential data 
analyses were used to analyze study results. Descriptive statistics was used to analyze the 
demographic data (age, gender, and ethnicity) while inferential statistics was used to 
draw conclusion from study data. Paired sample t-test was used to determine the 
difference between baseline CD4 counts and post treatment CD4 counts in both groups. 
Analysis of covariance (ANCOVA) was used to statistically control the effect of baseline 
CD4  counts in both groups and to examine the difference between both groups. Also, 
independent t-test was used to compare the differences between symptom cluster and 
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quality of life between both groups. With this, it was possible to determine if there was 
significant difference in treatment outcomes between the groups using conventional 
antiretroviral only (i.e. ARV group) and those using a combination of conventional 
antiretroviral medications and herbal therapy (i.e. the combined group). 
The focus of data analyses was on the following areas: 
(1) The difference between pre-treatment (baseline) CD4 counts and post treatment 
CD4 in group A (i.e. the difference in pre- and post-treatment CD4 counts in 
ARV group). 
(2) The difference between pre-treatment (baseline) CD4 counts and post treatment 
CD4 in group B (i.e. the difference in pre- and post-treatment CD4 counts in 
combined group). 
(3) The difference in CD4 counts of patient taking ARV only and those taking a 
combination of herbal therapies and conventional antiretroviral medications (i.e. 
differences in CD4 counts between ARV group and combined group). 
(4) The difference in the symptom experience of patient taking ARV only and those 
taking a combination of herbal therapies and conventional antiretroviral 
medications (i.e. differences in symptom experience between ARV groups and 
combined group). 
(5) The difference in the quality of life of patient taking ARV only and those taking a 
combination of herbal therapies and conventional antiretroviral medications (i.e. 
differences in quality of life between groups A and B). 
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Methods Used to Analyze Research Questions 
This study is carried out to answer five research questions. Appropriate statistical 
analytical methods were employed to investigate each of these research questions.   
Research Question #1: How do CD4 counts differ after treatment with antiretroviral 
medications only? 
 To answer this question a pair sample t-test was ran on IBM SPSS Statistics 22 
software. 
Research Question #2: How do CD4 counts differ after treatment with a combined 
therapy of herbal treatment and conventional antiretroviral medications? 
 To answer this question pair sample t-test was ran on IBM SPSS Statistics 22 
software. 
Research Question #3: What is the difference in CD4 counts of patient taking ARV only 
and those taking a combination of herbal therapies and conventional antiretroviral 
medications? 
 To answer this question ANCOVA was run on IBM SPSS Statistics 22 software. 
Research Question #4: What is the difference in the symptom experience of patient 
taking ARV only and those taking a combination of herbal therapies and conventional 
antiretroviral medications? 
 To answer this question independent t-test was ran on IBM SPSS Statistics 22 
software. 
Research Question #5: What is the difference in the quality of life of patient taking 
ARV only and those taking a combination of herbal therapies and conventional 
antiretroviral medications? 
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To answer this question independent t-test was ran on IBM SPSS Statistics 22 
software. 
Trustworthiness of Research Data 
To control the threats to external validity of the study result, randomization was 
used in sample selection. All patients that consented to participate in the study were 
screened for meeting the inclusion criteria. Among the patients that meet the inclusion 
criteria, sample selection was done randomly from matched subjects that are similar in 
terms of important extraneous variables. Randomization was done by flipping a coin for 
each of the patient that met the inclusion criteria and agreed to participate in the study. If 
the coin came up “heads” the subject was included in the actual study. If the coin came 
up “tails” the subject was excluded from the study. This method provided equal 
opportunity for all participants to be included in the actual study, irrespective of 
characteristics such as sex, age, tribe, or educational levels (Polit & Beck, 2012). 
Randomization is a useful method of assigning treatment or intervention to subjects or in 
sample selection, as it eliminates the sources of bias in the treatment (Burns & Grove, 
2009; Polit & Beck, 2012; Vickers, 2006; Wendler, 2009). Randomization enhanced the 
external validity of the study finding, as it ensured a representative sample, thereby 
enhancing the generalizability of study findings to overall Nigerian population. Matching 
of samples for important extraneous variables helped eliminate confounding variables 
that could affect study results.  
To further control for extraneous variables, the pretreatment (baseline) CD4 
counts were statistically adjusted and controlled using analysis of covariance 
(ANCOVA). ANCOVA is an appropriate tool to evaluate whether population means of a 
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dependent variable are equal across treatment, while statistically controlling for the 
effects of other continuous variables that are not of primary interest or for nuisance 
variables. The use of ANCOVA helped to ensure that the differences in the baseline CD4 
counts between the two groups were controlled for before comparison of the baseline 
CD4 counts with post treatment CD4. 
To control the threat to internal validity, extensively used and well-tested 
instruments were used for data collection. The Sign and Symptom Check-List for persons 
with HIV disease (SSC-HIVrev) (Holzemer et al., 2001) was used to evaluate symptom 
improvement. This instrument is reported to have high internal validity. “The six 
symptom clusters, the number of items in the factor and the Cronbach’s alpha reliability 
estimates for this instrument were Malaise/Weakness/Fatigue (six items with Cronbach 
alpha of 0.90), Confusion/Distress (four items with Cronbach alpha of 0.90), Fever/Chills 
(four items with Cronbach alpha of 0.85), Gastrointestinal Discomfort (four items with 
Cronbach alpha of 0.81), Shortness of Breath (three items with Cronbach alpha of 0.79) 
and Nausea/Vomiting (three items with Cronbach alpha of 0.77) (Holzemer et al., 2001, 
p. 1041).  
The World Health Organization Quality of Life (WHOQOL) instrument was 
developed by a group of reputable experts from World Health Organization (WHO). 
Using confirmatory factor analysis, Skevington et al. (2004) analyzed the internal 
consistency, item-total correlations, discriminant validity and construct validity and 
found that the instrument has good to excellent psychometric properties of reliability and 
good validity. The WHOQOL-HIV instrument was found to be an excellent cross-
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cultural valid assessment tool for quality of life within the physical, psychological, social 
and environmental domains (Skevington et al., 2004). 
To further ensure the validity of this study, research assistant was given adequate 
training about his role in situating patients for questionnaire administration and 
maintaining confidentiality and patients’ rights. A scientist was recruited to serve as 
research assistants for this study. Only physiological tests (CD4 counts) that were carried 
out in conformity with Osun State Specialist Hospital standard were used for this study. 
Although some of the subjects have information about their CD4 counts, only CD4 
counts obtained from patients’ medical records by the hospital staff were used in this 
study. 
Eliminating Confounding Variables 
To eliminate confounding variables meticulous approach was used in data 
selection and treatment. Research subjects must have been on treatment for similar length 
of time. It is necessary to only compare treatment outcome in subjects with similar length 
of therapy because outcome may have direct correlation with treatment duration. Also, 
subjects using similar ARV regime were used so as to be able to eliminate potential side 
effects that could impact on quality of life of subjects. Variables such as time of 
commencement of treatment, type of treatment and duration of treatment were similar for 
all the study subjects. Another potential source of confounder is the source of physiologic 
(CD4) data. CD4 counts were obtained from subjects’ medical records. The differences 
noted in the baseline CD4 were statistically controlled and adjusted for using analysis of 
covariance (ANCOVA) before the between group comparative analysis was done. 
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Summary 
The aim of this study was to seek better understanding of the impact of different 
therapies on the management of HIV. To gain deep insight into the efficacy of different 
HIV treatment modalities, two distinct, but interrelated measures were used to evaluate 
the treatment outcomes. The symptom outcome and perception of quality of life (QOL) 
were considered to be important in measuring the efficacy of different treatments. Since 
ARV is the gold standard for HIV treatment, it becomes imperative to compare the 
symptom outcomes and QOL in patients using combined treatment with patients using 
only conventional antiretroviral medications. 
The use of matching was useful in eliminating confounding variables and 
randomization ensured sample representativeness by eliminating bias in sample selection. 
Random sampling ensured that all subjects that met inclusion criteria have the same 
chance of participating in the study irrespective of characteristics such as sex, educational 
level, age, tribe or sexual orientations. Extraneous variables in the pre-treatment data 
were also statistically controlled and adjusted for using analysis of covariance 
(ANCOVA). Baseline CD4 data varies across patients and between the two groups. To 
compare the baseline CD4 with the post-treatment CD4 counts, the baseline CD4 were 
controlled and adjusted for using ANCOVA. This method helped to control for 
extraneous variables in the baseline CD4 counts. 
This study strictly adhered to ethical issues in research. The findings from this 
study have the potential to revolutionize HIV treatment protocol and could help in 
developing pragmatic treatment modalities for HIV, especially in resource-constrained 
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regions such as Sub-Saharan Africa while opening further opportunities for future 
studies. 
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CHAPTER 4 
RESULTS 
 The aim of this study was to compare the efficacy of ARV therapy only with that 
of a combination therapy of ARV and herbal medications among Nigerian HIV patients. 
The study compared the symptom outcome, quality of life and CD4 of patients taking 
ARV with those patients taking a combination of ARV and herbal medications. This 
study was divided into two parts. The first part was a pilot study designed to test the 
reliability of the study instruments. The second part was the actual study. This study 
involved the following two groups; 
➢ Group A- Comprised of subjects drawn from patients who are using only ARV 
for their treatment (ARV Group).  
➢ Group B- Comprised of subjects drawn from patients who are using a 
combination of herbal therapies and conventional antiretroviral medications for 
their treatment (Combine Group).  
Subjects were placed in a group on the basis of the treatment protocol (medications) used 
in the management of their HIV prior to contact for this study. No participants were 
required to change their treatment regimen.  
 The Statistical Package for Social Sciences Version 23 was used to determine the 
reliability of the study instruments, to calculate the frequencies, and determine 
differences between groups using independent t-tests. ANCOVA was used to control for 
confounding variables. In this chapter, the aspects of the study that will be discussed are 
the process of obtaining approval for the study, the pilot study, process of subject 
recruitment, recruitment for reliability pilot study, process of questionnaire 
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administration, and results of the pilot study. Also, the actual study, process of subject 
recruitment and recruitment for the actual study, process of questionnaire administration 
for the actual study, problems encountered during recruitment and results of the actual 
study are discussed in this chapter.  
Presentation of Findings 
The results obtained from the pilot and actual studies are methodologically 
presented for clarity. The results of the pilot study are presented under two sub-headings;  
➢ The results of demographic data and  
➢ Result of Cronbach’s alpha 
For the actual study, the results of demographic information were presented first, 
followed by the results of the five research questions. Demographic results from the 
actual study are presented under three sub-headings as follows: 
➢ Results of demographic information of all the participants in the actual study 
(both groups A and B). 
➢ Results of demographic information of participants in group A (ARV group). 
➢ Results of demographic information of participants in group B (Combine group). 
This chapter concludes with a summary of the findings of the pilot and actual study. 
Process of Obtaining Approval for the Study 
Because of the nature of this study, approval was obtained from three different 
authorities in Nigeria and in the United States. Ethical approval was obtained from Osun 
State Ministry of health, department of health planning, research and statistics. 
Application for approval was submitted to the state authority in December 2014 and 
approval was given on January 23, 2015. Because this study was carried out at the State 
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Specialist Hospital, Asubiaro, Osogbo, Osun-State, another institutional approval was 
obtained from the research and ethics committee of the Specialist Hospital. The State 
Specialist Hospital’s approval was granted on September 18, 2015.  
Following the approval of Osun State Ministry of Health and State Specialist Hospital 
authorities, Institutional Review Board approval was obtained from the University of 
Massachusetts, Amherst. It was after the necessary approvals were obtained that the pilot 
study was started.  
Pilot Study 
The main purpose of the pilot study was to determine the validity and reliabilities 
of the two instruments used in this study; the brief version of the World Health 
Organization Quality of Life Instrument for HIV (WHOQOL-HIV BREF) and the Sign 
and Symptom Check-List for persons with HIV disease (SSC-HIVrev). These are highly 
reliable and valid instruments. However, there is no record of their use in Nigeria or 
among Nigerian population. Determination of the study instruments’ reliability is very 
important because the reliability of these instruments will have a strong impact on the 
results of the final study. The pilot study also helped this researcher to test the process of 
conducting the final study, to test study design and navigate possible logistic issues that 
could come up during the actual study.  
To test the validity and reliability of these instruments, face validity and internal 
consistency of both instruments were evaluated. The face validity was done by the 
researcher. This researcher is an expert in Nigerian culture being originally from Nigeria 
and fluent in one of the Nigerian major languages. The researcher meticulously reviewed 
both questionnaires to determine if each item in both instruments is relevant to the 
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Nigerian population. Only the weight factor (in the SSC-HIVrev) was considered to be 
unimportant to the Nigerian population. Cronbach’s alpha was used to determine the 
internal consistency of both questionnaires. 
Process of Subject Recruitment 
A Nigerian scientist served as the research assistant for this study. The research 
assistant helped situate the subjects for the researcher to be able to communicate with 
them via telephone or Skype. The research assistant gave the informed consent form to 
each patient that meet the inclusion criteria and volunteered to participate in this study. 
Over the phone or via Skype, the researcher provided information about the study to the 
subjects. Subjects were given the opportunity to ask questions and the researcher clarified 
subjects' questions and concerns. Subjects were expressly told over the phone or Skype 
that they can opt out of the study at any time during the study. A few days after the initial 
information session, another telephone conversation was had with the subjects for a 
second time to identify those who still wanted to participate in the study. Only those 
patients that met the inclusion criteria and signified their willingness by signing the 
consent form were included in the reliability pilot study.  
Recruitment for Reliability Pilot Study 
Before the commencement of the actual study, the two instruments used for data 
collection were subjected to reliability testing. Twenty subjects were randomly selected 
from patients that meet the inclusion criteria for this study. Inclusion criteria for this 
study were as follows:  
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1.      Subjects must be between 18 years and 65 years. 
2.      Subject must have diagnosis of HIV 
3.      Subject must be a Nigerian citizen 
4.      Subject must reside in Nigeria 
5.      Subject must be able to read, write, speak and understand English. 
6.      Subjects must be receiving either antiretroviral medications only, or herbal 
medications only, or a combination of antiretroviral and herbal medications. 
For the pilot study, twenty subjects were randomly selected among HIV patients 
receiving treatment at the State Specialist Hospital, Asubiaro, Osun-State, Nigeria. 
Randomization was done by flipping of coins. This method helped to eliminate 
extraneous variables that could affect study results. A coin was flipped for each subject 
who agreed to participate in the study. If the coin came up “heads”, the subject was 
included in the pilot study. If the coin came up “tails”, the subject was excluded from the 
study. This method provided equal opportunity for all participants to be included in the 
actual study, irrespective of characteristics such as sex, age, tribe, or educational levels 
(Polit & Beck, 2012).  
The two questionnaires were administered to the 20 randomly selected subjects. 
The two questionnaires administered were; 
(a). The brief version of the World Health Organization Quality of Life Instrument for 
HIV (WHOQOL-HIV BREF) and  
(b). The Sign and Symptom Check-List for persons with HIV disease (SSC-HIVrev). 
The reliability pilot study was carried out between October 12, 2015 and October 28, 
2015. Study recruitment was done via a flyer.  
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Process of Questionnaire Administration 
Identification of subjects was done with the help of the Nigerian medical doctors 
and the research assistant. The Nigerian doctors and research assistant provided access to 
the patients but did not participate in the study, review the study nor were they 
involved in providing explanation to the subjects. Also, they did not play any role 
in obtaining informed consent from the subjects. Instead the Nigerian doctors were taking 
care of the patients and assisted in the distribution of recruitment flyer to potential 
subjects. The Nigerian doctors and scientist also helped situate the subjects for 
questionnaire administration. Informed consent and questionnaire administration were 
done via Skype and/or telephone after the researcher had provided information to study 
participants and clarified patients concerns and questions. After completion of the 
questionnaire, subjects were instructed to put their completed questionnaires in an 
envelope, sealed the envelope and asked to give the sealed envelope to the research 
assistant. All sealed envelope were sent to the researcher in the U.S. via courier service 
for reliability test.  
Results of Pilot Study 
The pilot study was conducted for many reasons. The primary reason was to 
determine the reliability of the two instruments used in this study. The other reasons were 
to use the pilot study to test-run the actual study, to become familiar with the Nigerian 
terrain, to identify possible problems that might occur during the actual study and to 
navigate a way toward resolving such problems. During the pilot study, questionnaires 
were administered to 30 participants. Out of this number, 6 (20%) did not complete the 
questionnaires in full and 4 (13%) participants changed their mind about participation and 
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dropped out of the study. Only fully completed questionnaires were included in the 
reliability analysis. Descriptive data obtained from the pilot study is presented in Table 5 
below. 
The results of the demographic data obtained from the Pilot study are presented in 
the Tables 5 to 13 below. 90% of the participants in the pilot study were women and 80% 
of the participants were below 49 years old. As shown in Table 8, less than 40% of the 
participants in the pilot study had secondary education, while 20% had university degrees 
and 10% had a post graduate education. 30% of the participants reported having more 
than elementary education but less than secondary education. 55% of the participants 
were married. The participants were predominantly from Yoruba tribe (85%). This is 
because the site of the study is located in Yoruba territory. The other Nigerian major 
tribes, Igbo and Hausa, constituted 5% each while the remaining 5% cut across other 
Nigerian tribes. Christians and Muslims constituted 55% and 45% of the participants 
respectively. 60% of the participants in the pilot study reported working full-time while 
20% work on a part-time basis. 15% of the participants were unemployed. Most of the 
participants were low-income earners with 85% of the participants having an annual 
income of less than N100,000 Nigerian Naira (approximately US$312 yearly income).  
 
Cronbach’s Alpha 
From the pilot data, the two instruments were analyzed for reliability. In the SSC-
HIVrev questionnaire one factor (the body changes) was omitted because it was not 
considered to be an important factor among the population of study. Five items are 
embedded in the omitted factor (body changes). The omitted items under the body 
changes are; 
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➢ weight gain in stomach area 
➢ concern over weight gain 
➢ hump on back of neck/shoulders 
➢ skinny arms and legs and  
➢ prominent leg veins 
With the omitted factor, the Cronbach’s alpha for the SSC-HIVrev instrument was .915. 
Cronbach’s alpha for each factor of the SSC-HIVrev instrument is presented in Table 14.  
The Cronbach’s alpha for the World Health Organization Quality of Life instrument 
(WHOQOL-HIV BREF) was found to be .840. Overall, both the SSC-HIVrev and 
WHOQOL-HIV BREF were found to be highly reliable instruments among Nigerian 
population. 
Actual Study 
The purpose of the actual study was to compare the efficacy of HIV treatment in 
patients using only ARV with those patients who are using a combined therapy of ARV 
and herbal medications. In doing this, this study was designed to compare symptom 
experience and quality of life of patients taking ARV with those patients using 
combination of ARV and herbal remedies. Physiological data (specifically CD4 counts) 
obtained from these two groups was also compared. 
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Process of Subject Recruitment 
 A process similar to the approach used in the recruitment of subjects for the pilot 
study was used to recruit subjects for the final study. After the pilot study had been 
carried out and the reliability of the two study instruments determined, recruitment 
process for the actual study began. Recruitment poster and fliers were distributed to HIV 
patients receiving treatment at the State Specialist Hospital, Osun-State, Nigeria. Consent 
was properly obtained from all patients that signify interest in participating in the study. 
Detailed explanation of the study and potential risks associated with the study were 
disclosed to potential subjects. Subjects were given the opportunity to ask questions and 
the researcher clarified subjects' concerns. All potential subjects were told of the 
voluntary nature of the study and were told that they could discontinue their participation 
in the study at any time without any repercussion. Two days after the initial discussion 
with each subject, another conversation was held with each subject to ask if they were 
still willing to participate in the study. Only those patients that met the inclusion criteria 
and signified willingness by signing the consent form were enrolled in the actual 
study. The actual study commenced only after each subject had given consent for the 
study. During administration of the informed consent, the research assistant helped 
situate the subjects for the researcher to be able to communicate with them via telephone 
or Skype.  
Recruitment for Actual Study 
After data from the pilot study had been analyzed and the reliability of the two 
instruments had been determined, recruitment for the final study commenced. Fliers were 
distributed to patients receiving treatment at State Specialist Hospital, Osun-State, 
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Nigeria. 150 patients initially consented to participate in this study; however, 22 patients 
withdrew midway into the study. Questionnaires from 18 subjects were discarded 
because of incomplete filing. Inclusion criteria for this study were as follows:  
1.      Subjects must be between 18 years and 65 years old. 
2.      Subject must have diagnosis of HIV 
3.      Subject must be a Nigerian citizen 
4.      Subject must reside in Nigeria 
5.      Subject must be able to read, write, speak and understand English. 
6.      Subjects must be receiving either antiretroviral medications only, or herbal 
medications only or a combination of antiretroviral and herbal medications. 
Participants were put in a group on the basis of the medications they were taking at the 
time of contact for this study. For each group, participants were selected randomly from 
matched subjects that have similarity in terms of important extraneous variables. Subjects 
with similar treatment protocol, same treatment duration, and same duration of HIV 
diagnosis were included in the study. Subjects in each group had started their treatment at 
about the same time and were taking the same antiretroviral medications. From the 
matched samples, participants in each group were selected by flipping a coin. For each 
group, a coin was flipped for each subject who agreed to participate in the study. If the 
coin came up “heads”, the subject was included in the actual study. If the coin came up 
“tails”, the subject was excluded from the study. This method provided equal opportunity 
for all participants to be included in the actual study, irrespective of characteristics such 
as sex, age, tribe, or educational levels (Polit & Beck, 2012).  
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Process of Questionnaire Administration 
The process of administering study questionnaires was similar to the method used 
in the pilot study. Identification of subjects was done with the help of the Nigerian 
medical doctors and a research assistant. The Nigerian doctors and the research assistant 
provided access to the subjects but did not participate in the study (they did not review 
the study, were not involved in providing explanation to subjects, and did not play any 
role in obtaining informed consent from the subjects). These Nigerian doctors were 
currently taking care of HIV patients and assisted in the distribution of recruitment flyers 
to potential subjects. The research assistant helped situate the subjects for questionnaire 
administration. Informed consent and questionnaire administration were done via Skype 
and/or telephone after the researcher had provided information to study participants and 
clarified patients concerns and questions. The two questionnaires administered were; 
➢ The brief version of the World Health Organization Quality of Life Instrument for 
HIV (WHOQOL-HIV BREF) and  
➢ The Sign and Symptom Check-List for persons with HIV disease (SSC-HIVrev). 
The actual study was carried out between November 16, 2015 and March 23, 
2016. After completion of the questionnaire, each subject put their completed 
questionnaire in an envelope, sealed the envelope and gave the sealed envelope to the 
research assistant. All sealed envelopes were sent to the researcher in the U.S. via courier 
service for evaluation.  
Problems Encountered During Recruitment 
 The process of recruiting subjects into this study was very tedious. Although the 
physicians that were primarily taking care of HIV patients in the Specialist Hospital, 
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Osun-State provided access to the patients, they played no role in explaining the study to 
the patients, nor did they help in the recruitment process. At the initial stage of the 
recruitment exercise, most of the patients contacted were very concerned about the 
breach of confidentiality. Many of the patients expressed fears that their video could 
secretly be taken and published in Nigeria and outside Nigeria. Discussions were held 
about the ethics of conducting research and the grave consequences of any breach of 
confidentiality or research ethics. It took concrete assurances from the principal 
investigator for the patients to feel comfortable. Strong assurance was given to subjects 
about maintaining confidentiality. 
 This study was initially designed to include three groups namely:  
➢ Group A: Subjects drawn from patients using herbal therapies only.  
➢ Group B: Subjects drawn from patients using conventional antiretroviral 
medications (ARV) only and  
➢ Group C: Subjects drawn from patients using a combination of herbal therapies 
and conventional antiretroviral medications. 
However, in the course of this study, the herbal-only group fell out because the 
study could not recruit enough subjects from this group. At a point it became apparent 
that patients using herbal therapy only were basically trying to go under the radar and 
avoid their status from becoming known to anybody. Several attempts were made to 
enlist patients in this group. The identified patients in the herbal group only stalled this 
study for several months, as they kept requesting for time to think about their 
participation in the study. Contacts were made to this group through their care providers. 
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During the course of questionnaire administration it was discovered that the 
combined group was covertly using herbal therapy in conjunction with the conventional 
ARV. In fact the patients using combined therapy were making concerted effort to avoid 
disclosure of their dual therapies to their care providers. These patients disclosed the use 
of dual therapy under strict assurance of confidentiality. However, the patients were 
encouraged to disclose all their co-concomitant medications to their care providers so that 
they could be better cared for. The reluctance of the patients to disclose dual therapy to 
physicians was attributed to the patients’ conviction that the physicians would stop them 
from continued use of the herbal medications. All the patients in this group believe that 
the improvement noted in their symptoms and quality of life was a result of the herbal 
remedies they were taking. 
Results of Actual Study 
The demographic information for all the participants in the actual study is 
presented below, followed by the demographic data for the ARV group and the combined 
group respectively. The results of the five research questions are presented after the 
demographic data. The results of the demographic data obtained from the actual study are 
presented in Tables 15-27. 
Results of Demographic Information for all Participants in the Actual Study 
The actual study was conducted to determine the effect of both treatment 
modalities on HIV symptoms and on the quality of life of HIV patients and to determine 
if there is any difference in treatment outcomes among the two groups. During the actual 
study, questionnaires were administered to 150 participants. Out of this number, 25 
(17%) did not complete the questionnaires in full and 15 (10%) participants changed their 
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minds about their participation and dropped out of the study. Only 110 participants that 
fully completed the questionnaires were considered in the final analysis. To obtain 
descriptive data for the actual study the frequency, mean and standard deviation were 
calculated (Table 15).  
The results of the demographic data obtained from the actual study are presented 
in Tables 15 to 23. 76.4% of the participants in the actual study were women and 23.6% 
were male. 63.6% of the participants were 45 years old or younger. As shown in Table 
18, 53.6% of the participants in the actual study had secondary education, 18.2% had 
university degrees, and 1.8% had a post graduate education. 72.7% of the participants 
were married while 4.5% were single. The participants were predominantly from Yoruba 
tribe (71.8%). This is because the site of the study is located in Yoruba territory. The 
other Nigerian two major tribes, namely Igbo and Hausa, constituted 10% and 10.9% 
respectively while the remaining 7.2% cut across other Nigerian tribes. Christians and 
Muslims constituted 43.6% and 56.4% of the participants respectively. 86.4% of the 
participants in the actual study reported working full time, while 3.6% reported working 
on a part-time basis. 7.3% of the participants were unemployed. Most of the participants 
were low income earners, with 84.6% of the participants having annual income of less 
than N200,000 Nigerian Naira (approximately US$624 yearly income).  
 
Results of Demographic Data for Participants in ARV Group and Combined Group  
The results of the demographic data obtained from the ARV group are presented 
in Table 24 and Tables 25-27. 80 percent of the participants in the ARV group were 
women and 20 percent were male. 61.8% of the participants were 45 years old or 
younger. As shown in Table 26, 61.8% of the participants in the ARV group had a 
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secondary education while 14.5% had university degrees. 78.2% of the participants were 
married while 1.8% of the participants were single. The participants were predominantly 
from Yoruba tribe (70.9%). This is because the site of the study is located in the western 
part of the country (Yoruba territory). The other two Nigerian major tribes, namely Igbo 
and Hausa, constituted 10.9% each while the remaining 7.2% cut across other Nigerian 
tribes. Christians and Muslims constituted 45.5% and 54.5% of the participants 
respectively in the ARV group. 85.5% of the participants in the ARV group reported 
working full-time, while 3.6% reported working on a part-time basis. 9.1% of the 
participants were unemployed. Most of the participants were low income earners with 
83.7% of the participants reporting an annual income less than N200,000 Nigerian Naira 
(approximately US$624 yearly income). The results of the demographic data obtained 
from the ARV group are presented in Table 24 and tables 25-27. 
 
The results of the demographic data obtained from the combine group are 
presented in Table 24 and tables 25-27. 72.7% of the participants in the combined group 
were women and 27.3% were male. 65.5% of the participants were 45 years old or 
younger. As shown in Table 26 below, 45.5% of the participants in the combine group 
had a secondary education while 21.8% had university degrees and 3.6 percent had 
postgraduate degrees. 67.3% of the participants were married while 7.3% of the 
participants were single. The participants were predominantly from Yoruba tribe 
(72.7%). This is because the site of the study is located in the western part of the country 
(Yoruba territory). The other two Nigerian major tribes, namely Igbo and Hausa, 
constituted 9.1% and 10.9% respectively. The remaining 7.3% cut across other Nigerian 
tribes. Christians and Muslims constituted 41.8% and 58.2% of the participants 
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respectively in the combine group. 87.3% of the participants in the combine group 
reported working full time, while 3.6% reported working on a part-time basis. 5.5% of 
the participants were unemployed. Most of the participants were low-income earners with 
85.5% of the participants reporting an annual income of less than N200,000 Nigerian 
Naira (approximately US$624 yearly income). The results of the demographic data 
obtained from the combine group are presented in Table 24 and tables 25-27. 
 
Results for Research Question 1 
Research Question #1: How do CD4 counts differ after treatment with antiretroviral 
medications only? 
To evaluate the difference between pre-treatment (baseline) and post-treatment 
CD4 counts among patient taking only ARV (ARV group), a pair sample t-test was run 
on IBM SPSS Statistics 22 software. Results show that there is a significant difference 
between the pre- and post-treatment CD4 counts among subjects taking ARV 
medications only with t-value=-6.713, sig. (2-tailed)=.000 and df=39 as shown in Table 
29. The paired sample statistics for ARV group is shown in Table 28. 
 
Results for Research Question 2 
Research Question #2: How do CD4 counts differ after treatment with combined 
therapy of herbal treatment and conventional antiretroviral medications? 
To evaluate the difference between pre-treatment (baseline) and post-treatment 
CD4 counts among patient taking a combination of ARV medications and herbal 
medications (combined group), a pair sample t-test was run on IBM SPSS Statistics 22 
software. Results show that there is a significant difference between the pre- and post-
                                                                97 
 
treatment CD4 counts among subjects taking a combination of ARV and herbal 
medications (t-value=-6.080, sig. (2-tailed)=.000 and df=39 as shown in Table 31. The 
paired sample statistics for combined group is shown in Table 30. 
 
Results for Research Question 3 
Research Question #3: What is the difference in CD4 counts of patient taking ARV only 
and those taking combination of herbal therapies and conventional antiretroviral 
medications? 
To determine if there is a difference in pre- and post-treatment CD4 counts 
between patient taking ARV only (ARV group) and patients taking combination of ARV 
medications and herbal medications (combined group), independent t-test was run on 
IBM SPSS Statistics 22 software. Results show that there is a significant difference in 
baseline CD4 counts between the two groups (p-value=.002). After statistically 
controlling the baseline CD4 counts with analysis of covariance (ANCOVA), results 
show that there is no significant difference between the two groups post-treatment CD4 
(p-value=.832) as shown in Table 32. 
Results for Research Question 4 
Research Question #4: What is the difference in the symptom experience of patient 
taking ARV only and those taking a combination of herbal therapies and conventional 
antiretroviral medications? 
To determine if there is a difference in symptom experience between patients 
taking ARV only (ARV group) and patients taking a combination of ARV medications 
and herbal medications (combined group), an independent t-test was run on IBM SPSS 
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Statistics 22 software. Results show that there is no significant difference between the 
two groups in many of the factors; fatigue factor (p=.229), fear factor (p=.471), GI upset 
factor (p=.891), SOB factor (p=.651), numbness factor (p=.597), headache factor 
(p=.314), rectal itch factor (p=.538), bruising factor (p=.497) as shown in Table 33. 
However, a significant difference was noted in fever (p=.003) and sore throat (p=.013) 
factors between the ARV group and combined groups. The fever factor mean scores for 
ARV group and combined group were .3045 and .6045 respectively. This signifies that 
the patients in ARV group recorded a significantly better outcome in fever factor 
compared to patients in the combined group. The intensity of fever episodes in the ARV 
group was significantly lower than the fever intensity among patients in combined group.  
Similarly, a significant difference was noted in sore throat factor (p=.013) among 
the ARV group and combined groups. The sore throat factor mean scores for ARV group 
and combined groups are .0273 and .1636 respectively. This signifies that the patients in 
ARV group recorded significantly better outcome in sore throat factor compared to 
patients in combined group. The intensity of sore throat in ARV group is significantly 
lower than the sore throat intensity among patients in the combined group.  
 
Results for Research Question 5 
Research Question #5: What is the difference in the quality of life of patient taking 
ARV only and those taking a combination of herbal therapies and conventional 
antiretroviral medications? 
To determine if there is a difference in the quality of life between patient taking 
ARV only (ARV group) and patients taking a combination of ARV and herbal 
medications (combined group), an independent t-test was run on IBM SPSS Statistics 22 
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software. Findings show that there is no significant difference in many domains such as 
physical domain (p=.183), psychological domain (p=.486), independence domain 
(p=.689), environment domain (p=.119), personal belief domain (p=.703), QOL (p=.670). 
Similarly, results show that there is no significant difference in overall quality of life 
between the two groups (p=.211) as shown in Table 34. However, a significant difference 
was noted in two domains-social relationship (p=.028) and health satisfy domains 
(p=.049) between the ARV group and combined groups. The health satisfaction mean 
scores for ARV group and combined groups were 4.1273 and 3.6545 respectively. This 
signifies that patients in ARV group reported significantly better satisfaction in their 
health compared to the combined group. A similar trend was noted in social relationship 
domain. The social relationship domain mean scores for ARV group and combined group 
are 16.2364 and 14.6364 respectively. This signifies that patients using ARV alone 
recorded significantly higher improvement in their social relationship as compared with 
patients using combination of ARV and herbal medications. 
 
Table 5: Descriptive Statistics for Pilot Study Participants (n=20) 
 
 Number Minimum Maximum Mean Standard 
Deviation 
Gender 20 1 2 1.90 .308 
Age 20 30 63 43.40 9.773 
Education 20 2 5 3.10 .968 
Marital Status 20 1 6 3.15 1.694 
Ethnicity 20 1.00 6.00 1.4000 1.18766 
Religion 20 1.00 2.00 1.4500 .51042 
Employment 20 .00 3.00 1.1500 .74516 
Income 20 1.00 13.00 10.900 4.01182 
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Table 6: Gender of Pilot Study Participants (n=20) 
 
 
 Frequency Percent Valid 
Percent 
Cumulative 
Percent 
Male 2 10.0 10.0 10.0 
Female 18 90.0 90.0 100.0 
Total 20 100.0 100.0  
     
 
 
Table 7: Age of Pilot Study Participants (n=20) 
 
 
Age Frequency Percent Valid 
Percent 
Cumulative 
Percent 
30 1 5.0 5.0 5.0 
32 3 15.0 15.0 20.0 
36 1 5.0 5.0 25.0 
37 1 5.0 5.0 30.0 
40 2 10.0 10.0 40.0 
41 2 10.0 10.0 50.0 
42 2 10.0 10.0 60.0 
44 1 5.0 5.0 65.0 
45 1 5.0 5.0 70.0 
48 1 5.0 5.0 75.0 
49 1 5.0 5.0 80.0 
54 1 5.0 5.0 85.0 
58 1 5.0 5.0 90.0 
62 1 5.0 5.0 95.0 
63 1 5.0 5.0 100.0 
Total 20 100.0 100.0  
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Table 8: Level of Education of Pilot Study Participants (n=20) 
 
 
 Frequency Percent Valid 
Percent 
Cumulative 
Percent 
Primary 6 30.0 30.0 30.0 
Secondary 8 40.0 40.0 70.0 
University 4 20.0 20.0 90.0 
Postgraduate 2 10.0 10.0 100.0 
Total 20 100.0 100.0  
 
 
 
Table 9: Marital Status of Pilot Study Participants (n=20) 
 
 
 Frequency Percent Valid Percent Cumulative 
Percent 
Single 1 5.0 5.0 5.0 
 
Married 11 55.0 55.0 60.0 
 
Living as 
Married 
1 5.0 5.0 65.0 
Separated  1 5.0 5.0 70.0 
 
Divorced 3 15.0 15.0 85.0 
 
Widowed 3 15.0 15.0 100.0 
 
Total 20 100.0 100.0  
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Table 10: Ethnicity of Pilot Study Participants (n=20) 
 
 Frequency  Percent Valid  
Percent 
Cumulative 
Percent 
Yoruba 17 85.0 85.0 85.0 
Hausa 1 5.0 5.0 90.0 
Igbo 1 5.0 5.0 95.0 
Other 1 5.0 5.0 100.0 
Total 20 100.0 100.0  
 
 
 
Table 11: Religion of Pilot Study Participants (n=20) 
 
 
 Frequency Percent Valid 
Percent 
Cumulative 
Percent 
Christian 11 55.0 55.0 55.0 
Muslim 9 45.0 45.0 100.0 
Total 20 100.0 100.0  
 
 
 
Table 12: Employment Status of Pilot Study Participants (n=20) 
 
 Frequency Percent Valid 
Percent 
Cumulative 
Percent 
Not 
Working 
3 15.0 15.0 15.0 
Full time 
Employment 
12 60.0 60.0 75.0 
Part Time 
Employment 
4 20.0 20.0 95.0 
Retired 1 5.0 5.0 100.0 
 
Total 20 100.0 100.0  
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Table 13: Income of Pilot Study Participants (n=20) 
 
 Frequency Percent Valid 
Percent 
Cumulative 
Percent 
>N1.2M 1 5.0 5.0 5.0 
 
N1m to less 
than N1.2m 
2 10.0 10.0 15.0 
N37K to less 
than N100K 
8 40.0 40.0 55.0 
0 to less than 
N37K 
9 45.0 45.0 100.0 
Total 20 100.0 100.0  
 
 
 
 
Table 14: Cronbach Alpha for Each Factor in SSC-HIVrev 
FACTORS CRONBACH’S ALPHA 
Fatigue Factor .83 
Fear Factor .716 
Fever Factor .698 
GI Factor .536 
Shortness of breath Factor 0 
Sore-throat Factor .647 
Numbness Factor .844 
Headache Factor .570 
Rectal Itch Factor .977 
Bruising Factor -.202 
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Table 15: Descriptive Statistics for Actual Study Participants (n=110) 
 
 
 N Minimu
m 
Maximu
m 
Mean Std. 
Deviation 
Gender 110 1.00 2.00 1.7636 .42679 
 
Age 110 22.0 65.0 42.9636 10.40371 
 
Education 110 2.00 5.00 2.9545 .72170 
 
Marital 
Status 
110 1.00 6.00 2.6636 1.44804 
Ethnicity 110 1.00 6.00 1.6273 1.25515 
 
Religion 110 1.00 2.00 1.5636 .49820 
 
Employment 110 .00 3.00 1.0182 .46888 
 
Income 110 1.00 13.00 11.4545 2.59370 
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Table 16: Gender of Actual Study Participants (n=110) 
 
 Frequency Percent Valid 
Percent 
Cumulative Percent 
Male 26 23.6 23.6 23.6 
Female 84 76.4 76.4 100.0 
Total 110 100.0 100.0  
 
 
 
Table 17: Age of Actual Study Participants (n=110) 
 
 
Age 
(Year) 
Frequency Percent Valid 
Percent 
Cumulativ
e Percent 
20-25 1 .9 .9 .9 
26-30 12 10.9 10.9 11.8 
31-35 23 20.9 20.9 32.7 
36-40 13 11.7 11.7 44.4 
41-45 21 19.1 19.1 63.5 
46-50 13 11.7 11.7 75.2 
51-55 12 10.8 10.8 86.0 
56-60 10 9.0 9.0 95.0 
61-65 5 4.5 4.5 100.0 
Total 110 100 100  
 
 
Table 18: Education of Actual Study Participants (n=110) 
 
 Frequency Percent Valid Percent Cumulative 
Percent 
Primary 
Education 
26 26.4 26.4 26.4 
Secondary 
Education 
59 53.6 53.6 80.0 
University 
Education 
20 18.2 18.2 98.2 
Postgraduate 
Education 
2 1.8 1.8 100.0 
Total 100 100.0 100.0  
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Table 19: Marital Status of Actual Study Participants (n=110) 
 
 
 Frequency Percent Valid 
Percent 
Cumulative 
Percent 
Single 5 4.5 4.5 4.5 
 
Married 80 72.7 72.7 77.3 
 
Living as 
Married 
2 1.8 1.8 79.1 
Separated  7 6.4 6.4 85.5 
 
Divorced 2 1.8 1.8 87.3 
 
Widowed 14 12.7 12.7 100.0 
 
Total 100 100.0 100.0  
 
 
 
 
Table 20: Ethnicity of Actual Study Participants (n=110) 
 
 Frequency  Percent Valid  
Percent 
Cumulative 
Percent 
Yoruba 79 71.8 71.8 71.8 
Hausa 12 10.9 10.9 82.7 
Igbo 11 10.0 10.0 92.7 
TIV/Idoma 2 1.8 1.8 94.5 
Ijaw 1 .9 .9 95.5 
Other 5 4.5 4.5 100.0 
Total 100 100.0 100.0  
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Table 21: Religion of Actual Study Participants (n=110) 
 
 Frequency Percent Valid 
Percent 
Cumulative 
Percent 
Christian 48 43.6 43.6 43.6 
Muslim 62 56.4 56.4 100.0 
Total 110 100.0 100.0  
 
 
 
Table 22: Employment of Actual Study Participants (n=110) 
 
 Frequency Percent Valid 
Percent 
Cumulative 
Percent 
Not 
Working 
8 7.3 7.3 7.3 
Full time 
Employment 
95 86.4 86.4 93.6 
Part Time 
Employment 
4 3.6 3.6 97.3 
Retired 3 2.7 2.7 100.0 
 
Total 110 100.0 100.0  
 
  
 
Table 23: Income of Actual Study Participants (n=110) 
 
 Frequency Percent Valid 
Percent 
Cumulative 
Percent 
>N1.2m 2 1.8 1.8 1.8 
N1m to less 
than N1.2m 
3 2.7 2.7 4.5 
N900K to less 
than N1m 
1 .9 .9 5.5 
N400K to less 
than N500K 
3 2.7 2.7 8.2 
N300K to less 
than N400K 
2 1.8 1.8 10.0 
N200K to less 
than N300K 
6 5.5 5.5 15.5 
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N100K to less 
than N200K 
11 10.0 10.0 25.5 
N37K to less 
than N100K 
40 36.4 36.4 61.8 
0 to less than 
N37K 
42 38.2 38.2 100.0 
Total 110 100.0 100.0  
 
 
 
Table 24: Age of Participants in ARV and Combined Groups in Actual Study  
 
 
Age 
(Year) 
 
                           ARV 
 
                            COMBINED 
 
 
 
 
 
Frequency 
 
 
Percent 
 
 
Valid 
Percent 
 
 
Cumulative 
Percent 
 
 
Frequency 
 
 
Percent 
 
 
Valid 
Percent 
 
 
Cumulative 
Percent 
 
 
20-25 
 
1 
 
1.8 
 
1.8 
 
1.8 
 
0 
 
0 
 
0 
 
0 
 
26-30 
 
5 
 
9.1 
 
9.1 
 
10.9 
 
7 
 
12.7 
 
12.7 
 
12.7 
 
31-35 
 
10 
 
18.2 
 
18.2 
 
29.1 
 
13 
 
23.7 
 
23.7 
 
36.4 
 
36-40 
 
7 
 
12.7 
 
12.7 
 
41.8 
 
6 
 
10.8 
 
10.8 
 
47.2 
 
41-45 
 
11 
 
20 
 
20 
 
61.8 
 
10 
 
18.2 
 
18.2 
 
65.4 
 
46-50 
 
8 
 
14.5 
 
14.5 
 
76.3 
 
5 
 
9.1 
 
9.1 
 
74.5 
 
51-55 
 
8 
 
 
14.5 
 
 
14.5 
 
 
90.8 
 
 
4 
 
 
7.2 
 
7.2 
 
 
81.7 
 
56-60 
 
3 
 
5.5 
 
5.5 
 
96.3 
 
7 
 
12.7 
 
12.7 
 
94.4 
 
61-65 
 
2 
 
3.6 
 
3.6 
 
100.0 
 
3 
 
5.4 
 
5.4 
 
100.0 
 
 
Total 
 
 
55 
 
 
100.0 
 
 
100.0 
 
 
 
 
 
55 
 
 
100.0 
 
 
100.0 
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Table 25: Descriptive Statistics for Participants in ARV and Combined Groups 
 
 ARV Combined  
 N Minimum Maximum Mean Std. 
Deviation 
N Minimum Maximum Mean Std. 
Deviatio
n 
Gender 55 1.00 2.00 1.8000 .40369 55 1.00 2.00 
 
1.7273 .44947 
Age 55 22.00 65.00 43.0364 10.09210 55 27.00 65.00 
 
42.8909 10.79896 
Educati
on 
55 2.0000 4.0000 2.90909
1 
.6168236 55 2.0000 5.0000 3.00000 .8164966 
Marital 
Status 
55 1.00 6.00 2.6000 1.38245 55 1.00 6.00 2.7273 1.52090 
Ethnicit
y 
55 1.00 6.00 1.6364 1.23773 55 1.00 6.00 1.6182 1.28367 
Religio
n 
55 1.00 2.00 1.5455 .50252 55 1.00 2.00 1.5818 .49781 
Employ
ment 
55 .00 3.00 .9818 .45096 55 .00 3.00 1.0545 .48756 
Income 55 1.00 13.00 11.1636 3.09578 55 1.00 13.00 
 
11.7455 1.95522 
 
 
Table 26: Demographics of Participants in ARV and Combined Groups 
 
  ARV Combined  
  Frequ
ency 
Perc
ent 
Valid 
Perce
nt 
Cum
ulati
ve 
Perc
ent 
Freq
uenc
y 
Perc
ent 
Valid 
Percen
t 
Cumulati
ve 
Percent 
Gender  Male  11 20.0 20.0 20.
0 
15 27.3 27.3 27.3 
 Female  44 80.0 80.0 100
.0 
40 72.7 72.7 100.0 
 total 55 100.
0 
100.
0 
 55 100.
0 
100.0  
Education  Primar
y  
13 23.6
4 
23.6
4 
23.
64 
16 29.1 29.1 29.1 
 Second
ary  
34 61.8
1 
61.8
1 
85.
45 
25 45.5 45.5 74.5 
 Univer 8 14.5 14.5 100 12 21.8 21.8 96.4 
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sity  5 5 .0 
 Postgr
aduate  
0 0 0 100
.0 
2 3.6 3.6 100.0 
 Total  55 100.
0 
100.
0 
 55 100.
0 
100.0  
Marital 
status  
Single 1 1.8 1.8 1.8 4 7.3 7.3 7.3 
 Marrie
d 
43 78.2 78.2 80.
0 
37 67.3 67.3 74.5 
 Living 
as 
marrie
d 
2 3.6 3.6 83.
6 
5 9.1 9.1 83.6 
 Separa
ted 
2 3.6 3.6 87.
3 
2 3.6 3.6 87.3 
 Widow
ed 
7 12.7 12.7 100
.0 
7 12.7 12.7 100.0 
 Total 55 100.
0 
100.
0 
 55 100.
0 
100.0  
Ethnicity Yorub
a 
39 70.9 70.9 70.
9 
40 72.7 72.7 72.7 
 Hausa 6 10.9 10.9 81.
8 
6 10.9 10.9 83.6 
 Igbo 6 10.9 10.9 92.
7 
5 9.1 9.1 92.7 
 TIV/Id
oma 
1 1.8 1.8 94.
5 
1 1.8 1.8 94.5 
 Ijaw 1 1.8 1.8 96.
4 
0 0 0 94.5 
 Others 2 3.6 3.6 100
.0 
3 5.5 5.5 100.0 
  Total 
 
55 100.
0 
100.
0 
 55 100.
0 
100.0  
Religion Christi
an 
25 45.5 45.5 45.
5 
23 41.8 41.8 41.8 
 Musli
m 
30 54.5 54.5 100
.0 
32 58.2 58.2 100.0 
 Total 55 100.
0 
100.
0 
 55 100 100.0  
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Employme
nt 
Unemp
loyed 
5 9.1 9.1 9.1 3 5.5 5.5 5.5 
 Full-
Time 
47 85.5 85.5 94.
5 
48 87.3 87.3 92.7 
 Part-
Time 
2 3.6 3.6 98.
2 
2 3.6 3.6 96.4 
 Retired 1 1.8 1.8 100
.0 
2 3.6 3.6 100.0 
 Total 55 100.
0 
100.
0 
 55 100.
0 
100.0  
          
 
 
Table 27: Income of Participants in ARV and Combined Groups 
 
 ARV Combined  
 Freque
ncy 
Percen
t 
Valid 
Percent 
Cumula
tive 
Percent 
Freque
ncy 
Percent Valid 
Percen
t 
Cumulativ
e Percent 
>N1,200,000 1 1.8 1.8 1.8 1 1.8 1.8 1.8 
 
N1,000,000 to 
less than 
N1,200,000 
3 5.5 5.5 7.3 0 0 0 1.8 
N900,000 to less 
than N1,000,000 
1 1.8 1.8 9.1 0 0 0 1.8 
N400,000 to less 
than N500,000  
1 1.8 1.8 10.9 2 3.6 3.6 5.5 
N300,000 to less 
than N400,000 
0 0 0 10.9 2 3.6 3.6 9.1 
N200,000 to less 
than N300,000 
3 5.5 5.5 16.4 3 5.5 5.5 14.5 
N100,000 to less 
than N200,000 
6 10.9 10.9 27.3 5 9.1 9.1 23.6 
N37,000 to less 
than N100,000 
20 36.4 36.4 63.6 20 36.4 36.4 60.0 
0 to less than 
N37,000 
20 36.4 36.4 100 22 40.0 40.0 100.0 
Total 55 100 100  55 100.0 100.0 
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Table 28: Paired Sample Statistics for ARV Group (n=40) 
 
 Mean N Std. Deviation 
Pair 1      
BaselineCD4 
                
PostTXCD4                
298.6750 
567.4500 
40 
40 
139.06987 
272.07276 
 
 
 
 
 
 
 
 
Table 29: Paired Sample t-test for ARV Group (n=40) 
 
 
 
 
 
 
                                  Paired Differences 
 
Mean 
 
Std. 
Deviation 
 
      t 
 
    df 
 
Sig (2-
tailed) 
Pair 1   BaselineCD4-
PostTXCD4 
268.77500 253.22661 -6.713 39 .000 
 
 
 
Table 30: Paired Sample Statistics for Combined Group (n=39) 
 
 Mean N Std. Deviation 
Pair 1     
BaselineCD4 
              
PostTXCD4 
378.3333 
598.5641 
39 
39 
177.97018 
210.81568 
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Table 31: Paired Sample t-test for Combined Group (n=39) 
 
 
 
 
 
 
 
 
 
                                Paired Differences 
 
 
Mean 
 
    Std. 
Deviation 
 
     t 
 
   df 
 
Sig. (2-
tailed) 
 
Pair 1    BaselineCD4 - 
PostTXCD4 
 
220.23077 
 
226.19803 
 
-6.080 
 
   38 
 
      .000 
 
 
Table 32: ANCOVA table for CD4 Count 
 
 
 Group 1  ARV(n=) Group 2 COMBINED 
GROUP(n=) 
  
 Mean  SD  Mean  SD  F  p 
Baseline 
CD4 
    10.533 .002 
Post CD4 567.4500 272.07276 598.5641 210.81568 .045 .832 
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Table 33: Independent t-test for SSC-HIVrev 
 
Variable  
Group 1 ARV 
(n=55) 
Group 2 COMBINED 
(n=55)   
 Mean (SD) Mean (SD) t p 
Fatigue Factor .5273 .68663 .7318 1.04622 -1.212 .229 
Fear Factor .5773 .5773 .4909 .52916 .723 .471 
Fever Factor .3045 .40737 .6045 .59840 -3.073 .003 
GI Upset Factor .2455 .35840 .2545 .33771 -.137 .891 
SOB Factor .0545 .24649 .0364 .16571 .454 .651 
Sore Throat Factor .0273 .09220 .1636 .38556 -2.551 .013 
Numbness Factor .6091 .82332 .6909 .79635 -.530 .597 
Headache Factor .3909 .43238 .4727 .41576 -1.012 .314 
Rectal Itch Factor .1333 .44721 .1879 .47904 -.617 .538 
Bruising Factor .0636 .15380 .0864 .19376 -.681 .497 
       
 
 
Table 34: Independent t-test for WHOQOL-HIV BREF 
 
Variable (Domain) Group 1 ARV (n=55) 
Group 2 COMBINED 
(n=55)   
 Mean (SD) Mean (SD) t p 
Physical Domain 16.2545 2.56918 15.5818 2.69218 1.341 .183 
Psychological 
Domain 16.9455 2.45416 16.3491 5.82564 .700 .486 
Independence 
Domain 14.3091 2.11584 14.8182 9.16938 -.401 .689 
Social relationship 
Domain 16.2364 3.27145 14.6364 4.18712 2.233 .028 
Environment 
Domain 16.0182 2.40170 15.2182 2.91033 1.572 .119 
Personal belief 
Domain 13.3638 3.77302 13.0909 3.70322 .383 .703 
QOL 4.4364 .71398 4.3818 .62334 .427 .670 
Health satisfy 4.1273 1.10645 3.6545 1.36379 .1.996 .049 
Sum WHOQOL 93.1273 10.31684 89.6945 17.38157 1.259 .211 
 
                                                                115 
 
CHAPTER 5 
DISCUSSION 
 The purpose of this study was to investigate HIV treatment outcomes among 
patients using only antiretroviral medications (ARV) and among those using a combined 
therapy of ARV and herbal medications. This study also compares treatment outcomes in 
these two groups. Two instruments, namely the SSC-HIVrev and the WHOQOL-HIV 
BREF, were used to evaluate and compare treatment outcomes in these two groups. 
Novel findings were obtained from this study. Many of the findings of this study are 
consistent with findings from previous studies. In this section, findings of this study will 
be discussed, as well as its strengths, limitations, and implications. This chapter 
concludes with recommendations and a summary statement.  
Discussions of the findings focus on the validity and reliability of the study 
instruments, discussion of demographic information, discussion of the findings of each 
research question, and discussion of treatment outcomes in the patients taking only ARV 
and patients taking a combination of ARV and herbal remedies. 
Reliability of Instruments 
 To ascertain the suitability of the study instruments, a reliability test was done 
with a pilot sample. The two study instruments were administered to twenty subjects. The 
subjects were selected randomly among HIV patients receiving treatment at the State 
Specialist Hospital, Osun-State, Nigeria.  
WHOQOL-HIV BREF 
The Cronbach’s alpha for the WHOQOL-HIV BREF among Nigerian patients 
was found to be .84. This indicated that this instrument has good reliability among 
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Nigerian patients. This finding is consistent with findings from previous studies among 
different populations (Akinboro et al., 2014; Razavi et al., 2012; Reychler, Caty, Vincent, 
Billo, & Yombi, 2013; Saddki et al., 2009). Akinboro et al. (2014) reported Cronbach’s 
alpha ranging between .81 and .85. A similar trend was reported by Saddki et al. (2009) 
with Malay’s version of WHOQOL-HIV having Cronbach’s alpha values ranging from 
0.60 to 0.87 across all domains. Also, in consistency with this study, the French version 
of WHOQOL-HIV was reported to have high reliability with Cronbach’s alpha of 0.944 
(for spiritual/religion/personal beliefs domain), 0.94 (level of independence domain), 
0.937 (psychological domain), 0.938 (environmental domain), 0.94 (social relationships 
domain), and 0.942 (physical domain) (Reychler, Caty, Vincent, Billo, & Yombi, 2013). 
Razavi et al. (2012) reported that the reliability alpha among Iranian populations ranges 
between 0.61 and 0.8. Based on the reliability findings for this instrument in the pilot 
study, it is evident that the WHOQOL-HIV BREF is a suitable and highly reliable 
instrument for this study.  
SSC-HIVrev 
Similarly, a very high reliability was obtained for the SSC-HIVrev among 
Nigerian patients. This instrument is composed of six factors. However, a factor (i.e. the 
body changes) was omitted in the SSC-HIVrev questionnaire because it was not 
considered to be an important factor among the population of study. With the omitted 
factor, the Cronbach’s Alpha for the SSC-HIVrev instrument was .915. A factor (i.e. 
shortness of breath factor) was found to be negative. This indicates that there was no 
variation among the participants’ responses to the question. The negative and low alpha 
scores seen in some factors may indicate mixed understanding of the way the participants 
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understood the item and items’ response options. The low alpha scores mean that items 
are not highly correlated. There may be a need to refine the wording of this questionnaire 
to be consistent with Nigerian cultural interpretation.  
Fundamental assumptions of this instrument might need to be refined as well. 
Records of reliability of this instrument among Nigerian population were not found in the 
literature. However, the high reliability found in this study is consistent with findings 
from Holzemer et al. (2001). The reliability Cronbach’s alpha obtained by Holzemer et 
al. (2001) ranges between 0.76 to 0.94. “The six symptom clusters, the number of items 
in the factor and the Cronbach’s alpha reliability estimates for this instrument were 
Malaise/Weakness/Fatigue (six items with Cronbach alpha of 0.90), Confusion/Distress 
(four items with Cronbach alpha of 0.90), Fever/Chills (four items with Cronbach alpha 
of 0.85), Gastrointestinal Discomfort (four items with Cronbach alpha of 0.81), Shortness 
of Breath (three items with Cronbach alpha of 0.79) and Nausea/Vomiting (three items 
with Cronbach alpha of 0.77” (Holzemer et al., 2001, p. 1041). This shows strong 
reliability and validity for this instrument. 
Face validity of both instruments was also evaluated by the researcher. Face 
validity was done to see if the items are culturally relevant to Nigerian population. Being 
originally from Nigeria and fluent in one of the dominant Nigerian languages, the 
researcher is an expert in Nigerian culture. Evaluating both the face validity and internal 
consistency of both questionnaires showed that the instruments were highly valid and 
culturally relevant to Nigerian population. Only the weight factor in the SSC-HIVrev was 
considered to be unimportant to the Nigerian population.  
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Trends from Demographic Data 
Findings from this study show that there is a disparity in the population of male 
patients seeking and receiving treatment for HIV. Over three quarter (76.4%) of 
participants in this study were females with only 23.6% male participants. Even in both 
the ARV group (80% females and 20% males) and the combined group (72.7% females 
and 27.3% males) more females were receiving treatments. The high population of 
female participants is a reflection of the large population of female patients receiving 
treatment in the clinic. Significantly lower numbers of male patients were receiving 
treatment at the clinic. The disproportionally large female population noted in this study 
is consistent with findings from Bello and Bello (2013). In Bello and Bello’s (2013) 
evaluation of the quality of life of HIV/AIDS patients in a secondary health care facility 
in the Nigerian city of Ilorin. 70% of the participants were female. Similarly, participants 
in Onyebuchi-Iwudibia & Brown (2014) and Ahmed et al. (2013) were 72.4% and 62.4% 
females respectively. Ahmed et al. (2013) reported the HIV testing rate among females 
(62.4%) to be significantly higher than that of male (37.6%) at facilities in Nigeria. 
Takarinda et al. (2016) also found that females in Zimbabwe tend to make themselves 
available for HIV testing. In determining the HIV testing rates among Zimbabwean males 
and females, Takarinda et al. (2016) reported testing rates of 61% among Zimbabwean 
females as compared to 39% males. The implication of this is that there is a high 
population of HIV-positive men that are not diagnosed. This translates into fewer males 
eventually entering into treatment, as noted in Egbe, Omoregie & Alex-Ighodalo (2015).  
The lower testing rates noted in males could have large negative public health 
consequences. It is likely that the male sense of invincibility is partially responsible for 
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the low testing and low treatment rates. Studies have shown that there is a high 
population of male HIV patients in Nigeria. According to the National HIV/AIDS and 
Reproductive Health Survey (NARHS) conducted in 2012, there is a national HIV 
prevalence of 3.4% (NACA, 2014). 58% of HIV-positive people in Nigeria are women, 
and 42% of HIV patients are men (NACA, 2012). This translates into over 1.4 million 
HIV positive males. This is an astonishingly high HIV population among Nigerian men. 
In the light of Smith’s (2007) assertion that sexual and economic disparities and 
contradictory moralities could contribute to an HIV epidemic in Nigeria, the Nigerian 
male population need to be encouraged to seek testing and treatment for HIV. If most of 
these male patients are not entering into treatment, this may portend grave public health 
issues particularly in society where polygamy is a generally acceptable and widely 
practiced cultural norm (Lawan, Envuladu & Abubakar, 2016). This becomes all the 
more serious, considering prevailing gender inequality and the inability of females to 
negotiate sexual relationships in many Nigerian cultures. It is necessary for coordinated 
efforts to pull male HIV patients into treatment in conventional HIV clinics.  
 This study revealed that a majority of study participants (80%) had secondary 
education or lower. Only 1.8% were found to have a postgraduate education and 18.2% 
were found to have a bachelor’s degree. This shows that highly educated Nigerians are 
not participating in treatment. A consistent finding by Suleiman & Momo (2015) found 
that 65.3% of HIV patients receiving antiretroviral therapy in two hospitals in Bayelsa 
state, Nigeria had secondary (high school) education or below. Similarly, Lubinga, Kintu, 
Atuhaire, & Asiimwe (2012) also found that 96.1% of patients in a western Uganda study 
had a secondary education or below. According to the United Nations Human 
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Development Report, Nigeria has a 62.6% poverty rate in 2016 
(http://www.ng.undp.org/content/nigeria/en/home/library/poverty/national-human-
development-report-2016.html). With the poverty index of Nigeria at all time high, 
highly educated HIV positive individuals have the financial advantage to attract 
individuals with less education into unprotected sex. This could lead to a higher incidence 
of HIV among Nigerians. Strategic approaches need to be adopted to encourage highly 
educated Nigerian professionals to seek treatment from orthodox HIV clinics and/or 
hospitals. It appears that a higher number of poor and economically disadvantaged people 
tend to seek treatment for HIV.  
The majority of patients (72.7%) who were receiving treatment in both groups 
were married, with an additional 1.8% living as married. 78.2% of subjects in the ARV 
group and 67.3% of subjects in the combined group were in a legal relationship. 
However, a majority of the married participants disclosed to the researcher that their 
spouses were not aware of their HIV status. Reasons given for non-disclosure include the 
stigma attached to HIV and the fear of being rejected by their spouses and family 
members.  Although tremendous improvements have been made to reduce the 
stigmatization of HIV patients, a substantial stigma is still attached to the infection in 
Nigeria. Onyebuchi-Iwudibia & Brown (2014) reported a high level of HIV-related 
stigma among HIV patients in the eastern part of Nigeria, noting a strong association 
between stigma and depression. A similarly high level of stigmatization against HIV 
patients was reported by Downshen, Binns & Garofolo (2009) and Simbayi et al. (2007). 
Stigmatization is known to have a significant impact on the physical health and the 
overall quality of health of HIV patients. As a result, more efforts have to be channeled 
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into education and increasing acceptance and support for HIV patients. Non-disclosure of 
HIV status to spouses is very dangerous, as this could put spouses of HIV patients at risk 
of contracting the disease. It is necessary that concerted efforts should be directed at 
encouraging disclosure of HIV status to spouse and family members.  
 Findings from this study show that although over 86% of participants are engaged 
in full time employment, a significantly high number of this population (90.1%) are low 
income earners with an annual income of less than N300,000 (three hundred thousand 
Nigerian Naira). This translates into an annual income of US$700 (seven hundred 
American dollars). This trend is indicative of poor financial status of most of the 
participants receiving treatment. Since HIV prevalence cuts across different income strata 
of the Nigerian population, it could be assumed that high income earners are not entering 
conventional treatment in comparable numbers to low-income earners. Also, it is possible 
that high-income earners could be avoiding treatment in conventional HIV clinics or 
going “under the radar” to source for alternative treatments which may include herbal 
remedies. During the initial but failed recruitment efforts into the herbal-only group, all 
the patients contacted for enrollment into the herbal group were in highbrow locations 
and working in top private and government establishments. Although their identities were 
essentially concealed, their care provider disclosed that they were not willing to be 
identified because of their prominent status in the society.  
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Research Questions 
 This study was carried out to seek answers to five research questions. These 
research questions could provide great insight into treatment outcomes in patients taking 
only ARV and in patients taking a combined therapy of ARV and herbal medications. 
Research Question 1 
 The first research question for this study was, “How do CD4 counts differ after 
treatment with antiretroviral medications only?”. Findings from this study show that there 
is a significant difference between pre- (baseline) and post-treatment CD4 counts among 
subjects taking ARV medications only (t=-6.713, sig (2-tailed)=.00 and df=39). CD4 
count is a good biomarker of HIV treatment outcome. This study shows that ARV 
resulted in significant improvements in CD4 counts after less than six months of ARV 
therapy. The difference noted in the post CD4 counts is consistent with findings from 
previous studies (Coetzee et al.,2004; Fairall et al., 2008; Idigbe et al., 2005). Fairall et al. 
(2008) also reported an increase of 15.1cells/μL in CD4 cell counts with each month of 
highly active anti-retroviral therapy (HAART) administration among South African 
patients, while Coetzee et al. (2004) reported good clinical outcomes among patients 
receiving ARV in Khayelitsha, South Africa. Among Nigerian patients, Idigbe et al. 
(2005) found that ARV led to an increase in CD4 counts and improvement in the overall 
physical wellness of Nigerian patients receiving a combination of Nevirapine, Stavudine 
and Lamivudine. The finding of this study supports the fact that ARV is currently the 
gold standard in the management of HIV infection. This could be noted in the significant 
increase in baseline CD4 counts from 298.6750 to 567.4500 post-ARV treatment across a 
six-month treatment period. 
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Research Question 2 
The second research question for his study was, “How do CD4 counts differ after 
treatment with a combined therapy of herbal treatment and conventional antiretroviral 
medications?” Findings from this study show that there is a significant difference 
between the pre- and post-treatment CD4 counts among subjects taking a combination of 
ARV and herbal medications (t=-6.080, sig. (2-tailed)=.00 and df=38. CD4 count is a 
good biomarker of HIV treatment outcomes. CD4 counts increased from 378.3333 
baseline to 598.5641 post-treatment with a combined therapy of ARV and herbal 
medications.  
The significant difference noted in CD4 counts in this group is consistent with 
findings from Ayuba et al. (2014). Ayuba et al. (2014) investigated the efficacy of a West 
African bicolor-based traditional herbal preparation (Jobelyn) used in combination with 
ARV among Nigerian patients.  Consistent with findings of this study, Ayuba et al. 
(2014) reported improvement in CD4 counts of patients receiving ARV only and those 
patients taking a combination of Jobelyn and ARV. However, Ayuba et al. (2014) found 
that patients that received a combination of ARV and Jobelyn recorded faster 
improvement in CD4 counts with a higher level of statistical significance at 6 weeks and 
12 weeks when compared with patients that received only ARV. Awodele et al. (2012) 
reported a marginal improvement in the CD4 counts and viral load of HIV patients using 
herbal medications when compared with those patients who are not in herbal therapy. 
However, the improvement noted between the herbal group and non-herbal group was 
found not to be statistically significant (Awodele et al., 2012). No side effects or cross 
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reactions were reported by patients taking combined therapy. Reasons given for taking 
herbal therapy include to improve general health and immune systems, to reduce pain, 
and to ameliorate symptoms of opportunistic infection.  
Research Question 3 
The third research question for this study was “What is the difference in CD4 
counts of patient taking ARV only and those taking a combination of herbal therapies and 
conventional antiretroviral medications?” This study compared the efficacy of ARV only 
therapy with a combined therapy of ARV and herbal remedies. Results show that there is 
no significant difference in the post treatment CD4 counts between the ARV group and 
the combined group. This result shows that when CD4 counts are used as biomarkers to 
evaluate treatment outcome between these two groups, there was no difference in 
treatment outcome. This finding is in contrast to findings by Ayuba et al. (2014) which 
found a significantly higher statistical difference in the treatment outcomes between 
patients receiving ARV only and patients that received a combination of ARV and herbal 
remedy with Jobelyn. Although Ayuba et al. (2014) found improvements in both the 
ARV only group and the combined group, the study found that the combined group 
achieved faster improvement in CD4 counts with a higher level of statistical significance 
at 6 weeks and 12 weeks when compared with the ARV only group. It could be assumed 
that herbal remedies produced no significant effect in treatment outcomes when used in 
combination with ARV. If herbal remedies contributed in any significant way, it is 
expected that the use of herbal remedies concomitantly with ARV should produce 
treatment outcome that will significant improve the post-treatment CD4 counts in the 
combined group when compared with ARV only group. If herbal medications produced 
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an additive therapeutic role to ARV when they were used concomitantly with ARV, the 
combined therapy is expected to result in better treatment outcomes and significant 
improvement in physiological factors such as CD4 counts. Although the mean CD4 count 
in combined group (598.5641) is higher than the CD4 counts in the ARV-only group 
(567.4500), the slight increase noted in the combined group is not statistically significant 
to confer superiority of treatment outcome on the combined group.  
Unlike the findings from Ayuba et al. (2014), the “no difference” noted between 
these groups may be because of the ineffective therapeutic nature of the specific herbal 
medications taken by the combined group. The therapeutic, pharmacodynamics and 
pharmacokinetics of the herbal medications used in this study were not known. Hence, 
the lack of difference seen in this study may show that the types of herbal medications 
used by participants of this study did not produce any therapeutic effects. While some 
herbal medications have shown superior efficacy (Ayuba et al., 2014; Onifade et al., 
2011a; Sangkitporn et al., 2005; Sugimoto et al., 2005) it could be assumed that not all 
herbal medications are resulting in similar treatment outcomes. The herbal medications 
used in this current study probably helped to reduce some side effects and reduced the 
incident of opportunistic infections.  
A very important finding of this study was that the use of herbal medications did 
not produce any undesirable outcome in CD4 counts. Since herbal remedies are widely 
used, widely available and easily accessible in Nigeria, it is important to note that the use 
of herbal medications with ARV did not result in any undesirable outcome. In the ARV 
group, mean baseline CD4 counts increased from 298.6750 to 567.4500 after treatment. 
Similarly, in the combined group, the baseline CD4 counts increased from 378.3333 to 
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598.5641 post-treatment. The initial statistical difference noted between the baseline CD4 
of the ARV group and combined group was statistically adjusted for using analysis of 
covariance (ANCOVA). 
 A striking finding was obtained from this study. This study showed that 100% of 
patients taking herbal medications concomitantly with ARV reported that their care 
providers were not aware of their use of herbal remedies. Reasons given for non-
disclosure include the fear of possible treatment denial and reproach from their 
physicians and care providers. Similar finding were recorded by Lubinga, Kintu, 
Atuhaire, & Asiimwe (2012) among HIV patients in Western Uganda where 92.3% of 
patients reported that their physicians were not aware of their concomitant use of herbal 
medications with ARV. Similarly, Peltzer, Preez, Ramlagan, & Fomundam (2008) also 
reported that 90% of HIV patients in KwaZulu-Natal, South Africa did not disclose 
concomitant use of herbal medications with ARV to their physicians. In addition, in a 
study among patients in Kumasi metropolis in Ghana, Gyasi, Tagoe-Darko, & Mensah 
(2013) found that 70% of patients used herbal medications. However, Gyasi, Tagoe-
Darko, & Mensah (2013) found that 93.9% of HIV patients did not disclose their use of 
herbal medications to their physicians. This pattern of non-disclosure was also reported 
by Shedlin et al. (2013) among Mexican-origin patients in a U.S.-Mexico border HIV 
clinic. Many reasons were given for the use of herbal medications. As also noted by 
Shedlin et al. (2013) patients using herbal medications reported using it to help their 
general health, improve their immune systems, and ameliorate symptoms of opportunistic 
infection and side-effects related to ARV use. This is consistent with the reported use of 
herbal medications in pain management (Gyasi, Tagoe-Darko, & Mensah, 2013; Peltzer, 
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Preez, Ramlagan, Fomundam, 2008), stress relief, appetite stimulation and to promote 
general physical well-being (Gyasi, Tagoe-Darko, & Mensah, 2013). 
Research Question 4 
The fourth research question for this study was, “What is the difference in the 
symptom experience of patient taking ARV only and those taking a combination of 
herbal therapies and conventional antiretroviral medications?”. The difference in 
symptom experience between the two groups was measured using the SSC-HIVrev 
instrument. A comparative analysis of overall symptom experience of patients in the 
ARV-only group and combined group shows that there is no significant difference 
between the two groups. Although no significant difference was noted in overall 
symptom experience in both groups, significant difference was noted in some factors of 
the symptom cluster. Specifically, significant differences were noted in fever (p=.003) 
and sore throat factors (p=.013). The fever factor mean scores for ARV group and 
combined group were .3045 and .6045 respectively. This signifies that the patients in the 
ARV group recorded significantly better outcomes in fever factor compared to patients in 
the combined group. The intensity of fever episode in ARV group was significantly lower 
than the fever intensity among patients in combined group.  
Similarly, a significant difference was noted in sore throat factors (p=.013) 
between the ARV group and combined groups. The sore throat factor mean scores for 
ARV group and combined group were .0273 and .1636 respectively. This signifies that 
the patients in ARV group recorded significantly better outcome in sore throat factor 
compared with patients in the combined group. The intensity or seriousness of sore throat 
in ARV group is significantly lower than the sore throat intensity among patients in the 
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combined group. This shows a consistently better treatment outcome in ARV group when 
compared with the combined group.  
Research Question 5 
The fifth research question for this study was, “What is the difference in the 
quality of life of patients taking only ARV, and those taking a combination of herbal 
therapies and conventional antiretroviral medications? This study compared the quality of 
life between patients taking ARV only (ARV only group) and patients taking 
combination of ARV and herbal medications (combined group). This comparison was 
done using the WHOQOL-HIV BREF instrument. Results show that there is no 
significant difference in the overall quality of life of both groups. This finding is 
consistent with findings from Bepe et al. (2011) among Zimbabwean HIV patients. 
Similar to this study, Bepe et al.’s (2011) study among Zimbabwean HIV patients 
showed that the use of herbal medications concomitantly with ARV did not produce 
significant improvement in the quality of life index when compared to patients using only 
ARV. Although in this study no significant difference was noted between both groups, a 
significant difference was noted in two domains (social relationship and health 
satisfaction domains) between the ARV group and combined groups. The health 
satisfaction mean scores for ARV group and combined group were 4.1273 and 3.6545 
respectively. This signifies that patients in ARV-only group reported significantly better 
satisfaction in their health compared to the combined group.  
A similar trend was noted in social relationship domain. The social relationship 
domain mean scores for ARV group and combined group were 16.2364 and 14.6364 
respectively. This signifies that patients using ARV only recorded significantly higher 
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improvement in their social relationship compared to patients using a combination of 
ARV and herbal medications. It is evident that there is a direct relationship between the 
social relationship and health satisfaction domains. It appears that patients with a good 
social relationship tend to enjoy better health satisfaction. It could be that the support 
from family members, friends, and significant others plays an important role in patients’ 
perception of wellness, and helps patients to navigate and better cope with diagnosis and 
treatment for HIV. 
As seen in the findings from research questions 4 and 5, some factors and 
domains in the SSC-HIVrev and WHOQOL-HIV BREF revealed that there are 
consistently better treatment outcomes in ARV group when compared with the combined 
group. The significantly better treatment outcomes noted in the ARV group in the two 
domains and factors explained above may translate into better quality of life for patients 
in the ARV group. It is doubtful if herbal medications play any significant additive role to 
justify impact in the overall quality of life of patients. It appears that the use of herbal 
medications play little role in the quality of life of patients when used concomitantly with 
ARV. It is important to know if the used of only herbal medications would produce 
significant treatment outcomes that is comparable or superior to ARV-only therapy group 
or to combined group.  
Several studies have shown that the use of herbal remedies only can be effective 
in the treatment of HIV (Onifade et al., 2011a; Sangkitporn et al., 2005; Sugimoto et al., 
2005). Among people living with HIV/AIDS in northeastern Thailand, Sugimoto et al. 
(2005) reported significantly better mental health scores in patients using herbal 
medications than non-users of herbal medications. Onifade et al. (2011a) found that 
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herbal therapy with a-Zam was an effective anti-HIV agent resulting in significant 
increase in CD4 counts and significant decrease in viral load after treatment with a-Zam 
from four months after initiation of herbal therapy. Onifade et al. (2016) reported no 
remarkable harmful drug interaction between a-Zam and Highly Active Anti-Retroviral 
Therapy (HAART). Another widely used herbal formulation in China, SH, was reported 
to be effective in HIV treatment. Each of the five constituents of SH was reported to be 
an individually effective anti-HIV agent, and the combined herbs are also reported to 
possess anti-retroviral activity (Sangkitporn et al., 2005). Findings from Sangkitporn et 
al. (2005) showed that HIV RNA decreased significantly from the baseline value in both 
the experimental and control groups from week 4 of treatment.  SH group was found to 
have a significantly lower HIV RNA compared to the control group. The CD4 counts 
after 12 weeks and beyond showed a significant increase in SH group from baseline 
value. Sangkitporn et al. (2005) found that a combination of SH herbs with two 
nucleoside reverse transcriptase inhibitor has a greater antiviral ability than conventional 
antiretroviral medications. It will be interesting to compare treatment outcomes in herbal 
only group, ARV only group, and with combined therapy. Like in this study no serious 
adverse effect was reported with concomitant use of SH with conventional antiretroviral 
medications.  
Implications of this Study 
This study has provided expanded insight into the treatment outcomes in patients 
using different treatment modalities in the management of HIV infection. Although the 
use of antiretroviral medications are generally and widely accepted as gold standard for 
HIV management, it was seen from this study that a large proportion of HIV patients also 
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use herbal medications concomitantly with ARV. While some used herbal medications as 
complimentary medications, many reportedly used them as alternatives to conventional 
antiretroviral medications. Many patients using herbal mediations reportedly did not 
disclose its use to their physicians and care providers for the fear of being refused 
treatment by their orthodox physicians and care providers. 
Awareness about HIV is very high among Nigerian populace. However, large 
scale discrimination and stigmatization are still prevalent, especially in non-official 
interactions. There is a large effort on the part of government to provide appropriate 
education and reduce stigmatization. However, it appears that the ignorance of the 
common people is still largely high. The hyperactive enlightenment program initiated by 
governmental and private agencies at the beginning of HIV epidemic in the early 90s 
seems to be now dormant. This is mainly because of the perceived belief that people are 
now well informed about the disease. The fight against HIV needs to be sustained at all 
levels of Nigerian social classes/strata. 
Equally important is the level of funding directed toward treatment, counseling 
and education of HIV. Nigeria as a country relies heavily on foreign sponsorship and 
donations in the war against HIV. Nigeria, being one of the largest economies in Africa, 
needs to show more commitment in taking control of its future and channel more of its 
own resources towards education and eradication of HIV. Indigenous researchers and 
scientists should be supported to devote their energies to fighting and finding a cure for 
HIV. Various claims of HIV cure that are rampant in Nigeria need to be scientifically 
investigated to protect the innocent citizen from depending on and patronizing ineffective 
treatment modalities. It is obvious that the patronage of non-conventional medications is 
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very high in Nigeria. The current over reliance on foreign governments and donors 
cannot be to the best advantage of the Nigerian nation. 
The aim of this study was to compare treatment outcomes in two groups of 
patients that were taking ARV only and those that were taking a combined therapy of 
ARV and herbal medications. Findings from this study have implications in nursing 
practice, research and education. 
Nursing Practice 
It is important to note that during data collection for this study that all the subjects 
in the combined group verbalized a desire not to disclose their dual therapy to their 
caregivers. Patients only disclosed that they were taking herbal medications after the 
researcher had gained their confidence and assured that confidentiality of subjects’ 
information would be protected and would not be disclosed to individuals outside the 
study group. However, the researchers strongly advised and counselled subjects to 
disclose their dual therapy to their caregivers so that they could be adequately cared for. 
Most of the subjects verbalized the fear that their caregivers would not take care of them 
if they disclose that they were taking herbal medications. Similarly, many of the subjects 
did not disclose their HIV status to their spouses and family members for the fear of 
rejection. In nursing practice it is important that nurses establish a professional and 
trusting relationship with patients so that patients can confide in them and disclose 
treatment information that is necessary for better outcome. Knowledge of this 
information will enable nurses and physicians to consider possible side effects and 
interactions that could occur between the conventional ARV and herbal remedies. Non-
disclosure of HIV status to spouses and significant others is a very big problem. In 
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practice, nursing staff could play an important role in providing sufficient education, 
encouragement, and support to HIV patients and facilitate voluntary disclosure of status 
by the patients to their loved ones. Knowledge gained from this study should guide 
nurses in professional interactions with patients. Nurses should specifically ask about 
dual therapy, and holistically look into issues relating to disclosure of HIV status. 
Nursing Research 
 Through this study a comparative analysis of two different treatment methods, 
ARV-only therapy and combined therapy, was carried out. This study is a precursor to 
other new nursing research on HIV treatment modalities. This study did not investigate 
the lived experience of HIV patients during the course of treatment with either ARV only 
or with a combination of ARV and herbal medications. Since nursing is essentially a 
caring and nurturing profession, nursing concentrates on holistic care. As a result of this, 
nursing care tends to foster healthy, nurturing and therapeutic relationship with patients. 
Findings from this study show that there was a disconnect between the patients and their 
care providers, at least in the population under investigation. This disconnection is 
apparent in the patients’ non-disclosure of their dual therapy. All subjects that were 
taking a combination of ARV and herbal medications reported non-disclosure of the use 
of herbal medications to their care providers. Nursing should be at the fore front of 
empirical research into reasons behind non-disclosure by carrying out studies to 
understand the different methods and approaches that could be used to foster trusting 
relationships between patients and their care providers. The profession of nursing is 
fundamentally equipped to investigate this essential phenomenon.  
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 In the course of recruitment for this study, it was discovered that many patients 
were using only herbal medications to treat HIV.  This situation is very dire, as the 
effectiveness of only herbal therapy in the treatment of HIV is still not widely reported. 
This has great implications in nursing research. Nursing research need to focus 
investigation on the lived experience of HIV patients using herbal medications only. The 
use of qualitative methodology in the investigation of the experience of this group would 
provide valuable insight. This could enable us to gain a rich understanding of the reasons 
for using herbal medications. It will enable us to investigate the impacts of herbal therapy 
on HIV. This will help our understanding of the perception of patients in this group on 
their quality of life and on their symptom modifications. 
Nursing Education 
 Evidence-based practice (EBP) is a cornerstone of nursing education. The focus 
of nursing education in the 21st century is to promote and incorporate evidence-based 
research findings into education. Transformation of practice environment is only possible 
when quality research findings are incorporated into education of nursing students and 
also into continuous in-service education of qualified nurses. Nursing education needs to 
emphasize the role of nursing in building therapeutic and trusting relationships with 
patients. The disconnection and distrust noted between patients in the combined group 
and the care providers could be prevented if the nursing staff in the hospital used their 
professional skills to foster trusting relationship with the patients in this group. With 
appropriate evidence-based practice, nurses could develop efficient pragmatic approaches 
to nursing care. 
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Strengths of this Study 
This study was meticulously designed to ensure strict adherence to ethical issues. 
Patients’ confidentiality was maintained and protected throughout the duration of this 
study. No subjects’ identifiable data were collected or stored in any research documents. 
While this study possesses no direct risk to patients’ physical health, it is possible that 
psychological and mental trauma may result if confidentiality of patients’ information is 
breached. Only a randomly assigned patient number was used in all research documents. 
No recording or videotaping was used during this study. Patient information was 
electronically stored in a password-protected computer system. All paper copies were 
stored under lock and key in a fireproof cabinet. The paper copies were shredded after 
information was stored electronically.   
Each subject was given extensive explanation about the study. Subjects were 
given the opportunity to ask questions. Patients’ were given full disclosure of possible 
risks associated with the study. In addition to obtaining informed consent from each 
patient, a continuous re-negotiation of consent was maintained through process consent. 
This provided opportunity to provide continuous clarification and opportunity for 
questions. Process consent provided the opportunity for subjects to discontinue 
participation from the study at any time should they choose to do so. 
Particular attention was paid to trustworthiness of data obtained from this study. 
The strength of the funding of this study is a function of the reliability of the study 
instruments. Instruments used for data collection were carefully selected to achieve high 
quality data. Two extensively used and well-tested instruments were used for data 
collection. The SSC-HIVrev was developed by renowned nurse scientists while the 
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WHOQOL-HIV BREF was developed by a group of reputable experts from World 
Health Organization (WHO). The two instruments used for data collection have been 
confirmed to have high reliability and validity. In spite of the documented reliability of 
these instruments, a pilot study was done at the beginning of this study. The pilot study 
was carried out prior to the main study to measure the Cronbach alpha reliability and face 
validity of the study instruments. The two instruments were found to be highly reliable in 
the population of study. Also, face validity of the instruments was determined by the 
researcher, and both instruments were considered to have high validity and high 
reliability. This high reliability was obtained even with the omission of the weight factor 
from the SSC-HIVrev instrument. 
The differences noted in baseline CD4 counts between ARV group and combined 
group were statistically adjusted and controlled using analysis of covariance (ANCOVA). 
ANCOVA statistically controlled the effect of continuous variables that are not of 
primary interest in this study. The use of ANCOVA helped to statistically adjust and 
control the differences noted in baseline CD4 counts between the two groups before 
comparative analyses of the two groups were done. 
The source of data used in this study was considered to be an important 
determinant of data quality. Hence, only data obtained from credible, verifiable sources 
was used in this study. The source of CD4 counts could be a potential source of 
confounding variable. Patients’ CD4 counts could be obtained from different sources or 
directly from the patients. However, to ensure credible data, only CD4 counts obtained 
directly from patients’ medical records were used in this study. CD4 count records given 
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by the patients were not used. This approach ensured that only quality and credible data 
sets were used for this study. 
 In selecting a sample for this study, a random assignment technique was used. 
Sampling was done randomly from matched subjects that are similar in terms of 
important extraneous variables. Randomization eliminated the sources of bias in the 
treatment, enhanced the external validity of the study finding, and ensured 
representativeness of sampling. This enhanced the generalizability of the study findings 
to the larger Nigerian population. The matching of samples for important extraneous 
variables helped to eliminate confounding variables that could adversely affect study 
findings. The study design and implementation, analytical procedure and reporting 
process for this study followed a high standard expected of sound scientific study. 
 
Limitations of this Study 
 This study was initially designed to have three groups namely;  
➢ Group A: Participants were to be drawn from patients who were using only herbal 
therapies for their treatment.  
➢ Group B: Participants were to be drawn from patients who were using only 
conventional antiretroviral medications.  
➢ Group C: Participants were to be drawn from patients who were using a 
combination of herbal therapies and conventional antiretroviral medications for 
their treatment. 
It was presumed that the inclusion of herbal group only would help the researcher 
to determine the impact of using only herbal medications on HIV treatment outcome and 
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to evaluate the efficacy of herbal therapy only. However, recruitment of subjects into this 
group was very difficult, as it was hampered by multiple factors. The first major factor 
was the stigmatization associated with HIV in Nigeria. During recruitment efforts for this 
group, it was found that patients using only herbal medications were trying to hide their 
status by not seeking treatment in conventional HIV clinics and hospitals. The second 
factor that hampered recruitment efforts for this group was the condition that needed to 
be met before recruitment into this group. Recruitment for this group could only be done 
if the researcher committed to funding the cost of herbal treatment for patients in this 
group. The budget for this study could not fund such treatment. Also, ethical issues may 
arise as a result of this undertaking, as it may appear that the researcher influenced the 
treatment choice of the patients. This study was designed to study treatment outcomes in 
patients already receiving a specific treatment but not to influence patients’ treatment 
choice. The inability to enroll into this group was a very important deviation from the 
initial plan of this research. It is the hope of this researcher that future studies will 
compare treatment outcomes in these three groups. 
 Also, this study was initially designed to use CD4 counts and viral load as 
biomarkers of physiological treatment outcomes. However, the state specialist hospital 
has no viral load records for any of the patients receiving treatment in the hospital. In 
fact, viral load was not available in many clinics contacted in Nigeria. The only available 
option for getting patients’ viral load was for the researcher to fund the test. However, 
this study lacked the funding for such an expensive laboratory test. Information about 
viral load could, in conjunction with CD4 counts, help determine the efficacy of different 
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treatment options. It is important that future studies should obtain viral load in addition to 
CD4 counts.  
HIV infection is a debilitating health problem that requires holistic treatment 
approach. It is important to evaluate the lived experience of Nigerian HIV patient in the 
course of their daily life and treatment regime. This study did not investigate the lived 
experience of the patients during their treatment regimens. It is recommended that future 
studies should employ qualitative methods to evaluate the lived experience of HIV 
patients during the course of their different treatments. In spite of the identified 
limitations of this study, the study provided findings that could shape future studies and 
improve treatment and care of HIV patients.    
Recommendations 
 This study is considered to be the beginning of exploration of the vast area of 
herbal therapy in the treatment of HIV. Further studies are necessary to provide expanded 
insight into the use of herbal remedies in HIV treatment. Similarly, further study is 
necessary to evaluate and compare different HIV treatment protocols. This study was 
unable to recruit and enroll sufficient number of patients taking herbal medications only. 
However, a lesson learned from the recruitment efforts for this group revealed that 
patients in this group could easily be enrolled into future studies if the researcher could 
provide partial or full funding of herbal treatment. Because of insufficient funds and 
possible ethical issues, this researcher was unable to enroll patients taking herbal 
medications only. It is therefore recommended that future studies should focus on 
comparing treatment outcomes in those patients taking ARV only, herbal medications 
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only and combined therapy. Findings from these studies would enable us to determine 
and compare efficacy of these treatment protocols.  
 Similarly, there is a need to evaluate the lived experience of patients in each 
treatment group. It is recommended that future studies explore qualitative methods to 
investigate the lived experience of patients receiving ARV only, combined therapy and 
herbal medications only. The use of qualitative methodology will show the richness of 
the experiences of individuals during the course of their respective therapies.  
Findings from this study show that stigmatization is still very high in Nigeria. The 
quality of life of HIV patients is a function of social factors such as stigmatization. The 
quality of life of HIV patients could be better enhanced if stigmatization attached to HIV 
is adequately addressed. Efforts should be increased by the government and other 
stakeholders to reduce stigmatization of HIV patients. To prevent targeting of HIV 
patients, efforts should be made to provide privacy for patients during treatment. This 
will make it possible for HIV patients to be cared for without compromising patients’ 
identity. There should be an interplay of community action and political initiatives to 
combat stigmatization and foster acceptance of HIV patients. 
Also, this study was initially designed to use CD4 counts and viral load as 
biomarkers of physiological treatment outcomes. However, records of viral loads of 
patients were not available in the State Specialist Hospital. As a result of this, the study 
could not compare the viral load of patients in each group. It is recommended that future 
studies should use both CD4 counts and viral load as biomarkers of physiological 
treatment outcomes. 
                                                                141 
 
A frightening trend was noted during this study. Finding from this study show that 
majority of people seeking treatment were disproportionately female, low-income earners 
and poor individuals. The question that arises is “Where are the men of affluence and 
elites seeking treatment?” Since HIV infection cut across social strata, it is important that 
educational efforts be designed to target Nigerian elites and the well-to-do members of 
the society. This will prevent a public health epidemic. In light of Smith’s (2007) 
assertion that sexual and economic disparities and contradictory moralities could 
contribute to HIV epidemic in Nigeria, Nigerian male populations need to be encouraged 
to seek testing and treatment for HIV. Any strategic efforts to combat the spread of HIV 
that exclude this group of Nigerians might be counterproductive because of their social 
power to negotiate sexual relationship with the poor members of the society. It is 
expected that future studies will look into ways and strategies to bring many well-to-do 
Nigerians into testing and treatment in conventional clinics and hospitals. 
Findings from this study revealed that100% of the participants did not disclose 
use of herbal medication to their primary physicians and care providers. Reasons given 
for non-disclosure include fear of being refused treatment, admonition by their 
physicians, and fear of incurring their displeasure. This disconnection and lack of 
disclosure could affect the overall health outcome of patients. Physicians and care 
providers need to have the totality of information needed to efficiently care for the 
patients. Also, there is a possibility of cross-reaction or possible interaction between the 
ARV and herbal medications that physicians might not be aware of. It is recommended 
that future studies look into strategic interventions and approaches that could foster trust 
and enhance disclosure on the part of the patients. 
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A trend similar to the above was also seen to be prevalent among many of the 
subjects of this study. It was found that majority of the patients did not disclose their HIV 
status to their spouses and loved ones. Reasons for non-disclosure include fear of 
rejection by their spouses and family members, fear of ostracization by the community 
and consequences of stigmatization. It is very sad to imagine the difficulty of facing HIV 
infection without the support of loved ones. Efforts need to be increased to encourage 
disclosure of HIV status to family members, especially to spouses of HIV patients. The 
patients need to be empowered to make the disclosure and there should be a continuous 
system to support patients and families throughout their journey. Extensive efforts and 
resources have been deployed toward HIV education. However, efforts should be 
increased to provide more education for the general public. Stigmatization stems from 
lack of education about HIV. Our generation needs to defeat HIV. However, non-
disclosure of HIV status to spouses will only take our generation further away from 
effective prevention of the disease. Health care providers need to encourage patients to 
disclose status to their partners and family members. It is also recommended that nurse 
scientists and researchers investigate methods and approaches that can foster disclosure 
of status without jeopardizing the right, confidentiality, and wellbeing of the patients. 
There is documented evidence of the efficacy of herbal medications in the 
treatment of HIV. However, there are many herbal medications with a similarly large 
number of claims of efficacy. Scientific efforts should be directed at investigating the 
potency and efficacy of different herbal medications. Specifically, herbal medications 
should be isolated and the safety and efficacy of each medication should be evaluated. It 
is also necessary to thoroughly investigate the pharmacodynamics and pharmacokinetics 
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of each herbal medication. This way, only herbal medications that can withstand sound 
scientific scrutiny will be available for patients’ use. 
Conclusion 
This study has provided expanded insight and understanding into the treatment 
outcome during HIV treatment with different protocols. The study compared the 
treatment outcomes in patients using only ARV and patients using a combined therapy of 
ARV and herbal medications. CD4 count was used as a biomarker of treatment outcome 
in the two groups. Outcome comparison was also done using quality of life index and 
symptom experience. Two highly reliable and well-tested instruments were used to 
evaluate patients’ quality of life and symptom improvement. In spite of the high quality 
of this study, it has its limitations as described above. 
 This study has enriched our understanding of the treatment outcomes in patients 
using only ARV and patients using a combination of ARV and herbal medications. The 
study has revealed salient points and issues that require further exploration and 
appropriate interventions. Findings from this study have shown that a vast majority of 
patients on combined therapy do so without disclosing the use of herbal remedies to their 
physicians and care providers. It is expected that physicians and care providers would 
incorporate this knowledge into their care model, build trusting and supportive 
relationships with patients and specifically solicit information about the use of herbal 
therapy in combination with ARV. This knowledge will enable physicians, nurses and 
other care providers to explore possible side effects and cross reactions between ARV 
and herbal remedies. Since herbal therapies are widely used in Sub-Saharan Africa and 
since access to ARV is still largely and comparatively difficult, further studies need to be 
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done, particularly in the group of patients using herbal remedies only. Incorporation of 
this group in future comparative study would enable researchers and scientists to 
determine the efficacy of herbal medications in comparison to ARV only and combined 
therapy.  
 It is important that the Nigerian government and all other stakeholders negotiate 
social policies to empower the female population and enhance the ability of Nigerian 
females to negotiate social relationships. Health care professionals, especially nurses 
should play pivotal roles in empowering Nigerian females with education and resources 
to engage in safe sexual relationships. Extensive education and support systems should be 
given to HIV patients to facilitate voluntary disclosure of their HIV status to their spouses 
and family members. Such support systems and education should be sustained and 
extended to family members of HIV patients after disclosure is made to them. Universal 
acceptance, reduced stigmatization, and continuous therapeutic support are important 
factors that can impact positively on the quality of life of HIV patients.  
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APPENDICES 
 
APPENDIX A 
 
SIGN AND SYMPTOM CHECK-LIST FOR PERSONS WITH HIV DISEASE 
(SSC-HIVrev) 
Below is a list of potential problems that you may experience today. If you have 
the problem, rate the degree of INTENSITY that best describe the extent of the problem. 
If you do not have the problem, do not check a box. 
 
INTENSITY 
Mild  Moderate  Severe   Problem 
FATIGUE 
____  _____   _____  Muscle aches 
____  _____   _____  Weakness 
____  _____   _____  Painful joint 
____  _____   _____  Fatigue 
FEAR 
____  _____   _____  Difficulty Concentrating 
____  _____   _____  Depression 
____  _____   _____  Memory loss 
____  _____   _____  Fear/worries 
FEVER 
____  _____   _____  Fever 
____  _____   _____  Chills 
____  _____   _____  Day sweats 
____  _____   _____  Night sweats 
GI UPSET 
____  _____   _____  loose stools 
____  _____   _____  Diarrhea 
____  _____   _____  Gas/bloating 
____  _____   _____  Abdominal pain 
____  _____   _____  Nausea 
____  _____   _____  Vomiting 
SOB 
____  _____   _____  Shortness of breath at rest 
____  _____   _____  Wheezing 
____  _____   _____  Shortness of breath with activity 
SORE THROAT 
____  _____   _____  Sore throat 
____  _____   _____  Painful swallowing 
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____  _____   _____  Mouth ulcers 
____  _____   _____  White spots in mouth/thrush 
NUMBNESS 
____  _____   _____  Numbness/tingling of arms 
____  _____   _____  Numbness/tingling of hands/fingers 
____  _____   _____  Numbness/tingling of legs 
____  _____   _____  Numbness/tingling of feet/toes 
HEADACHE 
____  _____   _____  Dizziness 
____  _____   _____  Headache 
____  _____   _____  Heart racing 
____  _____   _____  Chest pain 
RECTAL ITCH 
____  _____   _____  Rectal Itching 
____  _____   _____  Rectal bleeding 
____  _____   _____  Rectal discharge 
BRUISING/BLEEDING 
____  _____   _____  Sore/bleeding gums 
____  _____   _____  Nose bleeds 
____  _____   _____  Easy bruising 
____  _____   _____  Blood in spit/sputum 
Items that did not load on factor scores 
____  _____   _____  Swollen glands 
____  _____   _____  Swollen feet 
 
____  _____   _____  Dry mouth 
____  _____   _____  Thirst 
____  _____   _____  Coughing 
 
____  _____   _____  Lack of appetite 
____  _____   _____  Constipation 
____  _____   _____  Concern over weight loss 
____  _____   _____  Flushing 
 
____  _____   _____  Rash 
____  _____   _____  Itchy skin 
 
____  _____   _____  Insomnia/can’t sleep 
____  _____   _____  Anxious 
____  _____   _____  Blurred vision 
____  _____   _____  Seizure/tremors 
 
____  _____   _____  Nipple discharge 
____  _____   _____  Breast pain/changes 
____  _____   _____  Sores or lumps on genitals 
____  _____   _____  Burning with urination 
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GYN-RELATED PROBLEMS 
For women only 
____  _____   _____  Vaginal discharge 
____  _____   _____  Irregular period 
____  _____   _____  Heavy period 
____  _____   _____  Bad cramps 
____  _____   _____  Vaginal itching 
____  _____   _____  Vaginal odor 
____  _____   _____  Bleeding between periods 
____  _____   _____  Pelvic pain 
 
SCORING: 
1. Scaling: 0= not present today; 1= mild; 2= moderate; 3= severe 
2. Factor scores: Sum the item scores (0-3) for each item in a factor and divided by 
the number of items. 
3. Total score: Sum the item scores (0-3) for each of the 45 items from the factor 
scores. 
Sources: Holzemer, W.L., Hudson, A., Kirksey, K.M., Hamilton, M.J., & Bakken, S. 
(2001). 
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APPENDIX B 
 
DEMOGRAPHIC QUESTIONNAIRE 
 
Check the appropriate box 
 
Age 
 
18-19 ______  20-24 _______ 25-29 _______ 30-34 ______ 
35-39 ______  40-44 _______ 45-49 _______ 50-54 ______ 
>54    ______ 
 
Gender  
  
Male ______  Female _______ 
 
Ethnicity 
 
Yoruba _______ Hausa _______ Igbo ______ Tiv/Idoma _______ 
Ijaw      _______ Others _______ (Please specify) 
 
Religion 
 
Christain ________ Muslim ________ Traditionalist ________  
 Others __________ (Please, specify) 
 
Marital Status 
 
Single ______    Married Monogamous ________  
 Married Polygamous _________ Divorced/Separated  __________ 
Living with a partner _________ 
 
Education 
 
None _______   Elementary ________   
Some High School ________  High School ________  
Some College ____________  College_____________ 
Graduate ________________ 
 
Employment 
 
Full-time ________ 
Part-time ________ 
Retired   _________ 
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Income Level 
 
Which annual income bracket best describes your household? 
>N1,200,000     _______ 
N1,000,000 to less than N1,200,000  _______ 
N9000,000 to less than N1,000,000  _______ 
N800,000 to less than N900,000  _______ 
N700,000 to less than N800,000  _______ 
N600,000 to less than N700,000  _______ 
N500,000 to less than N600,000  _______ 
N400,000 to less than N500,000  _______ 
N300,000 to less than N400,000  _______ 
N200,000 to less than N300,000  _______ 
N100,000 to less than N200,000  _______ 
N37,000 to less than N100,000  _______ 
0 to less than N370,000    _______ 
 
HIV Medication 
 
Do you take antiretroviral Medications?  Yes______ No _______ 
Do you take herbal medication?    
Yes_______ (Please list all herbal medications including vitamins) 
 
No _______ 
 
 
Adapted from Sunmola, A. (2005). Sexual practices, barriers to condom use and its 
consistent use among long distance truck drivers in Nigeria. AIDS Care, 17(2), 208-221. 
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APPENDIX C 
 
WHOQOL-HIV BREF INSTRUMENT 
 
ABOUT YOU 
Before you begin we would like to ask you to answer a few general questions about 
yourself: by circling the correct answer of by filling in the space provided. 
 
What is your gender       Male / Female 
How old are you? (age in years)    _____________ 
What is the highest education you received?   None at all / Primary / 
Secondary /  
University/Postgraduate 
What is your marital status?   Single/ Married/ Living as 
married/  
Separated/ 
Divorced/Widowed 
How is your health? (G1.2) 
 
Very poor  Poor  Neither poor nor good  Good  Very 
good 
      1                               2                                  3                                   4                         5 
 
 
Do you consider yourself currently ill?     Yes / No 
If something is wrong with your health what do you think it 
is?___________________________ 
 
 
Please respond to the following questions if they are applicable to you: 
What is your HIV serostatus? Asymptomatic / Symptomatic / AIDS converted 
In what year did you first test positive for HIV? _____________________________________ 
In what year do you think you were infected? _____________________________________ 
How do you believe you were infected with HIV? (circle one only): 
Sex with a man / Sex with a woman / Injecting drugs / Blood products / Other (specify) 
 
 
 
Instructions 
This assessment asks how you feel about your quality of life, health, or other areas of 
your life. Please, answer all the questions. If you are unsure about which response to 
give to a question, please choose the one that appears most appropriate. This can often 
be your first response. Please keep in mind your standards, hopes, pleasures and 
concerns. We ask that you think about your life in the last two weeks. For example, 
thinking about the last two weeks, a question might ask: 
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Not at 
all 
 
A little 
 
A 
moderate 
amount 
 
Very 
much 
 
Extremely 
 
 
 
 
 
How well are you able to concentrate? 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
You should circle the number that best fits how well are you able to concentrate over the 
last two weeks. So you would circle the number 4 if you were able to concentrate very 
much. You would circle number 1 if you were not able to concentrate at all in the last two 
weeks. 
Please read each question, assess your feelings, and circle the number on the scale 
for each question that gives the best answer for you. 
 
 
 
 
 
Very poor 
 
Poor Neither poor 
nor 
good 
Good 
 
Very 
good 
 
 
1(G1) 
 
 
How would you rate your 
quality of life? 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
 
 
 
 
 
Very 
dissatisfied 
 
Dissatisfied 
 
Neither 
satisfied nor 
dissatisfied 
Satisfied Very 
satisfied 
 
 
2(G4) 
 
 
How satisfied are you with 
your health? 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
 
 
 
The following questions ask about how much you have experienced certain things in the 
last two weeks.  
 
 
 
 
Not at all 
 
A little 
 
A moderate 
Amount 
Very 
much 
 
An 
extreme 
amount 
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3(F1.4) 
 
 
To what extent do you feel 
that physical pain prevents 
you from doing what you 
need to do? 
 
 
1 
 
 
2 
 
3 
 
4 
 
5 
 
4(F1.4) 
 
 
 
How much are you bothered 
by any physical problems 
related to your HIV 
infection? 
 
 
1 
 
 
2 
 
3 
 
4 
 
5 
 
5(F1.4) 
 
 
How much do you need any 
medical treatment to 
function in your daily life? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6(F1.4) 
 
 
How much do you enjoy 
life? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
7(F1.4) 
 
 
To what extent do you feel 
your life to be meaningful? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
8(F1.4) 
 
 
 
 What extent are you 
bothered by people blaming 
you for your HIV status? 
 
 
1 
 
 
2 
 
3 
 
4 
 
5 
 
9(F1.4) 
 
 
 
How much do you fear the 
future? 
 
 
1 
 
 
2 
 
3 
 
4 
 
5 
 
10(F1.4) 
 
 
 
How much do you worry 
about death? 
 
 
1 
 
 
2 
 
3 
 
4 
 
5 
 
 
 
 
 
 
 
 
 
 
Not at all 
 
A little 
 
A moderate 
Amount 
Very 
much 
 
An 
extreme 
amount 
 
11(F5.3) 
 
How well are you able to 
concentrate?? 
1 
 
2 
 
3 
 
4 
 
5 
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12(F16.1) 
 
 
 
How safe do you feel in 
your daily life? 
 
 
1 
 
 
2 
 
3 
 
4 
 
5 
 
13(F22.1) 
 
 
How healthy is your 
physical environment? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
The following questions ask about how completely you experience or were able to do 
certain things in the last two weeks. 
 
 
 
 
 
 
 
 
Not at all 
 
A little 
 
Moderately 
 
Mostly 
 
Completely 
 
14(F2.1) 
 
 
Do you have enough 
energy for everyday life? 
 
 
1 
 
 
2 
 
3 
 
4 
 
5 
 
15(F7.1) 
 
 
 
Are you able to accept your 
bodily appearance? 
 
 
1 
 
 
2 
 
3 
 
4 
 
5 
 
16(F18.1) 
 
 
Have you enough money to 
meet your needs? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
17(F51.1) 
 
 
To what extent do you feel 
accepted by the people you 
know? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
18(F20.1) 
 
 
How available to you is the 
information that you need 
in your day-to-day life? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
19(F21.1) 
 
 
 
To what extent do you 
have the opportunity for 
leisure activities? 
 
1 
 
 
 
2 
 
3 
 
4 
 
5 
 
 
 
 
 
 
 
Not at all 
 
A little 
 
Moderately 
 
Mostly 
 
Completely 
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20(F9.1) 
 
 
How well are you able to 
get around? 
 
 
1 
 
 
2 
 
3 
 
4 
 
5 
 
 
The following questions ask you how good or satisfied you have felt about various 
aspects of your life over the last two weeks. 
 
 
 
 
 
 
 
Very 
dissatisfied 
Dissatisfied 
 
Neither 
satisfied nor 
dissatisfied 
satisfied 
 
Very 
satisfied 
 
21(F3.3) 
 
 
How satisfied are you with 
your sleep? 
 
 
1 
 
 
2 
 
3 
 
4 
 
5 
 
22(F10.3) 
 
 
 
How satisfied are you with  
your ability to perform 
your daily living activities? 
 
 
1 
 
 
2 
 
3 
 
4 
 
5 
 
23(F12.4) 
 
 
How satisfied are you with 
your capacity for work? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
24(F6.3) 
 
 
How satisfied are you with 
yourself? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
25(F13.3) 
 
 
How satisfied are you with 
your personal 
relationships? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
26(F15.3) 
 
 
 
How satisfied are you with 
your sex life? 
 
 
1 
 
 
2 
 
3 
 
4 
 
5 
 
27(F14.4) 
 
 
 
How satisfied are you with 
the support you get from 
your friends? 
 
 
1 
 
 
2 
 
3 
 
4 
 
5 
 
28(F17.3) 
 
 
 
How satisfied are you with 
the conditions of your 
living place? 
 
 
1 
 
 
2 
 
3 
 
4 
 
5 
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29(19.3) How satisfied are you with 
your access to health 
services? 
1 2 3 4 5 
30(F23.3) How satisfied are you with 
your transport 
1 2 3 4 5 
 
The following question refers to how often you have felt or experienced certain things in 
the last two weeks 
 
 
 
 
 
 
 
 
Never Seldom 
 
Quite often Very 
often 
 
Always 
 
31(F8.1) 
 
 
How often do you have 
negative feelings such as 
blue mood, despair, anxiety, 
depression? 
 
 
1 
 
 
2 
 
3 
 
4 
 
5 
 
 
 
Did someone help you to fill out this form?___________________________________ 
How long did it take to fill this form out? _____________________________________ 
Do you have any comments about the questionnaire? 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________ 
 
THANK YOU FOR YOUR TIME AND HELP 
 
 
 
Source: (WHO, 2012). Retrieved from 
http://www.who.int/mental_health/publications/whoqol_hiv_bref.pdf 
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